This week, the FDA’s Pharmacy Compounding Advisory Committee recommended adding six experimental peptides to the federal list of bulk substances that traditional compounding pharmacies may use. The list included BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon.

Peptide clinics and companies that profit from selling these products are already celebrating the decision and describing the substances as having been “cleared.” That language is misleading.

The FDA did not approve any of these peptides. It did not determine that they are safe. It did not determine that they work. It did not approve an indication, dosage, route of administration, manufacturing process, or product label. The committee’s vote was advisory and nonbinding, and nothing automatically changed at the pharmacy counter when the votes were counted.

What Actually Happened

What the committee considered was whether these substances should eventually be placed on the 503A Bulk List. That is a legal pathway allowing a compounding pharmacy to prepare an unapproved medication from a bulk ingredient for an identified patient with a prescription. It is not the process used to approve a new drug, which normally requires controlled human trials demonstrating safety, effectiveness, and an acceptable balance between benefits and risks.

Traditional compounding exemptions serve a legitimate purpose. A patient may need a special concentration, a liquid instead of a tablet, or a formulation without a particular inactive ingredient. Using that same pathway to manufacture injectable experimental compounds that have never been approved for human use is a very different proposition. It allows an unapproved drug to enter clinical practice without undergoing the evidentiary process we ordinarily require before injecting something into patients.

The FDA’s own scientific staff recommended against adding all seven substances reviewed. Their concerns included inadequate human evidence, uncertain effectiveness, limited safety data, possible immune reactions, peptide-related impurities and questions about product characterization and manufacturing consistency.

Despite those concerns, the committee voted in favor of six of them.

The Political Context

It is also difficult to ignore the political context. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly promoted peptides and has made his hostility toward the traditional medical and regulatory establishment well known. Several people with professional or commercial connections to peptide clinics, pharmacies or related businesses were added to the advisory committee before the meeting.

That does not prove that anyone was instructed how to vote. It does, however, raise reasonable questions about whether political ideology, personal enthusiasm and commercial pressure are beginning to outrun scientific judgment.

What This Means for You

Patients need to understand exactly what this decision means. It may eventually make these products easier for compounding pharmacies and clinics to sell. It does not make them FDA-approved medications, and it does not suddenly create the missing clinical evidence.

A physician may eventually be legally permitted to prescribe one through a compounding pathway. That does not necessarily make the prescription medically responsible. Legal availability and evidence-based medicine are not the same thing.

For those of you who want my full take on peptides: there is no clear safety record for these compounds, and there is no indication for any of them to be prescribed for any meaningful medical purpose. I have written about this at length before. If you want the deeper dive, refer to my prior SITREP here: The Truth About Peptides.

The SITREP Bottom Line

The science did not change this week. No major clinical trials were completed, no new safety data appeared and none of these peptides received FDA approval. An advisory committee simply voted to lower a regulatory barrier.

Until credible human trials establish appropriate dosing, meaningful clinical benefits and acceptable safety, these peptides remain experimental products surrounded by far more marketing than medicine.

Medical Disclaimer

The Men’s Health SITREP is for general educational and informational purposes only. It reviews and interprets published research. It does not constitute medical advice and does not create a physician-patient relationship.

Nothing here is a substitute for individualized care from your own physician, who knows your history, your laboratory results and your circumstances. Do not start, stop or change any medication or treatment based on what you read here.

By Christopher Piercecchi, MD

_{This article is for educational purposes only and is not personal medical advice. It does not create a physician-patient relationship. Decisions about your health should be made with a qualified clinician who knows your history.}

Gentlemen, in the first SITREP in this Human Performance Series, published last week, I laid out the basic problem. Men are constantly bombarded with claims about how to enhance their physical performance: how to become stronger and faster, improve their endurance, and recover more effectively. The truth is that most of these claims are nonsense. By nonsense, I mean that many have little or no basis in established fact. Others may show some promise, but they are not yet supported by high-quality evidence. At best, they remain hypotheses, ideas about what a product or compound might be capable of doing. As any scientist knows, a hypothesis may be worth investigating, but until it has been properly tested and supported by convincing evidence, it cannot be presented as proven.

The products and compounds being marketed to men cover a wide range. Some are simply forms of basic nutrition. Others claim to optimize nutrition in some particular way. A small number are legitimate ergogenic aids, meaning they have been shown to improve some aspect of exercise capacity, recovery, or physical performance. Many, however, are simply overmarketed supplements. More recently, we have also begun to see prescription hormones, peptides, and experimental compounds aggressively promoted as performance enhancers, often without sound evidence that they are effective, safe, or appropriate for the men being encouraged to use them.

Today we will begin a deeper review of the various performance enhancers being marketed to men. The goal is simple: to determine which of them actually work and which are nonsense.

Read more

Physician and Wellness Manager, Founder, The Men’s Clinic for Wellness & Vitality

This is a clinical and policy commentary. It’s for education, not personal medical advice. Full disclaimer at the end.

On July 15, 2026, Pete Hegseth announced that every service member 30 and older will now undergo mandatory annual testosterone screening as part of their periodic health assessment.[1] Troops under 30 can request it, and any resulting testosterone replacement therapy is voluntary. He framed it as a way to keep troops on the “leading edge of lethality.” The move comes as the FDA, this June, requested labeling changes easing a longstanding restriction on prescribing testosterone for age-related low testosterone, a limitation that had been in place since 2015.

Treating men clinically is what I do every day. I see hundreds of them a year, and a lot of them walk in thinking, or feeling, or having been told, that they have low testosterone. I screen them, diagnose them, and, in some cases, treat them. This is my business, and I understand it cold. That's exactly why I feel compelled to cut through the nonsense, especially now that the Secretary of War has stepped onto the stage to convince the country that low testosterone is some crisis hollowing out the force. It isn't.

Where This Came From

There is a large movement of physicians and self-styled experts who believe they have the testosterone question figured out. They believe men today have less testosterone than men did decades ago. They believe almost any man whose number isn’t high should be on therapy. And they’ve been loud enough, long enough, that the message now reaches people like Hegseth, who is not a physician, knows very little about testosterone physiology, and is listening to advisers who either have an agenda or don’t understand the medicine themselves.

Many of the loudest voices in this space aren't physicians at all, and plenty of the ones who are don't spend their days in clinical practice. A lot of them have never really followed a man on testosterone over the long haul, prescribed it, watched how it plays out, and seen what the outcomes actually look like.

You’ve heard me say I favor a more liberalized approach to testosterone treatment. The rigid rule that a man must fall below one specific number multiple times before treatment can even be considered is too strict, and some of the endocrine guidelines have been overly restrictive.[2] I’ll grant that freely.

What this really means: Roughly eighty percent of the men who come to me, convinced they need testosterone, or already on it from another provider, do not need it. Full stop.

Many of these men show up in my clinic after years of taking “TRT” and still have the fatigue, the poor sleep, the low motivation, the exact symptoms that supposedly justified the prescription. The reason is simple. Testosterone was never the cause of their problems, and it was never going to be the cure.

Testosterone Was Never the Cause

Take almost any man and ask whether he’s tired, sleeping poorly, gaining weight, or not feeling like himself. Then check his testosterone, and find it sitting in the lower third of the normal range, low-ish, but not deficient. The people advising Hegseth would say the answer is obvious: treat it.

Nothing could be more wrong. The real question is why that number is relatively low, and that's the part Hegseth and his people don't seem to be considering. If they were screening to actually work out why a man’s testosterone is low and treat that, fine. That’s medicine. But that’s not the message. The message is: screen the man, and if the number’s low, start injecting, as if a syringe of testosterone turns him into a super-warrior. Low testosterone has many causes, and most of them aren’t fixed by adding more testosterone. It just moves the value on the lab report. Testosterone will not fix untreated sleep apnea, chronic sleep deprivation, obesity, metabolic disease, depression, alcohol, or overtraining. Raising a laboratory number is not the same as treating the problem.

Hegseth said the modern battlefield is brutal and unrelenting, that it demands maximum psychological and mental readiness, and that catching these markers early keeps troops on the leading edge of lethality.

That’s a conclusion he has no business drawing. He’s not a physician, he’s not a scientist, and this isn’t a subject you get to reason your way into from a podcast. I say that as someone who agrees testosterone should reach more appropriately selected men than it does now. Testosterone does not manufacture readiness, toughness, resilience, or lethality. It restores normal physiology in specific men who are genuinely deficient. That is a narrow and different thing.

One Number Tells You Almost Nothing

Total and free testosterone also fluctuate far more than most people realize. I went back through years of my own patients’ labs and found fluctuations approaching 40 percent in the same men over time, low on one draw, considerably higher months later, down again after that. Excessive work, stress, poor sleep, hard training, undereating, weight gain, illness, medications, and shifts in binding proteins can all pull a single value down temporarily. One number is a snapshot, not a diagnosis.

That’s exactly why mass screening is the wrong tool. Testing every man over thirty, most of them without symptoms, guarantees a flood of borderline and temporarily low results, and each one becomes a prompt to treat rather than an occasion to think. This is well-trodden ground in medicine. Screen a large, mostly healthy population for a number, and you manufacture false positives, repeat tests, and pressure to prescribe, whether or not anyone is sick.

Now, the claim you’ll hear most: men today have less testosterone than their fathers. There’s some truth buried in it, and it deserves to be dealt with honestly rather than the way the internet does.

The observation is real and has been replicated. Average total testosterone has drifted down across several populations. What it means is another matter. The Massachusetts Male Aging Study followed men from 1987 to 2004 and found an age-independent, generation-over-generation drop that persisted after adjusting for weight, smoking, and health.[^3] A large Israeli health-system analysis of over 100,000 men reached the same conclusion, which the authors judged unlikely to be explained by obesity.[4]

But the mechanism is genuinely contested, and that matters. A large Danish survey series complicates that picture. Once you adjusted for rising body weight, the testosterone trend was no longer significant, calculated free testosterone hadn’t meaningfully declined at all, and the change tracked binding-protein shifts rather than falling testosterone production.[5] In other words, part of what looks like “men are losing testosterone” is men getting heavier and their binding proteins shifting.

And here’s the part the testosterone evangelists never mention. Even taking the decline at face value, the men who are genuinely, symptomatically deficient are a small minority. The European Male Ageing Study surveyed 3,369 men aged 40 to 79 and required real symptoms alongside a genuinely low level before making the diagnosis. Only about 2 percent qualified, and they were disproportionately the oldest and most obese.[6] A longitudinal analysis of the same cohort showed the decline is modified by weight and lifestyle, with weight loss raising testosterone and weight gain lowering it, which points the cause back at health rather than the calendar.[7] Then there’s the Healthy Man Study: researchers took men over 40 in genuinely excellent health with no symptoms, and their testosterone did not decline with age at all.[8]

In healthy men, the famous decline barely exists, and the men who are truly deficient are mostly the ones who are less healthy and overweight.

What this really means: The population’s testosterone is drifting down largely because the population is getting less healthy, not because a mysterious force is draining it out of otherwise healthy men. A trend line across millions of men is an argument for understanding the cause, not an excuse for injecting everybody with testosterone.

The Question Nobody Asked

There’s an operational issue Hegseth and his advisers appear not to understand at all. Injectable testosterone has to be given on a schedule, often weekly, to hold a stable level, which means it depends on reliable resupply.

Now consider the soldier who’s actually on it. He’s deployed across the world, in a war zone, and the supply chain breaks. Has anybody thought through what happens when he runs out and can’t get the next dose?

Here’s what most people don’t understand about testosterone therapy. The moment a man begins TRT and starts taking testosterone, his body stops making its own. Its ability to produce testosterone essentially shuts off, and from that point on he’s dependent on the injections. Pill forms exist in some cases, but the situation is identical.

Now you’ve created a dependence problem, and for a man deployed in a wartime theater, that’s a serious one. If he abruptly comes off testosterone because he can’t get it, a realistic concern in a war zone, he’s thrown into true hypogonadism. His body has no testosterone of its own to fall back on, because it can often take months, and in rare cases up to a year, before natural production comes back. Picture that soldier downrange when the supply runs out. The injected testosterone clears his system, his own production is still offline, and nothing bridges the gap. For that entire stretch he’s running on almost nothing: exhausted, weak, unmotivated, foggy, and materially worse off than before anyone decided to “optimize” him. You’ve taken a man whose body made its own testosterone and left him dependent on a shipment reaching a war zone.

The Policy Already Says This

This is something Hegseth should have worked through before he ever spoke, and something his advisers should have walked him through, because the military already has rules built around exactly this kind of problem.

Under the Defense Department’s own deployment policy, a service member whose condition requires periodic evaluation or treatment that isn’t readily available in theater can be found non-deployable without a waiver.[9] Testosterone therapy fits that description. It isn’t set-and-forget. It needs ongoing monitoring, periodic bloodwork to track hematocrit and other markers, careful dose management, and uninterrupted resupply. That’s precisely the kind of continuous medical dependency the policy is written to flag.

That same policy already treats insulin-dependent diabetes as deployment-limiting. The reason there is acute: lose the drug and the man can go down fast. Testosterone runs on a slower fuse, but the principle underneath is identical, and it’s the one Hegseth is walking straight past. The military restricts deployment for men whose function depends on a medication and a supply line a war zone can’t promise to deliver.

So follow his logic to the end and you arrive at one of two absurd outcomes.

Either you apply the rule as written, in which case every otherwise-healthy man you talk onto testosterone becomes a man you now have to monitor, resupply, or waiver downrange. You didn’t build a lethal warrior. You built a maintenance requirement.

Or you carve out an exception and send these men to a war zone dependent on a hormone shipment reaching them. But the moment you do, you’ve conceded that dependence on a resupplied medication isn’t disqualifying after all, and you’re left explaining why that logic applies to testosterone but not to the insulin-dependent diabetic you keep home. You’ve either got a standard or you don’t.

You cannot screen healthy men onto open-ended, resupply-dependent therapy and call it a readiness gain, when the military’s own rules already treat that kind of dependency as a liability to manage, not an advantage to chase.

This is not a hypothetical concern about sloppy prescribing, either. Testosterone testing and prescriptions have nearly tripled in recent years, and by some estimates up to a quarter of men started on it never had their levels properly tested first.[10] Now scale that culture across the force.

What the Military Should Actually Do

The military should absolutely care about the health and performance of its people. It should diagnose and treat legitimate testosterone deficiency, and it should keep that treatment available downrange for the men who truly need it. It should also do the harder, less marketable work: diagnosing and treating obesity, sleep deprivation, sleep apnea, poor nutrition, metabolic disease, training overload, and inadequate recovery, because those are the actual reasons most screened men will test low in the first place.

Fix those, and something predictable happens. In my clinical practice, about eighty percent of the men who’d otherwise be put on TRT by some testosterone clinic don’t actually need it. We address the real problem upfront, the fat, the apnea, the sleep, the training, and their testosterone climbs back on its own. They raise it naturally, and they never go on testosterone at all.

And here’s the question no one at the podium has answered. No one has shown that screening every man over thirty and nudging his number upward produces a fitter, tougher, more lethal force. That evidence doesn’t exist.

Testosterone is not a shortcut to lethality, and a low or borderline lab value is not proof that a man needs injections. Every physician pushing this message to the Secretary should be asked a harder question. Not whether they practice medicine, but how they consider themselves an expert in this when they don’t practice this kind of medicine at all. Most of them don’t. They’re researchers, or personalities with a brand to sell.

This is what happens when people stop treating testosterone as a hormone and start treating it as an ideology.

This was never about politics for me. It’s about the medicine, and the medicine here is wrong.

This article is for education and general information only. It is not personal medical advice and does not create a physician-patient relationship. Testosterone therapy carries real risks and benefits that depend on the individual, and decisions about testing or treatment should be made with a qualified clinician who knows your history, labs, medications, risk factors, and goals. If you are a service member, follow your command’s medical guidance and your treating provider’s direction.

Refrences

1. U.S. Department of War. Statement on enhanced screening protocol to optimize warfighter performance and enhance force readiness, July 15, 2026.

2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.

3. Travison TG, Araujo AB, O’Donnell AB, Kupelian V, McKinlay JB. A Population-Level Decline in Serum Testosterone Levels in American Men. J Clin Endocrinol Metab. 2007;92(1):196–202.

4. Chodick G, Epstein S, Shalev V. Secular trends in testosterone: findings from a large state-mandated care provider. Reprod Biol Endocrinol. 2020;18:19.

5. Andersson AM, Jensen TK, Juul A, Petersen JH, Jørgensen T, Skakkebaek NE. Secular Decline in Male Testosterone and Sex Hormone Binding Globulin Serum Levels in Danish Population Surveys. J Clin Endocrinol Metab. 2007;92(12):4696–4705.

6. Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123–135.

7. Camacho EM, Huhtaniemi IT, O’Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013;168(3):445–455.

8. Sartorius G, Spasevska S, Idan A, et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the Healthy Man Study. Clin Endocrinol (Oxf). 2012;77(5):755–763.

9. U.S. Department of Defense Instruction 6490.07, “Deployment-Limiting Medical Conditions for Service Members and DoD Civilian Employees,” February 5, 2010, Enclosure 3.

10. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423–432.

This article is for education only and is not personal medical advice. It does not create a physician-patient relationship.

Here we go again…...

A sponsored article running on The Gateway Pundit tells its readers that the medicine in their cabinet is a fraud, that the establishment has hidden the body’s real healing tools from them, and that a company called The Wellness Company has finally broken the secret open with a product called REGENERATE. The pitch is confident: thirty drops in cold water every morning, and you get “injectable-grade” doses of three peptides — BPC-157, TB-500, and KPV — with no needle, no prescription, no clinic, and no doctor in your way. It promises to rebuild your gut, calm your inflammation, heal your muscles and tendons, and get you back on your feet after an injury or surgery. A one-month bottle runs $299.99, or $269.99 if you subscribe. [1]

None of it was written by a journalist. It was a paid advertisement, and the site discloses that it makes money when you buy through the links. The entire piece is designed to read like medical information, even though it is actually a sales pitch.

First, they make you distrust the medicine

Before it sells you a drop, the advertisement goes after the medicine you already have. It tells you the anti-inflammatory drugs in your cabinet — the ibuprofen, the naproxen, the prescription NSAIDs — “don’t actually fix a single thing,” that they only mask your pain and keep you coming back for refills while a pharmaceutical executive gets rich off your suffering.

That claim is dishonest in a particular way, so let me address it directly.

The ad is right about one narrow thing: an anti-inflammatory does not regrow a torn tendon or rebuild a worn-out joint. No NSAID was ever meant to. But it stretches that one true fact into a lie — that because these drugs don’t rebuild tissue, they “don’t fix a single thing” and aren’t worth taking. That does not follow, and any physician who has treated an injured patient knows it. When you sprain an ankle or flare an arthritic joint, the pain and swelling are driven by inflammation, and NSAIDs blunt that inflammation through a mechanism understood for decades. It is a real, measurable effect — which is why national guidelines recommend topical NSAIDs as first-line treatment for acute musculoskeletal injuries, and oral NSAIDs as an option for appropriately selected patients. [2]

Are they risk-free? No, and no honest doctor would say so. Used too heavily or too long, they can irritate the stomach, cause bleeding, and strain the kidneys, which is why they belong at the lowest effective dose for the shortest time, with a physician watching. But “this medicine has real risks a doctor should help you manage” is a completely different sentence from “this medicine is a scam that does nothing.” The advertisement collapses the two because the entire sales pitch depends on you throwing out the treatment that has been studied so you will reach for the bottle that has not.

The effect is to make men in real pain distrust a proven treatment so a company can sell them an unproven one.

What the evidence actually shows

Now the product they are trying to sell you, starting with the claim that should end the conversation on its own: that you can drink these peptides and get the benefit of an injection.

Many therapeutic peptides have to be injected because the digestive tract is remarkably good at breaking them down — acid and enzymes break them into pieces, and whatever survives still has to cross the intestinal wall, which peptides do poorly. This is why conventional insulin cannot simply be swallowed, and why any credible oral peptide has to demonstrate, through human absorption studies, that a meaningful amount reaches the bloodstream intact. [3]

The Wellness Company says its “proprietary AQA delivery technology” solves this and delivers “injectable-grade” peptides orally. So ask the obvious question: where is the study? They have published no human data showing how much intact BPC-157, KPV, or TB-500 reaches the bloodstream after someone drinks these drops. A trademarked name for a delivery system is not evidence that the delivery system works.

And look at how many unproven steps are stacked inside the promise. Putting 1 milligram of a peptide into a dose does not mean 1 milligram reaches your blood. Even if some did, that would not prove it travels to the tendon that hurts. And even if it reached that tendon, it still would not prove it repairs anything. Each part of the healing process has to be demonstrated, not assumed, and the advertisement does none of that.

The peptides themselves are not supported by credible evidence, and you do not have to take my word for it, because the FDA said so in the materials it prepared for its July 2026 compounding review. For KPV and TB-500, the agency found no human clinical studies supporting the proposed uses at all — and for TB-500, no medical literature describing its use in patients for any condition, including wound healing. For BPC-157, the FDA identified only five small, methodologically limited human studies that used rectal, intra-articular, intravesical, or intravenous administration. None of them show that this oral product is absorbed or that it heals human tissue; the agency found no human data on oral absorption, and a registered oral trial has never posted results or published a paper. [4a–c]

That is the evidence base under a product sold as a whole-body regenerative breakthrough.

The company calls these ingredients “clinically researched.” That does not mean clinically proven.

A substance can be “researched” in a test tube, a mouse, a rat, or a handful of poorly controlled patients. The only question that matters to you is whether this exact oral product, at this dose, gets intact peptide into a human body and improves something real in a controlled trial. For REGENERATE, the answer is no.

The testimonials, and how the pitch works on you

In place of that evidence, the advertisement hands you testimonials. One woman says her shoulder healed in a week when nothing else worked; another says she woke up on day five with less soreness. Those experiences may be sincere. But pain comes and goes, injuries heal on their own timeline, and the placebo effect is real. People reach for a new product when they feel their worst, then credit it when they naturally drift back toward normal. A story about a shoulder cannot demonstrate tendon remodeling, gut repair, or immune regulation.

The advertisement uses four moves, and they’re the same ones every ad like this uses.

First, it gives you a villain: the pharmaceutical executive getting rich off your pain. That’s there to make you distrust anyone who might later tell you the product doesn’t work.

Second, it gives you a secret the establishment supposedly hid from you, and “freedom-minded physicians” who are finally revealing it.

Third, it sells you “no prescription gatekeepers” as freedom. But a prescription isn’t a gate someone put up to keep you down. It’s the testing and medical oversight a real treatment has to go through, and they’re bragging about skipping it.

Fourth, it uses scientific-sounding words to sound like proof when there’s no proof behind them.

The timing makes this worse

On July 23, the FDA’s Pharmacy Compounding Advisory Committee is scheduled to take up these exact three peptides, and the agency’s own scientists have already recommended that BPC-157, KPV, and TB-500 not be added to the Section 503A Bulks List — the pathway that would let a pharmacist compound them one prescription at a time when no other route applies. Their reason is the one running through this whole piece: the evidence isn’t there. [4a–d]

So consider the contradiction. The FDA’s scientists are questioning whether there is sufficient evidence to justify a pharmacist making them for one patient at a time under supervision. The Wellness Company has put all three into a single bottle and is selling it directly to the public as a finished, proven morning-routine breakthrough.

The physicians should know better

The Wellness Company puts a Chief Medical Board front and center: Peter McCullough, MD, MPH; Drew Pinsky, MD; Harvey Risch, MD, PhD; James Thorp, MD; and Kelly Victory, MD. It uses those names and credentials again and again to set its products apart from ordinary supplements on the shelf. [5]

I cannot tell from the public record which specific physician reviewed this advertisement, approved these exact claims, or is personally paid on this product, and I won’t pretend I can. But I don’t need to, to say this plainly: any physician who knowingly formulated this product, approved these claims, promoted it, or let his name and his degree be used to sell it should be ashamed. These are not laypeople who got fooled. They are doctors who know the difference between animal research and human evidence, who know oral absorption has to be measured before it is claimed, and who know that “we have no idea if this is safe” is not the same as “this is safe.” They do not get to plead ignorance. These substances are not even approved for human use! Think about that fact. And physicians are promoting these things….

The profession has already drawn the line. The AMA Code of Medical Ethics is explicit: physicians who sell or endorse health products create a financial conflict of interest, pressure patients, erode trust, and demean the profession, and should offer only products whose benefits rest on unbiased, reliable evidence while making the limits of the science clear. [6] This marketing does the opposite.

And the hypocrisy runs to the core of the pitch. The whole ad is built on the charge that Big Pharma profits by keeping you sick — and then The Wellness Company, the savior from big old bad pharma, comes in to save you by selling you a $300 bottle of REGENERATE with no clinical trial showing it works. Whatever fair criticisms exist of the drug industry, a prescription drug has to prove it works in human trials before it can make a claim on its label. REGENERATE skipped all of that and makes the claims anyway. [7] The Wellness Company wants the credibility of medicine without doing the work that earns it.

The gap is visible in the company’s own fine print. The large print promises healing and regeneration. The standard disclaimer in its supplement claims states that those statements have not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure, or prevent any disease.

The large print promises to heal your tendons and repair your gut. The fine print says it isn’t meant to treat anything. The disclaimer does not erase the message used to make the sale.

A company should not be free to market an experimental product this way. Regulators can weigh the claims against the evidence, and licensing boards can weigh the conduct of any physician who knowingly attached his name or credentials to medical claims this misleading in connection with a commercial product. Whether that warrants a warning, a suspension, or the loss of a license is a matter for evidence and due process, and I won’t render that verdict from the outside. But the principle is simple: a medical license is a public trust, and it should be on the line the moment it is knowingly used to deceive the patients it exists to protect.

The bottom line

REGENERATE has no published human trial showing it heals muscle, tendon, ligament, surgical wounds, or the gut. Its central promise — that you can drink these peptides and absorb them like an injection — has never been demonstrated in humans. Two of its three ingredients have essentially no human evidence behind them. And the testimonials cannot prove healing, because a personal story never could.

This is not a medical breakthrough.

It is animal research, scientific-sounding language, anti-pharma anger, and physician authority, assembled into a sales pitch.

The wellness industry keeps making bigger claims off thinner evidence, and too many physicians have decided their names are for rent — and that is how a man in real pain ends up trusting a marketing company over his own doctor, and paying $300 a month for it.

Enough. The product is experimental. The marketing is indefensible. And every physician who knowingly put his name behind it should be ashamed.

References

[1] The Gateway Pundit, “The Peptide Secret Big Pharma Has Been Sitting On,” sponsored post — link the specific run of the ad you copied from
[2] Qaseem A, et al. Nonpharmacologic and Pharmacologic Management of Acute Pain From Non–Low Back Musculoskeletal Injuries in Adults (ACP/AAFP clinical guideline). Ann Intern Med. 2020. — pubmed.ncbi.nlm.nih.gov/32805126
[3] Novel enabling strategies for oral peptide delivery. Int J Pharm. 2025. — pubmed.ncbi.nlm.nih.gov/40555357
[4a] FDA Pharmacy Compounding Advisory Committee. Briefing Document for BPC-157–Related Bulk Drug Substances, July 23–24, 2026 meeting. — fda.gov/media/193343/download
[4b] FDA Pharmacy Compounding Advisory Committee. Briefing Document for KPV–Related Bulk Drug Substances, July 23–24, 2026 meeting. — fda.gov/media/193346/download
[4c] FDA Pharmacy Compounding Advisory Committee. Briefing Document for TB-500–Related Bulk Drug Substances, July 23–24, 2026 meeting. — fda.gov/media/193349/download
[4d] FDA. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (docket FDA-2025-N-6895).
[5] The Wellness Company, Leadership — twc.health/pages/leadership
[6] AMA Code of Medical Ethics, Opinion 9.6.4, “Sale of Health-Related Products”
[7] FDA, Development & Approval Process | Drugs — fda.gov/drugs/development-approval-process-drugs

_{This is for educational purposes only and does not constitute individualized medical advice or create a physician-patient relationship. Talk to your own physician before acting on anything you read here.}

BLUF

For many men, a coronary artery calcium scan is a simple test that shows whether atherosclerosis has already begun. Calcification is a marker of established disease that has been building in the artery wall for years.[2,3]

A positive score means calcified plaque is present in at least one coronary artery. A score of zero is reassuring, but it does not prove that the arteries are free of plaque. The test is useful because the result may change how aggressively a man approaches prevention.

What the scan measures

A coronary artery calcium, or CAC, scan is a specialized CT scan of the heart. Small sensors are usually placed on the chest so the scanner can time the images to the heartbeat and reduce motion artifacts. It looks for calcium within the coronary arteries, the vessels that supply the heart muscle.

The computer measures the amount and density of calcium and produces an Agatston score. A score of 0 means none was detected. Scores of 1–10 indicate a minimal amount; 11–100, a mild burden; 101–400, a moderate burden; and above 400, an extensive burden.[4,5] The score does not tell us exactly how narrow an artery is or whether blood flow is reduced. It tells us whether calcified coronary plaque exists and approximately how much is present.

Why calcium appears

Coronary disease begins when cholesterol-containing particles, particularly ApoB-containing particles, become trapped beneath the inner lining of an artery. They can trigger inflammation. Immune cells enter the arterial wall, take up cholesterol, and become foam cells. Over time, cholesterol, inflammatory cells, damaged tissue, and scar tissue accumulate into an atherosclerotic plaque.[6,7]

As plaque persists, cells become injured and die. Calcium and phosphate begin to crystallize within the damaged tissue. Some smooth-muscle cells also begin acting more like bone-forming cells and deposit hydroxyapatite, the same basic mineral found in bone.[8,9]

This is not calcium from food sticking to an artery. It is an active biological response within established plaque. Calcification begins microscopically and eventually becomes large and dense enough to be detected by CT.

A positive score therefore means atherosclerosis already exists and has progressed far enough to calcify. It does not mean an artery is critically blocked or that a heart attack is imminent. In general, however, higher calcium levels reflect a greater total burden of coronary disease and a higher future risk.[2,3]

A positive score means the disease is present. It does not necessarily mean a heart attack is coming. Most of the time, it means you have found the problem early enough to do something about it.

For paid subscribers, we will soon begin a premium series called Medical School for the Masses, where we will examine cholesterol transport, inflammation, plaque formation, calcification, and heart attacks in much greater detail.

Why finding it early matters

Heart attacks may seem sudden, but the disease behind them develops over decades. A heart attack at 65 typically reflects a disease process that began decades earlier.

The heart attack in your sixties usually began quietly in your thirties or forties.

Even a calcium score of 1 or 2 matters because the answer has changed from “we did not detect calcified disease” to “calcified coronary disease is present.” This is especially meaningful in a younger adult. In the CARDIA study, adults aged 32–46 with any detectable calcium had approximately five times the risk of fatal or nonfatal coronary heart disease during 12.5 years of follow-up compared with those who had none.[10]

Current guidelines support selective CAC testing in men beginning at age 40 when the result would help settle a prevention or treatment decision.[1] A prevention-minded man in his 30s or 40s may also reasonably choose the test, particularly with high LDL or ApoB, elevated lipoprotein(a), hypertension, diabetes, smoking exposure, kidney disease, obesity, or a family history of early heart disease.

That goes beyond routine population screening, but the logic is straightforward: if a 35-year-old already has calcium, he has premature coronary disease and would benefit from knowing it.

What a zero score means

A score of zero is good news and is associated with a much lower near-term event rate than a positive score.[2,3] It does not mean no plaque exists.

Earlier plaque may consist mainly of cholesterol, inflammatory cells, and fibrous tissue and may not yet have calcified. Microscopic calcium may also be below the scan's resolution. In the Miami Heart Study, 16% of asymptomatic adults with a score of zero still had plaque visible on coronary CT angiography, although severe narrowing was uncommon.[11]

A zero score means, “We do not see CT-detectable coronary calcium today.” It does not mean, “You have no coronary disease and cannot have a heart attack.”

A score of zero lowers your near-term risk. It does not erase it, so your cholesterol, blood pressure, and family history still matter.

What should happen next?

If calcium is present, the response should be more deliberate prevention, not panic. That means examining LDL cholesterol, ApoB, lipoprotein(a), blood pressure, glucose control, smoking, and family history. Depending on total risk and calcium burden, cholesterol-lowering medication and other preventive therapies may be appropriate.[1]

If calcium shows up, the right response is focused prevention, not fear.

If the score is zero, one’s risk profile still matters.

The scan is often available on a self-pay basis for roughly $50–$150 and typically exposes the patient to about 1 millisievert of radiation, roughly a third of what the average person receives from natural background sources in a year.[13]

For many men, that is a reasonable tradeoff for information that may change the next 20 or 30 years of prevention.

One last point on where these recommendations come from. Guidelines are built on population data. They ask what makes sense across a large group, and they lean heavily on ten-year risk, which is driven mostly by age. That approach tends to pass over younger men, because a 35-year-old rarely carries a high ten-year risk even when disease is already forming in his arteries.

Personalized medicine works differently. It focuses on an individual, not the general population, and looks for early signs of coronary disease; knowing this now would benefit them, while decades remain to change the course. For a man in his 30s or 40s with real reasons to look, that individual answer can matter far more than the population average ever will.

Guidelines are written for the average person. You are not deciding for the average person; you are deciding what to do about your own arteries.

Two 35-year-olds

Picture two men, both 35 years old.

The first one gets a calcium scan and it shows calcium in one of his coronary arteries. Now he knows he has early coronary disease, and he knows it at an age when there is still time to do something about it. He and his physician start working on prevention. He gets his cholesterol and ApoB down, controls his blood pressure, makes the lifestyle changes that matter, and follows up regularly. Over the next several decades, all of that treatment adds up to a large reduction in his risk. He may delay a heart attack by many years, or he may prevent it from ever happening.

The second man never gets scanned. He feels fine, so he has no reason to think anything is wrong. He spends the next 25 years without the medications, the lifestyle changes, and the follow-ups that would have lowered his risk, because he never knew he needed them. At 55 or 60, he has a heart attack and ends up in the ER, and that is where he learns for the first time that he has coronary artery disease. The disease was there at 35 and might well have been detectable. He just never looked.

Both men had the same disease at 35. One of them found out in time to treat it. The other found out in the ER.

This is a simplified illustration, not a guarantee. A calcium scan doesn’t prevent heart attacks by itself; it gives you and your physician information that can change what you do next. Whether testing makes sense for you is a decision to make with your own physician.

Share

References

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia. Circulation. 2026. doi:10.1161/CIR.0000000000001423.

2. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336–1345. doi:10.1056/NEJMoa072100.

3. Budoff MJ, Young R, Lopez VA, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease events: the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2018;39:2401–2408. doi:10.1093/eurheartj/ehy217.

4. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–832. doi:10.1016/0735-1097(90)90282-T.

5. Radiological Society of North America and American College of Radiology. Cardiac CT for calcium scoring. RadiologyInfo.org. Reviewed March 25, 2024.

6. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592:524–533. doi:10.1038/s41586-021-03392-8.

7. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5:56. doi:10.1038/s41572-019-0106-z.

8. Onnis C, Virmani R, Kawai K, et al. Coronary artery calcification: current concepts and clinical implications. Circulation. 2024;149:251–266. doi:10.1161/CIRCULATIONAHA.123.065657.

9. Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM. Role of smooth-muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res. 2018;114:590–600. doi:10.1093/cvr/cvy010.

10. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391–399. doi:10.1001/jamacardio.2016.5493.

11. Nasir K, Cainzos-Achirica M, Valero-Elizondo J, et al. Coronary atherosclerosis in an asymptomatic U.S. population: Miami Heart Study at Baptist Health South Florida. JACC Cardiovasc Imaging. 2022;15:1604–1618. doi:10.1016/j.jcmg.2022.03.010.

12. Aurora Health Care. Heart scan: coronary calcium scoring. Accessed July 15, 2026.

13. Messenger B, Li D, Nasir K, et al. Coronary calcium scans and radiation exposure in the Multi-Ethnic Study of Atherosclerosis. Int J Cardiovasc Imaging. 2016;32:525–529. doi:10.1007/s10554-015-0799-3.

The Men’s Health SitRep is for general educational and informational purposes only. It reviews and interprets published research. It does not constitute medical advice and does not create a physician-patient relationship. Nothing here is a substitute for individualized care from your own physician, who knows your history, your labs, and your circumstances.

A coronary calcium scan is a screening decision, not a self-diagnosis. Whether to have one, how to read the result, and what to do about it all depend on your full risk profile and should be made with your own physician. A score of zero does not rule out coronary disease, and a positive score is not by itself an emergency. The scan involves a small dose of radiation, so the decision to undergo it belongs in a conversation with your doctor. Do not start, stop, or change any medication or treatment based on what you read here.

Share

By Christopher Piercecchi, MD

_{This article is for educational purposes only and is not personal medical advice. It does not create a physician-patient relationship. Decisions about your health should be made with a qualified clinician who knows your history.}

Gentlemen, this is the first installment of our premium SITREP series, Human Performance Optimization. Over the next month or so, this first run will focus on performance enhancers — the supplements, powders, hormones, and compounds the marketing world swears will make you stronger, faster, and more powerful. I’ll delve into the research and tell you what works, what doesn’t, and what the evidence actually supports.

This first SITREP will provide an overview of what’s to come.

Why am I focusing on this topic? Because the vast majority of what men hear about performance enhancement is nonsense, misinformation, exaggerated marketing, or unsupported claims being parroted by people who repeat whatever they’ve heard and already want to believe. It’s a minefield for the man who truly wants to optimize his physical performance.

The marketplace includes everything from ordinary nutrition and legitimate supplements to prescription hormones, experimental compounds, and illicit performance-enhancing drugs. These are often discussed in the same online environment and presented as though they’re all reasonable options on the same performance-enhancement continuum. A podcast might move from creatine to testosterone to BPC-157 to growth hormone without adequately distinguishing their differences in evidence, risk, medical legitimacy, or expected effect.

The sheer amount of information hasn’t made it easier for men to decide what’s worth using. It’s often made the decision more confusing because marketing, testimonials, proposed mechanisms, animal research, and actual human performance evidence are routinely mixed together.

This series will sort through that confusion and answer a more useful question:

What actually improves meaningful physical performance, for whom, by how much, under what conditions, and at what cost or risk?

What Counts as Physical Performance?

Before we can answer that question, we must first define what we mean by physical performance. Physical performance isn’t one thing. It includes strength, power, muscular endurance, repeated high-intensity effort, aerobic endurance, muscle growth, recovery, body composition, and the ability to remain alert and tolerate difficult exercise. One thing it doesn’t include is longevity. This series isn’t about lifespan, healthspan, or living better into your later decades. Some of these compounds get discussed constantly in that context, and a few of them may have a legitimate role there, but that’s a separate question I’m not addressing here. The only thing on the table in this series is whether something helps you lift more, run faster, produce more power, or otherwise do more work. If it makes you healthier but not more capable, it doesn’t belong here. These outcomes overlap, but they’re not interchangeable. Strength is the ability to produce force, while power is the ability to produce that force rapidly. Aerobic endurance is the ability to sustain physical output over time and delay fatigue. Repeated high-intensity performance refers to the ability to reproduce hard efforts, whether that means repeated sprints, intervals, cycling attacks, or demanding sets in the gym.

Muscle growth and body composition also need to be considered separately from performance itself. Greater muscle mass may support strength and function, and reducing excess body fat may improve movement and endurance. However, changes in appearance don’t automatically mean that someone performs better. The same is true of recovery. Feeling less sore isn’t necessarily evidence that the body has recovered more quickly. A meaningful recovery benefit should help restore strength, power, endurance, or readiness for the next training session.

Some interventions work through a different route. Caffeine and other stimulants may improve alertness, reduce perceived effort, or allow someone to tolerate a heavier workload. That can produce a legitimate performance benefit, but it’s different from directly increasing muscle strength, aerobic capacity, or the body’s ability to recover.

Throughout this series, every product or intervention will therefore be judged according to the specific outcome it’s supposed to improve.

Raising a hormone, increasing blood flow, changing a biomarker, producing a temporary pump, or making someone feel more energized isn’t enough by itself. The question is whether that change produces a measurable and meaningful improvement in what the person can actually do.

How Will We Decide What Actually Works?

To answer that question, we need to be clear about what counts as evidence. A compound may have a plausible biological mechanism, alter hormone levels, increase blood flow, reduce soreness, or produce a noticeable sensation during a workout. Those findings may be interesting, but they don’t establish that the product meaningfully improves physical performance. Increasing growth hormone doesn’t automatically mean faster healing. Increasing nitric oxide doesn’t necessarily mean better endurance. Feeling less sore doesn’t prove that strength or readiness for the next training session has recovered more quickly.

The same caution applies to animal studies, laboratory research, testimonials, and personal experience. These can help generate a hypothesis, but they can’t tell us with confidence what will happen when the product is used by actual people under real training conditions. Someone may genuinely believe that a supplement improved his energy, strength, or recovery, but that doesn’t separate the product's effect from changes in training, diet, sleep, expectations, or the simple fact that performance naturally varies from one day to the next.

I want to be very clear about this. I realize that many people who use these substances feel strongly that certain products work, and their personal experience may be all the proof they need. I’m not discounting that experience. In some cases, the product may legitimately be helping. In others, the person may believe it’s helping when the improvement is actually coming from something else. That’s the nature of anecdotal evidence. It can be real and honestly reported, but it can’t reliably tell us whether the same result will occur in other people or whether the product itself caused the improvement.

My job in this series is not to give you my opinion or repeat what other people believe. My job is to show you the evidence.

Every conclusion and every performance claim will be grounded in research, and we’ll examine that research critically. The fact that a study was published doesn’t automatically make its conclusion reliable. Some studies are poorly designed, too small, inadequately controlled, based on the wrong population, or focused on an outcome that doesn’t actually matter. Some findings are never replicated. Others may be statistically significant but too small to make any meaningful difference in the real world. We’re not going to accept a claim simply because someone can point to a research paper that appears to support it. We’ll scrutinize the study's quality, what was actually measured, and whether the conclusion is justified by the data.

Throughout this series, I’ll give the greatest weight to the highest-quality human research available and to outcomes that matter. Did the participants become stronger? Did they produce more power, complete more work, sustain a faster pace, recover their performance more quickly, or gain meaningful muscle mass? Was the effect repeated in more than one study? Was it seen in trained people or only in beginners? Was the improvement large enough to matter outside a research paper? These details are far more important than whether a study reported a statistically significant change in a laboratory value.

The evidence for each intervention will be placed into one of four categories:

Strong evidence — Multiple good-quality human studies consistently demonstrate a meaningful effect.

Moderate or context-specific evidence — The intervention appears to work, but only for certain types of exercise, populations, doses, or circumstances.

Preliminary or inconsistent evidence — Some findings are encouraging, but the research remains limited, conflicting, or inadequately replicated.

Insufficient evidence — The claims are supported mainly by theory, animal research, testimonials, or weak human data.

Even when something works, that doesn’t automatically mean it’s worth using. Every intervention will therefore receive a separate practical verdict based on the magnitude of benefit, medical risk, cost, product quality, and the uncertainty that remains. Some products may be effective and reasonable. Others may be useful only in narrow circumstances. Some may be harmless but unnecessary. Others may produce substantial effects while carrying risks that make them inappropriate for routine performance enhancement.

That distinction will remain central throughout the series. We’re not simply asking whether a substance affects the body. We’re asking whether it produces a meaningful improvement in human physical performance and whether that improvement is worth the risk, cost, and uncertainty required to obtain it.

The Performance-Enhancement Landscape

Before we examine each category in detail, it is helpful to step back and look at the overall performance-enhancement landscape. The products and substances men use don’t fall neatly into categories such as “good” and “bad,” “natural” and “unnatural,” or “legal” and “illegal.” The more useful comparison is between how convincing the evidence is that something meaningfully improves performance and how much risk, uncertainty, or concern about product quality comes with it.

Read more

_{This article is for educational purposes only and is not personal medical advice. It does not create a physician-patient relationship. Decisions about your health should be made with a qualified clinician who knows your history.}

Part 1. The wellness claims, tested against the human data

Who’s selling them. The wellness narrative around nicotine pouches has been amplified by media personalities, podcasters, and influencers with enormous audiences. Tucker Carlson promoted Zyn before launching his own nicotine-pouch brand, ALP, creating a direct financial interest in portraying nicotine favorably. He has linked nicotine to mental acuity, testosterone, and protection against Alzheimer’s and Parkinson’s disease. Joe Rogan has helped popularize the category among millions of listeners. Andrew Huberman has described nicotine as capable of improving attention, focus, and alertness, although his longer discussions also acknowledge addiction and cardiovascular effects. The important question is not whether these people are intelligent or influential. It is whether their claims are supported by credible human evidence.

These claims deserve unusually careful scrutiny because the people making them often present narrow, short-term pharmacologic effects as broad improvements in health and performance. Their discussions frequently give inadequate attention to tolerance, withdrawal, dependence, cardiovascular stimulation, and the near absence of long-term outcome studies in healthy pouch users. The scientific problem is not that nicotine has no measurable effects. It is that those effects are routinely extended into conclusions the research has never demonstrated.

The Claims

Every claim below follows the same structure: a real short-term drug effect gets presented as a lasting health benefit that no study has shown. Here’s each one, and what the evidence actually says.

They claim nicotine sharpens focus and boosts productivity. Nicotine is a stimulant, and controlled experiments confirm that a single dose can improve some laboratory measures of attention, reaction time, and short-term memory [2]. This claim is grossly overstated. Paul Newhouse, who’s run the main clinical trials on nicotine and cognition, has stated publicly that in cognitively normal people there’s little evidence nicotine improves normal function, and his own randomized trial showing benefit was conducted in patients with mild cognitive impairment rather than in healthy adults [2]. In a habitual user, much of the perceived gain is relief of withdrawal as nicotine levels fall rather than a true improvement in cognition. It’s also worth knowing that a good deal of the research promoting nicotine’s cognitive benefits was funded by the tobacco industry, which has marketed nicotine as a performance enhancer since the 1990s. The effect is real but small and short-lived, and no study shows that chronic pouch use makes a healthy person more productive or cognitively healthier over time.

Verdict: partially true, but overstated. A single dose can give a small, short-lived lift in attention, and for a regular user, most of that is just relief from withdrawal. Nothing shows it makes a healthy person sharper or more productive over time.

They claim it gives you energy, relieves stress, and improves mood. These claims describe the same stimulant effect. Nicotine raises sympathetic nervous system activity, so it can produce a feeling of alertness or short-term calm. This is a drug effect that also raises heart rate and blood pressure, and in a dependent user, the calming effect is largely relief of withdrawal symptoms caused by the dependence. No good human evidence shows that nicotine treats anxiety, chronic stress, or depression in healthy people, or that it provides lasting energy independent of dependence.

Verdict: misleading. The stimulant effect comes at a real cost to heart rate and blood pressure, and the calm is mostly the quieting of withdrawal the habit created. It doesn’t treat stress, anxiety, or low mood in a healthy person.

They claim it raises testosterone and improves male vitality. This claim relies on observational studies in which male smokers sometimes show higher measured testosterone. That’s a finding about smoking rather than isolated nicotine, and it’s confounded by body weight and hormone-binding proteins. No randomized human trial of nicotine gum, patch, or pouches has shown a meaningful rise in testosterone, treatment of low testosterone, or any measured gain in muscle, strength, or libido. It’s unsupported and rests on smoking data and marketing language.

Verdict: not true. No human trial of nicotine shows a meaningful rise in testosterone or any gain in muscle, strength, or libido. The claim borrows from smoking data that don’t isolate nicotine.

They claim it improves erections and sexual performance. Tucker Carlson has called nicotine pouches a male enhancer. The direct evidence contradicts this. In a randomized, double-blind, placebo-controlled trial, 28 healthy nonsmoking men were given isolated nicotine, and it reduced their physical erectile response to erotic films by about 23 percent [3]. A follow-up from the same group traced the effect to nicotine’s disruption of autonomic balance [4]. This is consistent with the underlying physiology: an erection depends on blood-vessel relaxation, and nicotine is a vasoconstrictor.

Verdict: false, and backward. When healthy men were given nicotine and measured, their erectile response went down. Nicotine narrows blood vessels, which is the opposite of what an erection needs.

They claim it helps you lose weight. Nicotine does suppress appetite and modestly raises energy expenditure, so this effect is real. However, the fat-loss evidence is mostly from animal studies; the human evidence is weak, and nicotine worsens insulin resistance and raises diabetes risk (see Part 2). Reduced appetite isn’t the same as improved metabolic health.

Verdict: technically real, but misleading. Nicotine does blunt appetite, but eating less isn’t the same as being healthier, and the same drug worsens insulin resistance and raises diabetes risk. Essentially, it can negatively affect your metabolic health.

They claim it protects the brain and guards against Alzheimer’s. A six-month randomized trial of a nicotine patch in patients with mild cognitive impairment improved some test scores but not the overall clinical rating [2]. This was a small study in patients who already had cognitive impairment, and it says nothing about preventing dementia in a healthy adult. A short-term improvement on an attention test isn’t evidence of protection against neurodegeneration.

Verdict: not supported. The one positive trial was in patients who already had cognitive impairment, and it didn’t change their overall clinical status. There’s no evidence nicotine prevents dementia in a healthy adult.

They claim it prevents or treats Parkinson’s. The claim begins with a real observation: smokers develop Parkinson’s less often. This is likely reverse causation, because the early biology of the disease can reduce the drive to smoke years before diagnosis. When nicotine was tested directly as a treatment, it failed. In a randomized multicenter trial in early Parkinson’s, transdermal nicotine didn’t slow the disease, and the nicotine group showed a trend toward worsening faster than placebo, with more dropouts including unstable angina [5]. A 2024 meta-analysis of five trials found no benefit.

Verdict: not supported, with no sign of the claimed protection. When nicotine was tested head-to-head as a treatment, it didn’t slow the disease, and the nicotine group trended worse than placebo, not better.

They claim it enhances athletic performance. Across the trial literature, of 16 performance measures in 10 studies, 12 showed no effect, 2 showed improvement, and 2 showed worsened performance [6]. The World Anti-Doping Agency keeps nicotine on its monitoring list but hasn’t banned it, because there’s no clear performance benefit. Because it raises heart rate and blood pressure and can cause nausea, it’s as likely to impair performance as to improve it.

Verdict: not supported. Most studies show no performance benefit, and some show worse performance. It raises heart rate and can cause nausea, so it’s as likely to hurt as help.

They claim it benefits the heart and can even fix atrial fibrillation. Nicotine acutely promotes arrhythmia, and no evidence shows it treats atrial fibrillation. A pooled Swedish analysis found that snus use wasn't associated with a higher incidence of atrial fibrillation [7], but no increase in risk isn't the same as a benefit. There's good reason to avoid acute dosing in anyone with heart disease. The American Heart Association's 2025 statement reports higher mortality among users of these products who already have ischemic heart or cerebrovascular disease [8], though that mortality signal is observational and based mainly on smokeless tobacco rather than tobacco-free pouches.

Verdict: no benefit, and risky in heart disease. Nicotine can trigger arrhythmia, and nothing shows it treats atrial fibrillation. In people who already have heart or vascular disease, these products are linked to higher mortality.

They claim it can cure rabies or purge nanotechnology from the body. A small amount of research suggests nicotine may reduce rabies-related aggression relevant to how the virus spreads between hosts. That’s far from curing an infection that’s nearly always fatal. The claim that pouches purge nanotechnology has no scientific basis.

Verdict: false. There’s no basis for either claim.

The FDA order they cite. On June 30, 2026, the FDA authorized 20 ZYN products to carry a claim that using ZYN instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis [9]. This authorization is narrower than it sounds. It’s a switching claim for smokers. The FDA continues to state that no tobacco product is safe. The authorization was granted largely based on Swedish snus data, and it applies only to those 20 ZYN products, not to ALP, Lucy, VELO, Rogue, or nicotine pouches in general.

What it actually means: the FDA authorized a lower-risk claim for smokers who switch from cigarettes to certain ZYN products. It says nothing about focus, testosterone, erections, or any benefit to someone who’d otherwise use no nicotine.

Get 50% off an annual subscription

Part 2. The documented harms

Pouches remove combustion but still deliver nicotine. Two limitations apply to all of the evidence below. Most long-term outcome data come from Swedish snus, the closest long-term model of oral nicotine use without combustion. Snus contains tobacco constituents in addition to nicotine, and the study populations are almost entirely Swedish men, so these data can’t attribute an outcome to nicotine alone or transfer directly to tobacco-free pouches. The direct pouch experiments are short and were often conducted in smokers, so applying them to years of heavy daily use is reasonable but unproven.

The core problem: pouches trade the smoke for the drug, and the drug is doing real damage on its own. “No combustion” isn’t “no harm.” Nicotine itself is what raises your heart rate and blood pressure, strains your blood vessels, disrupts your sleep, and drives the dependence that keeps all of it going.

Dependence. Regular use produces tolerance and withdrawal, so a person keeps dosing to relieve the irritability, anxiety, and poor concentration that appear as nicotine levels fall. High-strength products have the greatest effect: in a controlled study, the 30-milligram pouch delivered more nicotine than a cigarette and produced the strongest side effects [1]. This is the most certain harm on the list.

This isn’t a habit, it’s a chemical dependence. It’s the engine that turns every other harm below into a daily, chronic one, because it keeps you dosing many times a day for years.

Heart rate and cardiac workload. In an independent government-institute crossover study, a 20-milligram pouch increased heart rate by about 12 beats per minute and a 30-milligram pouch by about 25 beats per minute, along with higher systolic blood pressure and arterial stiffness readings [1]. A person using 10 to 15 pouches a day repeats this response many times through the day, which matters most in people with coronary disease, arrhythmia, or uncontrolled blood pressure.

You’re firing this stress response dozens of times a day, every day, for years. Each pouch raises heart rate and blood pressure, increases the heart's workload, and gives nothing in return.

Endothelial function. The endothelium is the thin inner lining of blood vessels, and one of its jobs is to signal the vessel to dilate and increase blood flow when the body needs it. In a controlled study, a 21-milligram patch cut that opening response in healthy nonsmokers by roughly half, down to the level seen in smokers, while the vessel’s own ability to relax was unchanged, which shows nicotine damaged the lining’s signaling rather than the vessel muscle [10]. A second study in nonsmokers found the same impairment [11]. One 2024 study found the opposite: more circulating vessel-repair cells and no adverse blood pressure effect [12]. The findings aren’t uniform, but most of the direct evidence shows nicotine making a healthy person’s blood vessels behave like a smoker’s, and that loss of normal vessel function is one of the earliest steps toward heart disease.

Autonomic balance. Heart rate variability is a measure of how well the body shifts between its stress and recovery states, and higher variability is healthier. A single 4-milligram oral dose of nicotine, the amount in one strong pouch, lowered it in healthy nonsmokers, meaning the nervous system moved toward a low-grade, stuck-on stress state and away from recovery [13]. This is a single-dose effect and isn't proof of arrhythmia; no study has tested whether frequent pouch use lowers heart rate variability over the long term. Even so, low heart rate variability is associated with worse cardiovascular outcomes over time.

Palpitations and chest discomfort. The largest human dataset here is nicotine-replacement therapy, studied in smokers rather than pouch users. A meta-analysis of 120 studies found that nicotine roughly doubled the odds of palpitations or chest pain [14], though in real terms the event stayed uncommon, about 2.5 percent of users versus 1.4 percent on placebo. A separate analysis found more minor cardiovascular events overall with nicotine, while serious events such as heart attack, stroke, and cardiac death weren’t significantly increased [15]. Overall, nicotine causes more cardiac symptoms than placebo, and short courses show no clear increase in major cardiovascular events. That short-term result doesn’t establish the safety of years of heavy pouch use.

Sleep. In 20 nonsmokers, a single overnight nicotine patch reduced total sleep by about 33 minutes, reduced sleep efficiency from about 90 to 84 percent, reduced dream (REM) sleep, and nearly tripled the time needed to fall asleep [16]. Across nicotine-replacement trials, insomnia was more common with nicotine [14]. Afternoon and evening use is the relevant pattern here. Poor sleep independently worsens blood pressure, blood sugar, appetite, and mood, compounding the effects of the others.

Stomach and systemic symptoms. The same meta-analysis found that nicotine raised the odds of nausea and vomiting and of general gastrointestinal complaints [14]. Direct pouch reports add mouth burning, dizziness, and headache, most pronounced with the strongest products [1]. Tolerance can reduce the nausea over time, but this reflects the body adapting and the dependence deepening rather than any reduction in exposure.

Insulin resistance and diabetes. A study of long-term nicotine-gum users found high insulin levels and reduced insulin sensitivity [17], which fits nicotine's known effects on stress hormones and fat metabolism. The long-term signal comes from pooled Swedish snus cohorts, in which heavy users had a higher risk of type 2 diabetes that increased with the amount used [18]. The gum study was observational, and the snus data come from a tobacco product, so neither proves that nicotine alone causes diabetes, but together they're the most credible chronic-harm signal, and they directly contradict the marketing of pouches as a weight- or metabolism-aid.

This is the strongest long-term signal, and it sinks the weight-loss pitch. Nicotine can blunt your appetite while making your body worse at handling blood sugar and raising your risk of type 2 diabetes.

Oral tissue injury. Pouches hold a chemically active product against the same small area of gum for long periods, which nicotine patches don’t. Every pouch caused mouth irritation in the controlled study [1], and a case series of pouch users found white lesions with inflammatory and cellular changes at the placement site [19], with clinicians advising biopsy of any lesion that persists or looks atypical. Case reports can’t tell us how common this is, but they document local tissue damage associated with use.

Acute poisoning. A published case describes nicotine toxicity in a young man after repeated pouch use, and accidental ingestion by children is reported [20]. High-strength products can deliver enough nicotine to cause vomiting, sweating, tremor, and rapid heart rate. Children and first-time users are the most vulnerable relative to their body size.

Erectile physiology. The 23-percent reduction in erectile response to isolated nicotine in healthy men [3], discussed above, is also a documented harm, and it’s consistent with nicotine’s constriction of blood vessels.

Long-term mortality and cardiovascular outcomes. No mature study has followed exclusive pouch users long enough to measure death or heart attack, so this section is indirect. In a pooled analysis of eight studies in more than 169,000 never-smoking men, exclusive snus users had higher all-cause and cardiovascular mortality [21], though that finding drew methodological criticism and another large cohort found no overall link to most cardiovascular disease [22]. The stroke data show this distinction. In 130,485 never-smoking men, snus use showed no increase in stroke incidence, which argues against nicotine causing the stroke, but worse survival once a stroke occurred [23]. The same pattern of worse survival appears after a heart attack. Because these are observational studies of a tobacco product, they can't tell us whether nicotine itself drove the worse survival or whether other constituents and residual confounding contributed.

Coronary plaque and cancer. These are the two largest unknowns, and neither should be described as safe. No adequate human study has examined whether chronic pouch use leads to coronary plaque formation. The intermediate findings above are all unfavorable, but they don’t prove it. Nicotine isn’t a genetic initiator of cancer, and in never-smoking snus users, pancreatic and most cancer sites show no increase [24]. Laboratory work shows that nicotine can promote the growth of existing tumors through cell-signaling receptors, which raises a question about tumor promotion that these studies can’t answer in humans. The long-term oral-cancer risk of pouches specifically is unknown.

Unstudied is not the same as safe. No one has followed pouch users long enough to measure plaque or cancer, and "we don't have the data yet" is exactly where the sellers hide. Nearly every early signal we can measure points the wrong way.

The bottom line

Frequent nicotine-pouch use isn’t biologically neutral. Its clearly established harms are dependence, repeated cardiovascular stimulation, palpitations, disrupted sleep, stomach upset, and local mouth injury, and direct human experiments indicate adverse effects on vascular function, autonomic balance, blood sugar, and erectile response. Short-term replacement-therapy trials don’t show a large increase in heart attack or stroke, which limits how strongly major-event risk can be stated. The long-term snus data add warning signs for mortality, worse survival after cardiovascular events, and diabetes in heavy users.

The distinction that settles it is who’s holding the pouch. For a smoker who switches completely off cigarettes, this is harm reduction and worth encouraging. For a healthy man who’d otherwise use no nicotine at all, it’s a different equation entirely.

If you don’t already smoke, there’s nothing here for you to gain and real harm to take on. Not sharper focus, not more testosterone, not better workouts, not a longer life. What you get is a chemical dependence and a daily dose of a drug that stresses your heart, your blood vessels, your sleep, and your metabolism. The people selling you the opposite are the last people you should be listening to.

References

1. Mallock-Ohnesorg N, Rabenstein A, Stoll Y, et al. Small pouches, but high nicotine doses: nicotine delivery and acute effects after use of tobacco-free nicotine pouches. Front Pharmacol. 2024;15:1392027. (PMID 38841367)

2. Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot trial. Neurology. 2012;78:91-101. (PMID 22232050); Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210:453-469.

3. Harte CB, Meston CM. Acute effects of nicotine on physiological and subjective sexual arousal in nonsmoking men: a randomized, double-blind, placebo-controlled trial. J Sex Med. 2008;5:110-121. (PMID 17971108)

4. Harte CB, Meston CM. Nicotine acutely inhibits erectile tumescence by altering heart rate variability. Urology. 2014. (PMID 24642073)

5. Oertel WH, Müller HH, Unger MM, et al. Transdermal nicotine treatment and progression of early Parkinson’s disease (NIC-PD). NEJM Evid. 2023. (PMID 38320207)

6. Mündel T. Nicotine: sporting friend or foe? A review of athlete use, performance consequences and other considerations. Sports Med. 2017. (PMID 28791650)

7. Hergens MP, Galanti R, Hansson J, et al. Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation. Epidemiology. 2014;25:872-876.

8. Dennison Himmelfarb CR, Benowitz NL, Blank MD, et al. Impact of smokeless oral nicotine products on cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2025;151:e1-e21. (PMID 39624904)

9. U.S. Food and Drug Administration. Modified risk granted orders for 20 ZYN nicotine pouch products (Swedish Match USA). June 30, 2026.

10. Sabha M, Tanus-Santos JE, Toledo JC, et al. Transdermal nicotine mimics the smoking-induced endothelial dysfunction. Clin Pharmacol Ther. 2000;68:167-174. (PMID 10976548)

11. Chalon S, Moreno H Jr, Hoffman BB, et al. Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther. 2000. (PMID 10801248)

12. Liu YY, Tien TY, Hung CL, et al. Transdermal nicotine patch increases the number and function of endothelial progenitor cells in young healthy nonsmokers without adverse hemodynamic effects. Clin Pharmacol Ther. 2024;116:128-135.

13. Sjöberg N, Saint DA. A single 4 mg dose of nicotine decreases heart rate variability in healthy nonsmokers. (PMID 21350044)

14. Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy for smoking cessation: a systematic review and meta-analysis of 120 studies involving 177,390 individuals. Tob Induc Dis. 2010;8:8. (PMID 20626883)

15. Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. 2014. (PMID 24323793)

16. Davila DG, Hurt RD, Offord KP, et al. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med. 1994. (PMID 8049831)

17. Eliasson B, Taskinen MR, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation. 1996;94:878-881.

18. Carlsson S, Andersson T, Araghi M, et al. Smokeless tobacco (snus) is associated with an increased risk of type 2 diabetes: results from five pooled cohorts. J Intern Med. 2017;281:398-406.

19. Miluna-Meldere S, et al. Oral mucosal changes caused by nicotine pouches: case series with histopathological examination. 2024. (PMID 39300504)

20. Nicotine toxicity from repeat use of nicotine pouches. Nicotine Tob Res. 2025. (PMID 39087735)

21. Byhamre ML, Araghi M, Alfredsson L, et al. Swedish snus use is associated with mortality: a pooled analysis of eight prospective studies. Int J Epidemiol. 2021;49:2041-2050.

22. Titova OE, Baron JA, Michaëlsson K, Larsson SC. Swedish snuff (snus) and risk of cardiovascular disease and mortality. BMC Med. 2021;19:111. (PMID 33957912)

23. Hansson J, Galanti MR, Hergens MP, et al. Snus (Swedish smokeless tobacco) use and risk of stroke: pooled analyses of incidence and survival. J Intern Med. 2014;276:87-95. (PMID 24548296)

24. Araghi M, Galanti MR, Lundberg M, et al. Use of moist oral snuff (snus) and pancreatic cancer: pooled analysis of nine prospective observational studies. Int J Cancer. 2017;141:687-693. (PMID 28486772)

This article is for education only and is not personal medical advice. It does not create a physician-patient relationship. Medical decisions should be made with a qualified clinician who knows your history, labs, medications, risk factors, and goals.

_{This article is for general educational purposes only. It is not medical advice, diagnosis, or treatment, and reading it does not create a physician-patient relationship.}

This SITREP is intentionally long and detailed because GLP-1 medications deserve more than a quick take. Start with the BLUF if you want the short version, or use the table of contents below to jump directly to the sections that matter most to you. The goal is to separate the real medicine from the marketing, the hype, and the fear, and to explain how these drugs should actually be understood and prescribed.

Table of Contents

• BLUF: The Short Version

• What Are GLP-1 Medications?

• What the Research Actually Proves

• Weight Loss No Prior Drug Has Matched

• Cardiovascular Risk: Real, but in a High-Risk Group

• Sleep Apnea: A Real Role, Not a Replacement

• Kidney Protection in Diabetic Kidney Disease

• Heart Failure With Preserved Ejection Fraction

• Fatty Liver Disease (MASH)

• Diabetes Prevention and Glucose Control

• Why One Drug Does So Much

• What Are the Criticisms of These Drugs?

• Stopping the Drug Often Means Regaining Weight

• Muscle Loss and Frailty

• They Cause Gastroparesis

• Ozempic Face

• Gallbladder and Pancreatitis

• Bone Density

• The Eye Signal (NAION)

• Delayed Emptying and Surgery

• Thyroid Cancer and Suicidality

• Why Bad Outcomes Happen

• Who Should Take a GLP-1, and How It Should Be Prescribed

• Bottom Line

• Medical Disclaimer

• References

BLUF: The Short Version

If you read nothing else, read this. This is the whole argument in one section. Everything that follows this BLUF is the evidence and the clinical detail behind it.

This SITREP is written to cut through both the hype and the fear. Some people talk about GLP-1s as if they are miracle drugs that ask nothing of the patient: take the injection and change nothing else. Others talk about them as if they are dangerous pharmaceutical poison. Both views are wrong. Some of the criticism is legitimate and worth taking seriously, but much of it is poppycock. By analyzing the evidence and combining it with clinical experience, we can separate real clinical concerns from overblown claims and explain how these medications should actually be used.

Regardless of your stance on these drugs, both sides agree that GLP-1s work. Semaglutide and tirzepatide are the two dominant drugs in this class today. They are branded and sold as Ozempic, Wegovy, Mounjaro, and Zepbound, and produce weight loss no previous drug has matched. In the right patient, semaglutide also reduces real cardiovascular risk, and tirzepatide has a legitimate role in obesity-related sleep apnea. Those claims are not hype.

But a drug that “works” and a drug that helps a man become healthier are not always the same thing. A man can lose thirty pounds on one of these medications and still end up weaker, less fit, and less healthy than he was before, especially if that weight loss includes significant muscle loss. That is one of the most important criticisms that we will discuss later.

In short: GLP-1 medications are legitimate, powerful medical tools. They are not fake wellness products, and they are not inherently bad, despite what many so-called experts might suggest. But their value depends on whether they improve a man’s actual health rather than simply lowering his scale weight. Used correctly, they can be real medicine. Used carelessly, they can become a shortcut that produces a less healthy man.

What Are GLP-1 Medications?

GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut releases after you eat. One of its jobs is to help regulate blood sugar. Another is to send signals to your brain to tell you if you are full or hungry. GLP-1 medications are engineered to activate that same pathway, which is why they can reduce appetite and caloric intake so effectively. Semaglutide is a GLP-1 receptor agonist. Tirzepatide works differently. It activates two hormone pathways instead of one: GLP-1 and GIP. GIP stands for glucose-dependent insulinotropic polypeptide, another gut-derived hormone released after eating. That dual GLP-1/GIP activity is part of why tirzepatide tends to produce greater weight loss than semaglutide. In SURMOUNT-5, the head-to-head trial, tirzepatide produced about 20.2% weight loss versus about 13.7% for semaglutide over 72 weeks.⁶

Before going further, it is worth clarifying one issue, because peptides have become a major marketing tool in the longevity space. Many products sold online or through longevity clinics are promoted as peptides with vague promises of increasing growth hormone, burning fat, improving recovery, or slowing aging. But a peptide isn’t a magic drug; it’s simply a short chain of amino acids. GLP-1-based medications, like semaglutide and tirzepatide, are peptide-based drugs, but they should not be lumped together with the peptides commonly marketed in wellness and gray-market circles. These are FDA-approved medications with defined dosing, large human clinical trials, measured clinical outcomes, and rigorous safety evaluation. That does not make them risk-free, but it does make the comparison misleading. Semaglutide and tirzepatide should be evaluated as regulated medications supported by clinical trial data, not dismissed or promoted simply because they fall under the broad biochemical category of peptides.

Get 50% off an annual subscription

Read more

The short version, for anyone who wants it before the details: I do not recommend buying a home red light device for most of what it’s sold to do. The therapy has a few narrow, legitimate uses, and a couple of them, skin and hair, can work at home. But for the reasons most people actually buy these panels, recovery, joints, tendons, fat loss, the thyroid, the brain, the evidence either does not exist or was produced with clinical equipment a home device cannot reproduce. The SITREP is the evidence behind that conclusion, condition by condition.

Photobiomodulation, commonly marketed as red light therapy, is increasingly promoted for tissue repair, joint and tendon healing, athletic recovery, skin rejuvenation, fat loss, thyroid disease, brain function, and as an adjunct to orthobiologic procedures. The proposed mechanism involves absorption of light by intracellular chromophores, principally cytochrome c oxidase within the mitochondrial respiratory chain, with proposed downstream effects on adenosine triphosphate production, nitric oxide release, reactive oxygen species signaling, and modulation of inflammatory and reparative pathways [1]. In plain terms: red light gets absorbed by a part of your cells that helps make energy, and in a lab that can influence how cells produce energy, handle inflammation, and repair themselves. That is a real effect, and it is the entire basis for every claim that follows. The problem is that a real effect inside a cell is a long way from fixing a knee, a tendon, a thyroid gland, or a workout, and the rest of this piece is about that gap.

The marketing has moved well ahead of that evidence. These devices are sold by recovery centers, longevity clinics, physical therapy practices, medical spas, and direct-to-consumer manufacturers, and the claims they make are far broader than what the studies actually show. A plausible mechanism of action is not the same as a demonstrated result. The purpose of this review is to evaluate, indication by indication, whether the published evidence supports the claims being made, and to state in plain terms whether it works.

One point on regulatory status, because it is frequently invoked in marketing. The United States Food and Drug Administration recognizes red light therapy devices as a regulated device category and has issued draft guidance addressing non-clinical testing, clinical study requirements, energy output, irradiance, labeling, and safety considerations [2]. Regulatory recognition of the device category should not be interpreted as validation of specific therapeutic claims. Being FDA-cleared means a device is allowed on the market for a specific use, usually through substantial equivalence to a legally marketed device, not that it was proven to repair cartilage, heal tendons, burn fat, reverse thyroid disease, or speed up recovery. And “red light therapy” is not one thing. A face mask, a handheld laser probe, a wrap, a helmet, a broad home panel, and a clinical laser in a doctor’s office may all emit red or near-infrared light, but they are not automatically the same medical intervention.

Subscribe now

What the Research Actually Says

The sections below are ordered from the strongest evidence to the weakest. A separate but critical question, whether a device you can actually buy for home use can reproduce any of these studies, is addressed inside each indication, because that changes what the research means for a consumer.

Oral mucositis: the strongest evidence

The strongest evidence for red light therapy is for preventing oral mucositis in cancer patients. Oral mucositis is the painful, raw sores and inflammation that break out along the lining of the mouth and throat when chemotherapy or radiation damages that tissue; it can get bad enough that patients struggle to eat, drink, or swallow. The major cancer supportive-care guidelines from MASCC/ISOO recommend red light therapy to help prevent oral mucositis in specific adult cancer-treatment situations [3].

This is the strongest and most clinically legitimate evidence in the article, but it is narrow in scope. Oral mucositis represents a defined mucosal injury of specific etiology, treated under clinical supervision with standardized protocols. The demonstrated efficacy in this context does not extend to musculoskeletal tissue, and evidence from this indication should not be applied to claims regarding joint, tendon, thyroid, brain, cosmetic body contouring, or connective tissue repair.

Does it work? Yes. For prevention of oral mucositis in specific cancer-therapy settings, the evidence is sound and guideline-endorsed. But this is not a home-device claim. This is a supervised medical use with defined protocols in an oncology setting. A consumer red light panel does not reproduce this indication, and this evidence has no bearing on musculoskeletal, cosmetic, neurologic, endocrine, or regenerative claims.

Hair loss: androgenetic alopecia

A 2021 systematic review and meta-analysis of FDA-cleared home-use low-level light and laser devices for pattern hair loss identified seven double-blind randomized controlled trials and reported increased hair density relative to sham devices [6]. A separate 24-week randomized, double-blind, sham-controlled trial of a helmet-type device reported improved hair density and diameter, though the sample was small and long-term durability and comparative effectiveness against standard therapies were not assessed [7].

This evidence supports a defined dermatologic indication. It does not support orthopedic or regenerative claims. Follicular response to red light therapy has no established bearing on cartilage, tendon, joint pathology, thyroid autoimmunity, or athletic recovery, and device efficacy in this context does not validate devices marketed for musculoskeletal or systemic applications.

Does it work? Yes, within a narrow cosmetic indication. Specific studied home-use caps, helmets, or comb-like devices modestly increase hair density in androgenetic alopecia. This is one of the few categories where the home-device question is partly answered, because some of the studies actually tested home-use devices. But the benefit applies only to appropriately designed and studied hair-loss devices, not to a generic red light panel, and the effect does not generalize beyond the scalp.

Skin aging and photorejuvenation

Skin aging is one of the more plausible and better-supported home-device uses because the target is superficial and several studies use LED-based interventions rather than deep-tissue laser delivery. A split-face randomized controlled trial of 137 women reported an approximate 30% reduction in periocular wrinkle volume using red 660 nm and amber 590 nm LED at a controlled dose [18]. Earlier controlled trials of red and near-infrared light reported improvements in fine lines, skin roughness, and measured intradermal collagen density, and a systematic review of oncologic safety concluded that, within established parameters, current evidence does not support the proposition that red light therapy for aesthetic skin rejuvenation induces malignant change [19][20].

The stress test concerns magnitude, measurement, and durability rather than the existence of an effect. The improvements are cosmetic and incremental, not equivalent to procedural interventions, and the outcomes are surface metrics: wrinkle volume, skin roughness, collagen density, patient-reported appearance, observer ratings, and photographic or device-based measurements. Several of these depend on photographic conditions, measurement technique, and rater judgment that are difficult to blind completely. The benefit also requires sustained, repeated sessions, and durability beyond the short trial windows is poorly characterized. There is also a dosimetry problem worth naming, since this article holds every other indication to a dose-reproducibility standard. The most-cited periocular wrinkle trial drew a published critique noting that its reported irradiance and radiant-exposure values do not internally reconcile, meaning even this favorable study does not cleanly document the dose that produced the effect [18]. The finding of reduced wrinkle volume stands; the precise dose behind it does not.

Does it work? Yes, modestly, for skin appearance. Consistent red or near-infrared treatment can produce measurable, incremental improvement in fine lines and skin quality. This is also one of the few areas where a home LED device can plausibly map onto the research, because the target is superficial and several studies used LED-based treatment. But that assumes the device has verified wavelengths, adequate irradiance, and a protocol reasonably similar to the trials, and even the trials do not always report their own dose reliably. This is a superficial cosmetic dermatologic effect, not evidence for deeper tissue, joint, endocrine, neurologic, or systemic claims.

Knee osteoarthritis

Knee osteoarthritis is the indication most directly relevant to marketed regenerative claims. A 2024 systematic review and meta-analysis of 10 studies comprising 542 participants reported a reduction in resting pain relative to placebo, with the certainty of evidence graded very low, unclear-to-high risk of bias across included studies, and no significant improvement in the Timed Up and Go test [8]. The authors concluded that the evidence does not support red light therapy as an isolated therapy, though it may complement established interventions.

A 2022 randomized placebo-controlled trial provides a methodologically instructive example. Fifty patients were allocated to low-level laser therapy plus strength training or placebo laser plus strength training, using a defined 904 nm protocol delivered three times weekly, with follow-up to 52 weeks [9]. No significant between-group differences were observed in the primary pain outcomes, and pain improved substantially in both groups, implicating the shared strength-training intervention as the principal driver. Notably, no significant treatment effect on cartilage thickness was demonstrated. Because structural outcomes are the appropriate standard for any claim of regeneration, the absence of a demonstrable effect on cartilage is directly pertinent: this trial does not support a regenerative interpretation.

A blinded randomized study of 42 women with knee osteoarthritis evaluated exercise plus sham red light therapy, exercise plus active red light therapy, and control, assessing WOMAC scores and serum biomarkers including IL-1β, IL-6, IL-8, IL-10, TNF-α, and CTX-II [10]. Functional improvement was attributable to exercise. Active red light therapy increased IL-10 relative to control but conferred no additional benefit for pro-inflammatory markers, cartilage-degradation markers, or functional capacity. Biomarker modulation of this kind does not constitute evidence of structural repair or disease modification.

Does it work? Not as a regenerative or disease-modifying treatment. At most, it may confer a low-certainty symptomatic reduction in resting pain. It does not regenerate cartilage or modify the disease, and the trial designed to look for structural change found none. The home-device translation makes the claim even weaker. The more relevant studies used defined clinical protocols, often with laser or targeted application at specific treatment points, not a broad consumer LED panel used at an uncontrolled distance. A home red light panel should not be expected to reproduce the knee osteoarthritis studies, and it should not be sold as joint repair.

Tendinopathy

A 2021 systematic review and meta-analysis of 17 randomized controlled trials comprising 835 participants concluded that exercise therapy remains the primary treatment for tendinopathy and that high-quality evidence supporting red light therapy is lacking [11]. When compared directly with other interventions, red light therapy produced comparable rather than superior pain reduction. When added to exercise and compared with sham plus exercise, it was associated with greater pain reduction and improved function; however, the certainty of evidence ranged from very low to moderate, with documented risk of bias, inconsistency, imprecision, incomplete reporting of treatment parameters, and substantial heterogeneity.

The available evidence is consistent with a possible adjunctive effect on pain and function when red light therapy is combined with exercise. It does not establish tendon remodeling, collagen restoration, or structural healing, and it does not support substitution of the therapy for progressive mechanical loading, which remains the mechanistic and clinical basis of tendinopathy management.

Does it work? Not as a tendon-healing treatment. It may add to an exercise program’s effect on pain and function. It does not repair the tendon, and it does not replace progressive loading. The home-device translation is poor. Tendinopathy studies generally use defined treatment parameters directed at specific anatomic sites, often alongside exercise. A generic home LED panel does not automatically deliver the studied exposure to the tendon, and the evidence does not justify using a home device as a tendon-regeneration tool.

Diabetic foot ulcers

A 2021 meta-analysis of 13 randomized controlled trials comprising 413 patients reported that low-level laser therapy improved complete healing rates, reduced ulcer area, and shortened healing time relative to control [4]. The same analysis graded the certainty of evidence as very low and recommended higher-quality trials to confirm the effect and define appropriate treatment parameters.

Two limitations constrain interpretation. First, a positive pooled estimate at very low certainty does not constitute a settled treatment effect. Second, diabetic foot ulcers occur in metabolically impaired tissue characterized by vascular insufficiency, neuropathy, and compromised wound healing, a pathophysiologic context distinct from musculoskeletal injury. An additional review noted that cutaneous pigmentation influences optical absorption and that many protocols fail to account for this variable, further limiting generalizability [5].

Does it work? Possibly, as an adjunct in supervised wound care. There is very low-certainty support for benefit in diabetic foot ulcers. This does not mean a consumer panel can be used for wound care. The studies involve clinical treatment of a defined chronic wound condition, usually alongside standard wound care. This evidence cannot be extrapolated to joints, tendons, muscle, athletic recovery, or at-home self-treatment of wounds.

General neck and low back pain

Red light is broadly promoted for everyday neck and back pain, and the evidence is mixed and thinner than the marketing implies. A meta-analysis published in The Lancet found that low-level laser therapy reduced pain in neck-pain patients relative to placebo, a genuine positive signal [29]. For low back pain the picture is inconsistent: one meta-analysis concluded the therapy relieves pain in nonspecific chronic low back pain, but the same analysis found no convincing evidence for durable functional improvement [30].

The stress test is the familiar pattern. Where an effect appears, it is mainly on subjective, short-term pain scores, not on structural change, durable disability improvement, or disease correction, and the trials are heterogeneous in wavelength, protocol, dose, and comparator. A short-term reduction in a pain score is a real but limited outcome and does not establish that the underlying condition has changed.

Does it work? Partially, for short-term pain. The evidence is more supportive for neck pain than for low back function. It does not establish structural change, durable disability improvement, or disease correction. It also does not establish home-device equivalence. Many pain studies use clinical laser or defined devices with specific application sites and treatment parameters. A consumer LED panel used broadly over the neck or back should not be assumed to reproduce those protocols or those results.

Exercise recovery and performance

A 2024 meta-analysis of 34 randomized controlled trials evaluating pre-exercise red light therapy in healthy individuals reported statistically significant improvements in muscle endurance, strength recovery, and creatine kinase [12]. Interpretation is limited by several factors. The interventions were predominantly pre-exercise, whereas consumer applications are typically post-exercise, representing a distinct protocol. Reported outcomes are largely surrogate markers; creatine kinase and lactate dehydrogenase reflect muscle damage or clearance but do not establish reductions in injury, gains in muscle mass, improvements in aerobic capacity, or enhanced athletic performance. A separate 2024 meta-analysis of running performance found no improvement in time-trial or time-to-exhaustion outcomes and no dose-response relationship [13].

Does it work? Not in the way it is usually sold. It may affect selected surrogate markers under controlled pre-exercise conditions. It does not establish meaningful real-world recovery or performance benefit from home-use devices. This distinction matters because the studies generally test defined pre-exercise protocols, often directed at specific muscle groups, while consumer use is usually post-exercise, casual, and poorly dosed. A home panel should not be expected to reproduce the exercise-recovery literature.

Thyroid and Hashimoto’s disease

This indication is promoted in near-miraculous terms and aimed directly at patients on lifelong thyroid medication, which makes the gap between the marketing and the evidence consequential. The original clinical signal rests on a small research lineage. A randomized, placebo-controlled trial of 43 patients with hypothyroidism from chronic autoimmune thyroiditis, using near-infrared low-level laser therapy, reported that many treated patients reduced or discontinued levothyroxine, alongside lower thyroid peroxidase antibodies and improved thyroid ultrasound appearance [23]. The same group’s six-year follow-up reported that the effects appeared durable and that no malignancy or other harm was observed [24].

The stress test is severe, and it starts with who produced the evidence. This is a small, specialized literature, and much of the recent supportive work, including a 2025 review often cited to suggest the field is maturing, comes from a single research group whose members are affiliated with a commercial laser-medicine clinic [25]. That review identified only six clinical studies published between 2010 and 2025. A field’s own practitioners reviewing their own therapy is the same conflict seen with the body-contouring literature below, and it should lower confidence, not raise it. Separately, other sham-controlled work in Hashimoto’s has found improvements in oxidative-stress markers and quality of life without clear changes in thyroid function or autoimmunity between active and sham groups [26]. The literature is not empty, but it is small, commercially entangled, and not independently replicated at scale.

The clinical risk is concrete. A patient with autoimmune hypothyroidism who reduces levothyroxine because of a light device can become undertreated. That is the exact behavioral consequence the marketing creates when it tells patients a device may restore thyroid function.

Does it work? No, not in a way that should change clinical practice. There are small studies suggesting possible effects on medication requirement, antibodies, and ultrasound features, but the evidence is limited, largely produced by interested parties, and not independently replicated, and no patient should reduce levothyroxine because of a light device. The home-device translation is especially weak. The studies used targeted near-infrared laser over the thyroid region, not generic home LED panels, and a consumer device should not be considered a thyroid treatment.

Brain function: cognition, dementia, and mood

Light directed at the skull or delivered intranasally is marketed for memory, focus, depression, and dementia, and these are among the largest claims made for the therapy relative to the maturity of the human evidence. Systematic reviews report that transcranial red light therapy may improve some cognitive measures in older adults or in selected neurologic populations, and meta-analytic work has reported signals for depressive symptoms [27][28]. The mechanistic premise, that near-infrared light may affect mitochondrial signaling and cerebral blood flow, is at least plausible.

The stress test is the state of the evidence itself. The human trials are few, small, frequently uncontrolled or inadequately sham-controlled, and heterogeneous in device, wavelength, dose, treatment site, treatment schedule, and outcome selection. Some pilot trials enroll only a few dozen participants. Much of the supporting rationale derives from animal models, and there remains a practical question about whether therapeutically meaningful light reaches the intended brain targets through the adult skull, especially with consumer devices.

Does it work? Unproven, and weaker than the raw meta-analyses suggest. Pooled analyses report a positive signal for depressive symptoms, but the better-controlled, blinded, sham-controlled trials have not clearly beaten sham, which is exactly the pattern seen when an effect is real in open studies and evaporates under proper blinding. There are early human signals for cognition and mood, but nothing approaching the trial quality, replication, dose certainty, or clinical standard required to recommend it for dementia, depression, focus, or brain optimization. The home-device claim is even less defensible. Brain studies use transcranial or intranasal protocols designed around skull penetration and target exposure. A consumer red light panel is not equivalent, and marketing a home device for memory, depression, dementia, or brain performance runs far ahead of the science.

Body contouring and “spot fat reduction”

This is the claim that most deserves suspicion, and the evidence weakens quickly under scrutiny. Trials do report circumference reductions: randomized studies found waist, arm, or combined-girth decreases versus sham [21][22]. But the nature of that evidence is the central problem. An independent literature review found that six of the seven published low-level-laser body-contouring studies used a single manufacturer’s device, and the pivotal arm and waist trials were sponsored by that manufacturer and used to obtain FDA marketing clearance [22]. The manufacturer’s own materials list these as sponsor-run studies conducted in support of clearance submissions. This is not an independent evidence base; it functions largely as a marketing dossier.

The stress test compounds the problem. The endpoint is circumference, a cloth tape measured around the body, which is among the most manipulable outcomes in clinical research: posture, hydration, breathing, exact tape placement, bowel contents, time of day, and assessor expectations can each move it by more than the reported effect. The outcome is not body weight, not fat mass on imaging, and not a metabolic measure. The proposed mechanism, that light causes fat cells to leak their contents, is a laboratory hypothesis that does not establish durable fat loss in humans. Even accepted at face value, the change is small and, by the proposed mechanism, potentially transient.

Does it work? No, not for fat loss as consumers understand that phrase. There is no credible, independent basis to say red light removes meaningful fat mass or reduces body weight. What exists is a small, device-specific circumference effect, generated largely in manufacturer-sponsored studies, on an endpoint that is easy to influence. The home-device translation is poor: even the positive studies used specific clinical contouring systems, not generic panels, and measured circumference rather than fat. Buying a home red light device for fat loss is not evidence-based.

PRP and orthobiologic enhancement

Claims that red light therapy enhances the outcomes of platelet-rich plasma or other orthobiologic procedures carry significant clinical and financial consequence and require direct comparative evidence: PRP alone versus PRP plus red light therapy, with adequate power and clinically meaningful endpoints including pain, function, durability, and need for repeat intervention.

A registered trial designed to address this question in knee osteoarthritis compared physical therapy, physical therapy plus PRP, physical therapy plus red light therapy, and physical therapy plus PRP plus red light therapy, with assessment of synovial and serum biomarkers alongside clinical endpoints (NCT06122116). The trial is listed as terminated [14]. A terminated trial neither confirms nor refutes efficacy; it indicates that the direct human evidence required to support this claim has not been generated. A contemporary review has proposed red light therapy as a potential adjunct to orthobiologic interventions, but this represents a hypothesis rather than demonstrated efficacy, and several of its authors are affiliated with the regenerative medicine field [15].

Does it work? Unproven, which functionally means no. No completed human trial demonstrates that red light therapy improves the outcome of PRP or comparable procedures. Charging for it as a regenerative enhancer is not evidence-based. The home-device claim is even weaker. The necessary evidence would have to show that PRP plus red light therapy outperforms PRP alone under a defined clinical protocol. There is no basis to assume that a patient using a home LED device before or after an orthobiologic procedure improves the result.

Subscribe now

The Home Device Problem: Can You Even Reproduce These Studies?

Everything above describes what happened in controlled trials using clinical or laboratory equipment. Whether any of it applies to a device a consumer can buy is a separate question, and it is the one that matters most for a reader deciding whether to spend money. There are two distinct problems: whether the home device is even comparable to the instrument used in the study, and whether the device delivers a consistent light exposure at all.

First, the type of device and the delivery geometry. Most of the musculoskeletal, thyroid, and pain trials used defined laser protocols, often applied in contact at specific points, with fixed treatment times and known parameters. Many home panels use non-contact LED arrays across a broad field, at variable distances, with variable beam spread and uncertain exposure at the target tissue. The issue is not simply that lasers are coherent and LEDs are not. In tissue, scattering rapidly alters beam behavior. The more important point is practical: a contact laser probe delivering a defined dose to specific anatomical points is not the same intervention as standing several inches from a broad LED panel. Once distance, beam spread, tissue depth, pigmentation, and target anatomy change, the delivered exposure changes.

For deeper targets, a home LED panel cannot be assumed to reproduce the studied protocol. The relevant issue is not the color of the light alone, but the delivered exposure at the target tissue. That depends on wavelength, irradiance, fluence, distance, beam geometry, contact versus non-contact application, tissue depth, skin pigmentation, and treatment time. A positive study using a defined laser protocol cannot be converted into a generic recommendation for a home panel unless the device can reproduce the relevant wavelength, irradiance, fluence, treatment geometry, and target-tissue exposure.

Second, dose consistency. Even where a home device is the right type, the therapeutic agent is the delivered light exposure at the target tissue, not the device itself. A 2022 study measuring 24 clinical-grade laser devices in routine use reported measured power output ranging from 2% to 134% of manufacturer-declared values and beam diameter ranging from 38% to 543% of nominal values [16]. These were professional clinical devices; the authors called for improved standardization and routine output monitoring, as fluctuations of this magnitude alter delivered treatment. A 2025 pilot study of home-use LED devices reported heterogeneous wavelengths, unstable output, and manufacturer dosimetry that did not adequately account for beam divergence and tissue attenuation [17]. When output, beam geometry, treatment distance, and tissue attenuation are uncontrolled, the user cannot reliably reproduce the exposure employed in any positive clinical trial.

Applied to each claim, this sorts the entire article:

Skin. Superficial target, and several of the trials used LEDs. A quality home panel or mask with verified wavelengths and adequately documented irradiance can plausibly reproduce part of the studied intervention, assuming the device is used according to a protocol that resembles the research. This is one of the few categories where a home device can credibly map onto the evidence.

Hair loss. The pattern-hair-loss trials specifically tested FDA-cleared home-use devices, so an appropriate cleared cap or helmet does correspond to the evidence, within that narrow indication.

Body contouring. The trials generally used clinical systems and circumference endpoints, not broad home panels and not objective fat-mass endpoints. A home device does not reproduce a meaningful fat-loss intervention.

Thyroid. The studies used targeted near-infrared laser over the neck to reach a deep glandular target. A home LED panel should not be assumed to deliver a comparable exposure to the thyroid gland, and the clinical evidence is not strong enough to justify thyroid treatment or medication adjustment anyway.

Brain, cognition, and mood. These used transcranial or intranasal protocols, and whether meaningful light reaches target brain tissue is uncertain even with clinical equipment. A consumer panel is not equivalent.

Knee, tendon, and most pain. The relevant studies commonly use clinical lasers or defined devices applied in specific patterns to specific anatomical locations. A home LED panel does not automatically reproduce the studied protocol or the target-tissue exposure.

The conclusion is blunt. Of every indication in this article, a home device can most credibly reproduce the skin and hair-loss research, both narrow cosmetic uses. For fat loss, thyroid disease, brain function, joint and tendon problems, and most pain, the studies cited to sell these devices either used different equipment, different delivery geometry, weaker endpoints, or inadequate evidence. Seeing a positive study for one of those conditions and then buying a home panel is not a smaller version of the treatment. It is often a different thing that happens to emit red light.

Should a Patient Buy a Home Red Light Device?

My recommendation is no for most medical purposes, and the reasoning follows directly from the evidence above.

Of the indications with sound evidence, oral mucositis is delivered in an oncologic setting rather than through a consumer device, which leaves the two narrow cosmetic uses, hair density and skin appearance, as the only home-relevant indications with genuine support. Every other indication for which these devices are marketed, knee osteoarthritis, tendinopathy, recovery, fat loss, thyroid disease, brain function, and orthobiologic enhancement, is supported by low-certainty, symptomatic, confounded, commercially entangled, or absent evidence. For the reasons most consumers purchase these devices, the supporting data do not exist.

It is worth pointing out what actually drives these purchases, because it is not the evidence. Open any wellness influencer’s “day in my life” video and there is a good chance it opens with the same shot: the subject rolls out of bed and stands in front of a glowing red panel in the closet. It reads as discipline, optimization, self-care. For nearly every purpose implied, it is of no demonstrated benefit. People adopt it because they saw someone they admire do it, not because a study told them to, and they spend real money on that impression. This is the economic engine of the modern wellness and supplement industry. The product is aspiration, not efficacy, and it is sold the way limited-edition sneakers are sold, on image and belonging rather than function. Red light therapy is a near-perfect example: a genuine but narrow biological effect, inflated into a lifestyle purchase and marketed to everyone.

Taken together, the recommendation is straightforward. A home device represents expenditure on an intervention that, for the purchaser’s actual objectives, is either unsupported by evidence or incapable of reliably reproducing the exposure that generated what limited evidence exists. Use as a personal, relaxing routine, or for skin and hair with an appropriate device and realistic expectations, is a defensible individual choice. Purchase as a medical intervention for recovery, joints, tendons, fat loss, the thyroid, the brain, or regeneration is not justified.

Bottom Line

Red light therapy is not without therapeutic merit. It has demonstrated efficacy in preventing oral mucositis in specific oncologic populations, in modestly improving hair density in androgenetic alopecia, and in incrementally improving skin appearance, and it has plausible mechanistic grounding. The evidence does not support its promotion as a treatment for cartilage regeneration, tendon healing, joint disease modification, athletic recovery, fat loss, thyroid disease, cognitive enhancement, or orthobiologic enhancement.

The recurrent problem is not fabricated data but overextension of real data: a mechanism is presented as clinical proof, symptomatic improvement is presented as structural repair, biomarker modulation is presented as regeneration, a tape-measure change is presented as fat loss, and evidence from one indication is applied to unrelated conditions. In the musculoskeletal literature specifically, frequent co-administration of exercise or standard care, combined with reliance on subjective and surrogate endpoints, precludes attribution of observed benefit to red light therapy itself. And for most indications, the home device a consumer actually buys cannot be assumed to reproduce the clinical equipment, treatment geometry, or delivered exposure that generated the evidence in the first place. Red light therapy may warrant consideration as an adjunct in specific, well-defined contexts. It should not be marketed or employed as a universal modality for recovery, repair, or regeneration. The governing principle is that a study supports only the specific claim it was designed to test, delivered by the specific device and protocol it was tested with.

This article is for education only and is not personal medical advice. It does not create a physician-patient relationship. Medical decisions should be made with a qualified clinician who knows your history, labs, medications, risk factors, and goals.

Share

Share The Men's Clinic For Wellness and Vitality

References

[1] Dompe C, Moncrieff L, Matys J, et al. Photobiomodulation—Underlying Mechanism and Clinical Applications. Journal of Clinical Medicine. 2020.

[2] U.S. Food and Drug Administration. Photobiomodulation Devices: Premarket Notification [510(k)] Submissions. Draft Guidance for Industry and Food and Drug Administration Staff. 2023.

[3] Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. Cancer. 2020.

[4] Huang J, Chen J, Xiong S, Huang J, Liu Z. The Effect of Low-Level Laser Therapy on Diabetic Foot Ulcers: A Meta-Analysis of Randomised Controlled Trials. International Wound Journal. 2021.

[5] Dhlamini T, Houreld NN, Abrahamse H. Clinical Effect of Photobiomodulation on Wound Healing of Diabetic Foot Ulcers: Does Skin Color Really Matter? 2022.

[6] Lueangarun S, Visutjindaporn P, Parcharoen Y, Jamparuang P, Tempark T. A Systematic Review and Meta-Analysis of Randomized Controlled Trials of United States Food and Drug Administration-Approved Home-Use Low-Level Light/Laser Therapy Devices for Pattern Hair Loss. 2021.

[7] Suchonwanit P, et al. Low-Level Laser Therapy for the Treatment of Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Sham Device-Controlled Trial. 2019.

[8] Oliveira S, et al. Effectiveness of Photobiomodulation in Reducing Pain and Disability in Patients With Knee Osteoarthritis: A Systematic Review With Meta-Analysis. Physical Therapy. 2024.

[9] Stausholm MB, et al. Short- and Long-Term Effectiveness of Low-Level Laser Therapy Combined with Strength Training in Knee Osteoarthritis: A Randomized Placebo-Controlled Trial. Journal of Clinical Medicine. 2022.

[10] Vassão PG, et al. Effects of Photobiomodulation and a Physical Exercise Program on Inflammatory and Cartilage Degradation Biomarkers and Functional Capacity in Women with Knee Osteoarthritis: A Randomized Blinded Study. 2021.

[11] Tripodi N, Feehan J, Husaric M, Sidiroglou F, Apostolopoulos V. The Effect of Low-Level Red and Near-Infrared Photobiomodulation on Pain and Function in Tendinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BMC Sports Science, Medicine and Rehabilitation. 2021.

[12] Li BM, et al. Can Pre-Exercise Photobiomodulation Improve Muscle Endurance and Promote Recovery in Healthy Individuals with Different Activity Levels? A Meta-Analysis of Randomized Controlled Trials. 2024.

[13] do Nascimento ANAP, et al. A Meta-Analysis of Randomized Controlled Trials on the Effects of Photobiomodulation Therapy on Running Performance. 2024.

[14] Clinical trial listing. Investigating Orthobiologics After PRP and Photobiomodulation for Knee Osteoarthritis. NCT06122116.

[15] Hanney W, Rodriguez J, Wilson A, Rothschild C, Kolber M, Varela A, Salamh P. The Utility of Photobiomodulation as a Supplement to Orthobiologic Interventions: A Contemporary Review. Biologic Orthopedics Journal. 2023.

[16] Girasol CE, Braz GdA, Bachmann L, Celli J, Guirro RRdJ. Laser Light Sources for Photobiomodulation: The Role of Power and Beam Characterization in Treatment Accuracy and Reliability. PLOS ONE. 2022.

[17] Cronshaw M, Parker S, Hamadah O, Arnabat-Dominguez J, Grootveld M. Photobiomodulation LED Devices for Home Use: Design, Function, and Potential—A Pilot Study. Dentistry Journal. 2025.

[18] Mota LR, Duarte IDS, Galache TR, et al. Photobiomodulation Reduces Periocular Wrinkle Volume by 30%: A Randomized Controlled Trial. Photobiomodulation, Photomedicine, and Laser Surgery. 2023;41(2):48–56. (See also Jenkins PA, published response noting dosimetry discrepancies, same journal, 2023.)

[19] Wunsch A, Matuschka K. A Controlled Trial to Determine the Efficacy of Red and Near-Infrared Light Treatment in Patient Satisfaction, Reduction of Fine Lines, Wrinkles, Skin Roughness, and Intradermal Collagen Density Increase. Photomedicine and Laser Surgery. 2014.

[20] Glass GE. Photobiomodulation: A Systematic Review of the Oncologic Safety of Low-Level Light Therapy for Aesthetic Skin Rejuvenation. Aesthetic Surgery Journal. 2023.

[21] Caruso-Davis MK, Guillot TS, Podichetty VK, et al. Efficacy of Low-Level Laser Therapy for Body Contouring and Spot Fat Reduction. Obesity Surgery. 2011.

[22] Nestor MS, Zarraga MB, Park H. Effect of 635 nm Low-Level Laser Therapy on Upper Arm Circumference Reduction: A Double-Blind, Randomized, Sham-Controlled Trial. Journal of Clinical and Aesthetic Dermatology. 2012. (Manufacturer-sponsored; used for FDA clearance.)

[23] Höfling DB, et al. Low-Level Laser in the Treatment of Patients with Hypothyroidism Induced by Chronic Autoimmune Thyroiditis: A Randomized, Placebo-Controlled Clinical Trial. Lasers in Medical Science. 2013.

[24] Höfling DB, et al. Safety and Efficacy of Low-Level Laser Therapy in Autoimmune Thyroiditis: Long-Term Follow-Up Study. International Journal of Endocrinology. 2018.

[25] Berisha-Muharremi V, et al. Photobiomodulation Therapy in Chronic Autoimmune Thyroiditis: A Systematic Review of Molecular Mechanisms and Clinical Applications. 2025. (Authors affiliated with a commercial laser-medicine clinic.)

[26] Tunç S, Altuntaş SL, Atmaca M, et al. The Effect of Low-Level Laser Therapy on the Oxidative Stress Level and Quality of Life in Patients with Hashimoto’s Thyroiditis. Free Radical Research. 2024;58(4):249–260.

[27] Lee TL, Ding Z, Chan AS. Can Transcranial Photobiomodulation Improve Cognitive Function? A Systematic Review of Human Studies. Ageing Research Reviews. 2023.

[28] Cho Y, Tural U, Iosifescu DV. Efficacy of Transcranial Photobiomodulation on Depressive Symptoms: A Meta-Analysis. Photobiomodulation, Photomedicine, and Laser Surgery. 2023;41(9):460–466.

[29] Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of Low-Level Laser Therapy in the Management of Neck Pain: A Systematic Review and Meta-Analysis of Randomised Placebo or Active-Treatment Controlled Trials. The Lancet. 2009.

[30] Huang ZY, et al. The Effectiveness of Low-Level Laser Therapy for Nonspecific Chronic Low Back Pain: A Systematic Review and Meta-Analysis. 2015.

Since then, the most legitimate new development in this space in years posted a late-phase readout, so I’m updating. Part of the job here is to revise when the evidence does, and this one earns the attention: VDPHL-01, an extended-release oral minoxidil that could become the first FDA-approved oral pill for pattern hair loss in nearly 30 years. Here’s what the data actually shows, and what it doesn’t.

VDPHL-01: What the New Data Shows

The claim: VDPHL-01, a new extended-release oral minoxidil, may produce stronger hair growth than standard oral minoxidil while lowering the cardiac risk that comes with the immediate-release version.

The evidence: this isn’t a new anti-androgen or a new pathway; it’s minoxidil, a drug that already grows hair, delivered differently. Veradermics built it as an extended-release formulation with a gel-matrix system meant to hold drug levels above the threshold that stimulates hair growth while avoiding the sharp peak plasma concentrations that drive minoxidil’s cardiovascular effects. [1] That design is the whole pitch: same proven drug, engineered pharmacokinetics. The readout that put it on the map is Study ‘302,’ announced in April 2026. It was Part A of a randomized, double-blind, placebo-controlled Phase 2/3 trial in 519 men aged 18 to 65 with mild-to-moderate androgenetic alopecia, randomized to VDPHL-01 8.5 mg once daily, 8.5 mg twice daily, or placebo, with co-primary endpoints of change in non-vellus target-area hair count by digital image analysis and a patient-reported “improved” or “much improved” rating on the Androgenetic Alopecia Impact Rating Scale, both at month 6. [2] The objective endpoint is the one to anchor on, and it was strong: hair count rose 30.3 hairs/cm² in the once-daily arm and 33.0 in the twice-daily arm, versus 7.3 for placebo, all at p<0.0001, with separation reported as early as month 2. [2] The patient-reported numbers were also high, 79.3% and 86.0% reporting improved coverage versus 35.6% on placebo, and those are better read as supportive than as definitive, because minoxidil causes body-hair growth that makes a hair-loss trial hard to keep fully blinded, and the softer the endpoint, the more expectancy can move it. On safety, the company reported a profile consistent with its Phase 2 data, with discontinuation rates lower than placebo and adverse-event-related discontinuation similar between drug and placebo; Veradermics also reported no cardiac adverse events of special interest through six months, which is the company’s own topline summary and worth confirming against the full release. [2] A second pivotal Phase 3 in men finished enrolling in early 2026, bringing the two Phase 3 trials to more than 1,000 participants combined, and if the program holds up, Veradermics is positioning VDPHL-01 as the first FDA-approved oral pill for pattern hair loss in nearly 30 years. [3]

The limits: this is a strong signal that hasn’t finished proving itself, and several things keep it short of settled practice. It’s topline, company-reported data, not a full peer-reviewed publication, so the complete adverse-event tables, pharmacokinetics, subgroup breakdowns, and dropout details aren’t public yet, and the safety statement above is the company’s own summary of its own data. The trial compared VDPHL-01 with placebo, not with topical minoxidil, immediate-release oral minoxidil, finasteride, or combination therapy, so it proves superiority to placebo, which isn’t the same as superiority to anything men already use; and the reminder there is that a 2024 randomized trial found ordinary oral minoxidil 5 mg no better than topical 5% over 24 weeks, so “oral and easier” shouldn’t slide into “oral and better.” [4] The dose deserves attention: 8.5 mg once daily, and 17 mg a day in the twice-daily arm, sits well above the 1.25 to 5 mg most men take off-label, and while peak concentration rather than total dose is what drives minoxidil’s cardiac risk, which is exactly what the extended-release design is meant to blunt, the serious problems like pericardial effusion track with higher doses, so the full pharmacokinetic and cardiac data aren’t a formality. [5] Six months is enough to show an early growth signal and not enough for a condition men manage for decades, the trial studied selected men with mild-to-moderate loss rather than older men with cardiac disease or women with female-pattern loss, and the drug isn’t FDA-approved. For the broader backdrop, a 2025 single-arm meta-analysis of 2,933 patients across 27 oral minoxidil studies found meaningful benefit alongside a pooled adverse-event rate around 27%, which is the kind of large-scale evidence oral minoxidil has mostly lacked and which VDPHL-01 is trying to generate properly. [6]

Evidence grade: B, provisional. The trial design is genuinely strong, randomized, double-blind, placebo-controlled, over 500 men, with an objective hair-count endpoint at p<0.0001, which is better than most of the oral minoxidil literature. It’s held below that by the fact that the data are topline rather than published, placebo-controlled rather than head-to-head, six months long, and not yet confirmed by the second Phase 3 or cleared by the FDA. If it publishes in full and the second trial holds, it moves up.

VDPHL-01 is probably the most legitimate new hair-loss drug in years, and it’s still investigational, not proven standard of care. The efficacy signal is strong and the early safety signal is reassuring, and the data we can actually interrogate is topline, six-month, company-reported, and placebo-controlled, so it doesn’t change today’s recommendations. It’s the right thing to watch closely, and not yet the thing to switch anyone to.

What This Does and Doesn’t Change

For now, nothing about the recommendations in the original piece. VDPHL-01 isn’t FDA-approved, the data we have is topline and six months long, and it was tested against placebo rather than against the topical minoxidil, finasteride, or dutasteride that men already use. So it doesn’t replace the framework: address DHT for androgen-driven miniaturization, use minoxidil for growth stimulation, and consider procedural options when medical therapy isn’t enough.

What it does change is what’s on the horizon. This is the first oral minoxidil formulation built specifically for hair loss, with the first large randomized, placebo-controlled efficacy and safety data in the category, and the signal is strong. If the full manuscript publishes and the second Phase 3 confirms, it could become a genuinely useful option, and I’ll update again when that happens. For now, watch it closely, and don’t switch anyone to it yet.

Here is the original SITREP with updates:

This article is for education only and is not personal medical advice. It does not create a physician-patient relationship. Medical decisions should be made with a qualified clinician who knows your history, labs, medications, risk factors, and goals.

References

1. Veradermics. VDPHL-01: non-hormonal oral therapeutic for hair regrowth (formulation and mechanism). veradermics.com.

2. Veradermics. Oral VDPHL-01 achieved early, consistent, and robust hair growth in positive Phase 2/3 ‘302’ clinical trial in male pattern hair loss. News release. April 27, 2026.

3. Veradermics. Veradermics completes enrollment in second pivotal Phase 3 clinical trial of VDPHL-01 for male pattern hair loss. News release. February 2026.

4. Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(6):600–605. doi:10.1001/jamadermatol.2024.0284.

5. Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations. Front Pharmacol. 2025;16:1718208.

6. Liu C, Liu X, Shi T, et al. Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review. Front Pharmacol. 2025;16:1556705.

A reader asked me about a commercial imaging company, one whose name starts with P, that sells direct-to-consumer whole-body MRI as a proactive longevity and early-detection strategy. He wanted to know whether he should go get his whole body scanned. I’m not going to name the company, because the problem isn’t one business, it’s the whole premise. My answer is no, and I want to be direct about why, and fair about it, because the marketing makes a genuine argument and deserves a direct answer.

Let me define the question precisely, because the marketing depends on blurring it. This isn’t about whether MRI is a good test. It’s an excellent test when it’s aimed at a real clinical problem: staging a known cancer, working up neurologic symptoms, characterizing a liver lesion, screening someone with a hereditary cancer syndrome. That’s not the person being sold a scan. The person being sold a scan is a healthy adult with no symptoms, no family cancer syndrome, and no reason for the test other than the belief that more imaging equals better prevention. The real question is narrow and answerable: does scanning asymptomatic, average-risk adults with whole-body MRI actually reduce late-stage cancer, cancer death, or all-cause death, at an acceptable cost in false alarms, biopsies, and harm?

There’s no evidence that it does, and there’s a growing body of evidence describing the harm it causes along the way.

A scan finding something is not the same as a scan helping you. Whole-body MRI is very good at detecting abnormalities in healthy people. What it has never been shown to do is make those people live longer or better. Those are two different claims, and the entire industry is built on treating the first as if it were the second.

The Case for It, Stated Fairly

Let me make the strongest case for whole-body MRI before I turn to the evidence against it, because it should get an honest hearing. Unlike a CT scan, MRI uses no ionizing radiation, so the scan itself carries essentially no direct physical risk. It occasionally finds real, early, curable cancers, and it can find them in organs that have no routine screening test at all, since there’s no standard screening for kidney, ovarian, or pancreatic cancer in an average-risk person. It sometimes turns up other things that matter, like an unsuspected aneurysm. And the underlying intuition, that catching disease earlier ought to beat catching it later, is one every physician shares; it’s the basis of the screening programs we already recommend. If whole-body MRI reliably delivered that in healthy people, I’d send patients for it. Whether it does is an evidence question, not a matter of opinion, so let’s look at the evidence.

What the Scan Actually Finds

The relevant studies are detection-yield studies. They tell you what the scan finds. They don’t tell you whether finding it helped anyone, and that distinction is the entire question.

Start with the most-cited review. In 2020, Zugni and colleagues pooled 12 studies covering 6,214 whole-body MRI screening exams in asymptomatic people. Only about 5% of subjects had a clean scan. The other 95% had at least one abnormal finding. Findings that needed further investigation showed up in 30% of subjects, cancer was suspected in just 1.8%, and the rate of histologically confirmed cancer was 1.1%.¹ The newer evidence says the same thing with more people behind it. A 2025 meta-analysis in European Radiology pooled 10 studies and 9,024 asymptomatic individuals: the confirmed cancer detection rate was 1.57%, the biopsy rate ran from 2% all the way to 22% across studies, and there were no survival outcomes and no cost-effectiveness data anywhere in the literature.² A 2026 family-medicine evidence summary landed in the same place: roughly 94% of asymptomatic people scanned have a radiologic abnormality, up to 30% need further workup, about 1.6% end up with a confirmed cancer, and no mortality data and no randomized trials exist comparing whole-body MRI screening against not screening.³

Abnormal findings are the rule. Confirmed cancer is the exception. Across thousands of scanned healthy people, roughly 19 out of 20 walk away with an abnormality on the report, while only about 1 in 100 has a cancer that pathology confirms. The scan reliably produces findings; it rarely produces the diagnosis it’s sold to produce.

The marketing reads that as “the scan catches early cancers.” The accurate reading is that the scan catches a large volume of abnormalities, the overwhelming majority of which are not cancer, in order to confirm cancer in a small minority of the people scanned. That isn’t proof of benefit; it’s a description of a test that finds a great deal of biological noise. And it leaves the single most important fact standing untouched.

Not one study has ever shown that scanning a healthy person saves a life. There’s no randomized trial, and there’s no mortality data of any kind, comparing whole-body MRI screening against no screening.²ˑ³ Every promise that this catches cancer “in time” is running ahead of evidence that does not exist.

Why an Abnormal Finding Isn’t a Harmless Piece of Information

The most common misconception here is that if the scan finds something and it turns out benign, no harm was done. That’s wrong, and it’s the heart of the issue.

An abnormal MRI finding isn’t just data; it’s an obligation. Once a lesion is on the report, a doctor and patient usually can’t simply ignore it unless the imaging can call it clearly benign. When the appearance is indeterminate, and in this setting it very often is, the next steps are more imaging, a specialist referral, a period of surveillance, or a biopsy. That chain has a name, and it’s a well-described phenomenon in the medical literature, not a rhetorical device: the diagnostic cascade, a sequence set off by an unnecessary test or an unexpected finding that proceeds, almost inevitably, step by step, to further tests and treatments that can cause avoidable harm.⁴ In a national physician survey, nearly every doctor reported having seen these cascades follow an incidental finding, and they reported real consequences: patient anxiety, wasted resources, and physical harm.⁵

Picture how it plays out. A healthy man who feels fine pays for a whole-body scan, and it turns up an indeterminate spot on a kidney, something that never would have been found otherwise. It’s probably a benign cyst, but the imaging can’t say so with certainty, so he’s sent for more imaging, then to a urologist, and possibly for a needle biopsy. A kidney biopsy is reasonably safe when it’s genuinely indicated, but it’s still an invasive procedure that carries a risk of bleeding, hematoma, pain, infection, and a result that still isn’t diagnostic,⁶ and serious bleeding can rarely need a transfusion or a procedure to repair the vessel.⁷ Weeks later, the lesion turns out benign. He’s relieved, but he hasn’t been helped. He’s been run through a cascade that existed only because someone went looking for disease in a body that had no sign of it.

The same logic applies to liver lesions, adrenal nodules, thyroid nodules, pancreatic cysts, ovarian cysts, bone lesions, lymph nodes, lung findings, spine findings, and brain lesions. Most are benign, some need surveillance, some are indeterminate, and some trigger an invasive procedure or years of follow-up scans. The point isn’t that every one of those workups is wrong; it’s that broad screening in low-risk people manufactures abnormalities far faster than it produces any proven benefit, and each abnormality carries its own cost and risk.

The size of the false-alarm problem is measurable. A large BMJ systematic review by Gibson and colleagues looked at incidental findings across brain and body MRI in apparently asymptomatic adults and found potentially serious incidental findings in a meaningful minority of people. Here’s the part the marketing never mentions: of the potentially serious findings that had follow-up data, only about one in five (48 of 234, roughly 20%) turned out to have a serious final diagnosis.⁸ The other four in five were false alarms that still had to be chased down with more tests, more referrals, and more worry. A separate systematic review of whole-body MRI for preventive screening found a pooled false-positive proportion of 16%, and noted that not a single included study had verified its negative scans with more than five years of follow-up.⁹ The worry itself is a measurable harm: a 2024 study in the Journal of Magnetic Resonance Imaging documented the psychological consequences of abnormal findings from screening whole-body MRI in asymptomatic people, with the emotional impact tracking the content of the report.¹⁰

The harm isn’t radiation. It’s the cascade. People assume whole-body MRI is consequence-free because it doesn’t use X-rays. But the danger here was never radiation. It’s that the scan creates findings, findings create obligations, obligations create downstream testing, and downstream testing carries real bleeding, infection, cost, and anxiety, most of it spent ruling out disease that was never there.

The Incidentaloma Problem

The proper term for most of what these scans turn up is incidentaloma: an unexpected abnormality found while looking for something else. Incidentalomas are common because human bodies are full of benign cysts, nodules, anatomic variants, and degenerative changes, and they get more common with age.

The math makes a high abnormal-finding rate almost unavoidable. Deyo noted that with an ordinary panel of just 12 laboratory tests, there’s about a 46% chance that at least one result comes back abnormal in a completely healthy person, purely by statistical chance.⁴ A whole-body MRI interrogates far more than 12 things across the entire body. Scanning that much anatomy in someone with a low probability of disease doesn’t occasionally generate a false alarm; it’s mathematically built to generate them. The 95% abnormal-finding rate isn’t a surprise; it’s the expected output of the test.

Low-risk screening is the worst possible setting for this. In a patient with symptoms, the pretest probability of disease is higher and the imaging is aimed at a specific question. In an asymptomatic person, the odds of hidden life-threatening disease are low and the scan covers an enormous amount of anatomy. That combination is an engine for false positives and indeterminate findings, and the published data show exactly that pattern: abnormalities in nearly everyone, further workup in a third, and confirmed cancer in about 1%.¹ The problem was never that the scan finds nothing; it’s that it finds too much, and most of what it finds is not the disease you were trying to avoid.

Finding a Cancer Isn’t the Same as Changing Your Outcome

A screening test earns its keep through outcomes, not detection. Early detection only helps if catching the disease early actually changes what happens to the patient, and that means evidence that screening lowers advanced disease, cancer death, or overall death without doing more harm than good. Whole-body MRI has never shown that in average-risk, asymptomatic adults, and there are several concrete reasons detection can fail to translate into benefit.

Some cancers the scan finds are indolent or overdiagnosed. Overdiagnosis means diagnosing a condition that would never have caused symptoms or harm in the person’s lifetime, and it’s harmful precisely because it leads to stress and treatment the person never needed.¹¹ Aggressive cancers cut the other way; they can arise and progress in the gap between scans, or show up poorly on a broad-field protocol, so they aren’t caught early enough to change anything. Other cancers simply aren’t well screened by whole-body MRI at all, which is why even the companies selling these scans concede they don’t replace colonoscopy, dedicated breast imaging, cervical screening, or low-dose CT for lung cancer in high-risk patients. And in some cases the scan leads to treatment of a lesion that would never have hurt the patient, turning a healthy person into a patient for no gain.

It Also Gives False Reassurance

There’s a second, opposite harm. A person buys a whole-body MRI, gets a largely negative result, and walks away believing they’ve been comprehensively checked for cancer, when they haven’t been.

A negative whole-body MRI doesn’t replace the screening tests that actually have outcome evidence behind them: colonoscopy, which finds and removes precancerous polyps before they ever become cancer; mammography or dedicated breast imaging; cervical cancer screening; a skin exam; and low-dose CT when lung cancer screening is indicated. And it doesn’t reliably rule out small mucosal lesions, early gastrointestinal cancers, or many pulmonary and breast lesions.

The mammography point is worth spelling out, since the obvious objection is that MRI is the better machine. A dedicated breast MRI is in fact more sensitive than mammography, but the whole-body survey scan isn’t a breast MRI; it uses no breast-specific, contrast-enhanced protocol, and in the company’s own study it missed two breast cancers. Even a true breast MRI is recommended alongside mammography rather than instead of it, and isn’t recommended for average-risk women at all, so a negative whole-body scan is no substitute for a mammogram.

The same scan can hurt you in two opposite directions at once. It can raise a false alarm over a benign incidental finding, and it can hand you false reassurance about the cancers it can’t reliably detect. A man can walk out both over-worked-up and under-screened from a single test.

The Company’s Own Study, Read Carefully

To its credit, the company selling this scan has tried to close the evidence gap with its own data, and that data deserves to be taken seriously rather than waved off. In its largest real-world study, it followed just over 1,000 mostly asymptomatic patients and reported biopsy-confirmed cancer in about 2.2%, including kidney, bladder, and ovarian cancers, many caught early.¹² That’s the strongest number the industry has produced. Here’s what it does and doesn’t show.

A 2.2% detection rate isn’t an outlier that overturns the skeptical literature; it sits directly on top of it. The independent reviews already put confirmed cancer detection at 1.1% to 1.6%.¹ˑ²ˑ³ The headline figure essentially reproduces the number the critics have cited all along. It confirms the detection yield; it doesn’t establish that the yield helps anyone.

Roughly half of the biopsies the scan prompted came back positive.¹² Read that the other way, because the other way is the harm: about half of the people sent for an invasive biopsy on the strength of the scan did not have cancer. A positive rate near 50% for a biopsy triggered by a screening test means every cancer detected came at the cost of roughly one healthy person undergoing an unnecessary invasive procedure.

The decisive problem is that the study has no survival data and no comparison group. It reports what the scan found, not whether the people scanned lived longer or better than comparable people who weren’t. The results were presented at a conference rather than published as peer-reviewed patient outcomes, and the study was run by the company that sells the scan. Detecting a cancer earlier isn’t the same as extending a life; a cancer found earlier can simply be known about for longer with no change in the outcome (lead-time bias), or it can be an indolent cancer that never would have caused harm but now gets treated anyway (overdiagnosis). The company’s own chief executive has conceded the point, acknowledging that gathering the data to prove a survival benefit would probably take decades.¹³ That’s an admission that the benefit being sold is, as of today, unproven.

The published limitations on the company’s own website cut the other way as well, against the comprehensive-screening impression the marketing creates. They state that the scan is an adjunct to, and not a replacement for, established screening like colonoscopy and mammography; that it generally can’t identify a cancer until the lesion reaches about a centimeter; and that it may miss lesions in the mucosal lining of the mouth, throat, and gastrointestinal tract.¹⁴ In that same study, two breast cancers were missed by the whole-body scan.¹³ The test can hand a healthy person false reassurance about exactly the cancers standard screening is built to catch.

One more number does heavy lifting in the marketing: the claim that only about 14% of cancers are caught by standard screening, with the implication that whole-body MRI should fill the gap.¹³ That number doesn’t say what it’s implied to say. Many cancers that standard screening misses are missed because no effective screening test exists for them, or because they’re aggressive enough that earlier detection doesn’t change the outcome. Finding more of them on a scan helps only if finding them earlier actually alters survival, which is the precise link the evidence hasn’t established. A larger detection rate isn’t a benefit; it’s a larger detection rate.

The best evidence the company has produced confirms the criticism rather than answering it. Its own study reproduces the detection rate the skeptics already cited, shows that half the biopsies it triggered found no cancer, and contains no survival data at all, while its own chief executive concedes that proving a survival benefit would take decades. That’s not a rebuttal of the evidence gap; it’s a description of it.

Every Major Body That Has Looked at This Says the Same Thing

This isn’t my idiosyncratic opinion. The professional consensus is close to unanimous.

The American College of Radiology states plainly that there isn’t sufficient evidence to recommend total-body MRI screening for people with no symptoms, no risk factors, and no relevant family history, that there’s no documented evidence it’s cost-efficient or prolongs life, and that these scans tend to turn up numerous nonspecific findings that don’t improve health but do drive unnecessary follow-up testing, procedures, and expense.¹⁵ The Canadian Association of Radiologists issued a 2025 policy statement recommending against whole-body MRI screening in asymptomatic individuals.¹⁶ The Choosing Wisely campaign, through the American Academy of Family Physicians, lists it directly: don’t use whole-body scans for early tumor detection in asymptomatic patients.¹⁷ And the authors of the largest preventive-screening systematic review concluded that, on current evidence, providers should not offer whole-body MRI for preventive health screening.⁹ Meanwhile, academic cancer centers are increasingly fielding referrals from healthy people who paid out of pocket for a commercial scan and now need someone to work up the incidental findings it produced.¹⁸

When the radiologists themselves, the people who read these scans for a living, tell you not to buy one, that’s worth hearing. The consensus against screening whole-body MRI in healthy adults isn’t coming from cost-cutters or skeptics of imaging. It’s coming from the specialty that performs it.

Why the Evidence Base Is Weak Where It Counts

For the question that actually matters, whether screening healthy people saves lives, the evidence supporting commercial whole-body MRI is low quality. The studies answer a technical question, “what does the scan find,” and not the clinical one, “do the people who get scanned live longer or better.” The recurring problems are consistent across the literature.

There are no randomized trials showing that average-risk, asymptomatic adults assigned to whole-body MRI have lower cancer death or lower all-cause death than similar adults getting standard care.²ˑ³ The reported outcomes are detection counts, suspected cancers, confirmed cancers, false positives, and follow-up rates, none of which are the same as survival, quality of life, or reduced late-stage disease. The incidental-finding burden is high, with abnormalities in most people scanned and confirmed cancer in a small fraction.¹ False positives pooled to 16%.⁹ The people scanned are self-selected, able to afford elective imaging, and not representative of the general population. Protocols vary wildly across studies in coverage, sequences, contrast, and reading thresholds, so the studies aren’t even measuring the same thing. There’s no established cost-effectiveness.¹⁵ And the follow-up is too short to confirm that negative scans were truly negative or that any cancers caught actually changed an outcome rather than triggering harm.

Bottom Line

Commercial whole-body MRI is best understood as a detection product, not as proven preventive medicine. The technology and the images are real, and so are some of the cancers it finds. A small number of individual people may genuinely benefit. But the population-level claim, that scanning healthy people saves lives, has never been proven, and the evidence that does exist describes a high rate of abnormal findings, a heavy follow-up and biopsy burden, and a low confirmed-cancer yield, with no demonstrated reduction in cancer death or all-cause death.

None of this means the technology is worthless, or that it will always lack support. It means that on the evidence that exists today, the claim being sold to healthy people hasn’t been earned. If the ongoing studies eventually produce controlled, long-term data showing that screening healthy people with whole-body MRI actually lowers cancer death, that would change the calculation, and I’d change my answer with it. That evidence doesn’t exist yet, and until it does, the honest description is that this is a detection product being marketed as proven prevention.

So when the reader asks whether he should go get his whole body scanned, my answer is no. Not because the scan can’t find anything, but because for a healthy person the most likely result isn’t a life-saving diagnosis. It’s a benign or indeterminate finding that now has to be managed, at real cost and real risk, to rule out a disease he never had reason to think he had.

If you scan hard enough, you will find something. The trouble is that most of what you find won’t be the cancer you were trying to prevent, and it can still pull you into more imaging, surveillance, biopsy, cost, and months of anxiety. That’s why whole-body MRI shouldn’t be sold to healthy people as established prevention. It hasn’t earned that claim.

References

1. Zugni F, Padhani AR, Koh DM, Summers PE, Bellomi M, Petralia G. Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. Cancer Imaging. 2020;20:34. doi:10.1186/s40644-020-00315-0.

2. Martins da Fonseca J, Trennepohl T, Pinheiro LG, et al. Whole-body MRI for opportunistic cancer detection in asymptomatic individuals: a systematic review and meta-analysis. Eur Radiol. 2025. doi:10.1007/s00330-025-11976-5.

3. Tools for Practice #410. Whole-body MRI for cancer screening: many findings, little benefit. College of Family Physicians of Canada (CFPCLearn). 2026.

4. Deyo RA. Cascade effects of medical technology. Annu Rev Public Health. 2002;23:23–44. doi:10.1146/annurev.publhealth.23.092101.134534.

5. Ganguli I, Simpkin AL, Lupo C, et al. Cascades of care after incidental findings in a US national survey of physicians. JAMA Netw Open. 2019;2(10):e1913325. doi:10.1001/jamanetworkopen.2019.13325.

6. RadiologyInfo.org (RSNA/ACR). Kidney (renal) biopsy.

7. National Kidney Foundation. Kidney biopsy: procedure, side effects, recovery.

8. Gibson LM, Paul L, Chappell FM, Macleod M, Whiteley WN, Al-Shahi Salman R, Wardlaw JM, Sudlow CLM. Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis. BMJ. 2018;363:k4577. doi:10.1136/bmj.k4577.

9. Kwee RM, Kwee TC. Whole-body MRI for preventive health screening: a systematic review of the literature. J Magn Reson Imaging. 2019;50(5):1489–1503. doi:10.1002/jmri.26736.

10. Conti L, Mazzoni D, Marzorati C, et al. Observations regarding the detection of abnormal findings following a cancer screening whole-body MRI in asymptomatic subjects: the psychological consequences and the role of personality traits over time. J Magn Reson Imaging. 2024. doi:10.1002/jmri.29461.

11. InformedHealth.org, Institute for Quality and Efficiency in Health Care (NCBI Bookshelf). In brief: what is overdiagnosis?

12. Real-world whole-body MRI screening study (Polaris): early results in ~1,011 mostly asymptomatic patients, ~2.2% biopsy-confirmed cancer, ~50% positive biopsy rate; presented at the American Association for Cancer Research annual meeting, April 2025 (reported in Radiology Business and Applied Radiology, May 2025).

13. Reporting on commercial whole-body MRI screening, including the provider’s study results, missed breast-cancer cases, the chief executive’s statement on survival evidence, and the standard-screening statistic. Axios. July 24, 2025.

14. Commercial provider, whole-body MRI product and scan-limitations pages. Accessed 2026.

15. American College of Radiology. ACR statement on screening total-body MRI. 2023.

16. Canadian Association of Radiologists. Whole-body MRI screening in asymptomatic individuals: policy statement. 2025.

17. Choosing Wisely, American Academy of Family Physicians. Don’t use whole-body scans for early tumor detection in asymptomatic patients.

18. Dontchos BN, Dighe M. Whole-body MRI and cancer screening: why we don’t recommend full-body MRIs for healthy people without symptoms. Fred Hutch / UW Medicine. 2025.

Update — July 2026. Since this first published, positive late-phase topline data emerged for VDPHL-01, an extended-release oral minoxidil that could become the first FDA-approved oral pill for pattern hair loss in nearly 30 years. I’ve added a new section on it below, marked as an update and placed right after the existing oral minoxidil section, and I’ve covered it in more depth in a companion post: [link to the companion update]. The rest of the piece is unchanged from original publication. The field moves, and part of the job here is to update the record when the evidence does.

Hair loss in men is common, visible, emotional, and heavily marketed, and that combination makes it easy to sell products that don’t work. A man notices his temples receding or his crown thinning, and he’s quickly marketed shampoos, gummies, serums, peptides, oils, lasers, stem cells, exosomes, and “natural DHT blockers.”

The deeper problem is that most men don’t actually know what they’re trying to do. Stopping further loss, regrowing hair that’s already miniaturized, moving hair surgically, and making existing hair look thicker are four different goals, and regrowing follicles that are already dead is a fifth that mostly isn’t on the table. Hair-loss marketing blurs these together on purpose. A product that makes hair look thicker for six hours isn’t doing what a medication that slows androgen-driven miniaturization does; a supplement that corrects a real deficiency isn’t treating male-pattern hair loss; and a transplant can change the look of a hairline without touching the biology that caused the loss.

Most evidence-based treatment for male-pattern hair loss isn’t about regrowing follicles that are already dead; it’s about preserving miniaturizing follicles while they’re still alive, improving hair caliber where it’s possible, and turning to transplant surgery when medication can no longer recover density.

That’s the frame for the whole discussion.

First, What Kind of Hair Loss Are We Talking About?

This is mainly about androgenetic alopecia, the common inherited male-pattern hair loss. It usually shows up as recession at the temples, frontal thinning, crown thinning, or some mix of those, and it’s driven by genetics, androgen signaling, and how sensitive a man’s follicles are to dihydrotestosterone, or DHT.

DHT doesn’t simply make hair “fall out”; that oversimplifies what actually happens. In genetically susceptible follicles it drives miniaturization, where thick terminal hairs are gradually replaced by thinner, shorter, less pigmented ones, until the follicle produces hair so small the area looks bald. That’s why timing matters. A thinning crown still holds miniaturizing follicles that can respond; a slick bald scalp may hold follicles that are too far gone.

Thinning hair is treatable. A completely bald scalp is much less so. That doesn’t make advanced loss hopeless, but it does mean expectations have to be realistic.

Make Sure It’s Actually Male-Pattern Hair Loss

Not every man who’s shedding has androgenetic alopecia. Hair can fall out from illness, surgery, major stress, rapid weight loss, severe caloric restriction, medications, thyroid disease, iron deficiency, inflammatory or autoimmune scalp disease, fungal infection, traction, or scarring alopecia. Classic male-pattern loss is slow, patterned, and progressive, so sudden shedding, patchy loss, pain, scale, scarring, redness, pustules, rapid diffuse loss, or systemic symptoms should push the workup in a different direction.

The history and the scalp exam carry most of the weight here: when it started, whether it’s diffuse or patterned, whether there’s family history, whether there was a recent illness or stressor or medication or diet change, whether there’s itching or pain or scaling or scarring, whether the man is using testosterone or anabolic steroids, and whether there’s visible miniaturization. Labs aren’t mandatory for every classic case, but when the story points elsewhere, labs and a dermatology evaluation are worth getting.

The first rule isn’t “start a supplement”; it’s making sure you’re treating the right diagnosis.

How I’m Judging the Evidence

I’m not going to call a treatment effective because one study, one meta-analysis, one clinic website, or one influencer says so. For each one, the questions are the same: How good were the studies, were they randomized and blinded, was there a placebo or sham or active comparator, how many people, how long, and was the endpoint objective like hair count and density or soft like satisfaction and photographs? Did it actually regrow hair or just slow the loss, was the result cosmetically meaningful or only statistically significant, was it tested alone or only stacked with something else, was the benefit durable, and what did the study fail to prove?

This matters because hair-loss studies are easy to overread. A small trial can show a statistically significant bump in hair count without any visible change in the mirror; a combination study can make a weak adjunct look strong; a shampoo can calm scalp inflammation without touching miniaturization; a supplement can fix a deficiency without helping male-pattern loss; and a transplant can change appearance without changing the disease.

The real question isn’t whether there’s evidence; it’s whether the evidence is strong enough to justify the claim being made.

The SITREP evidence scale, same as my other reviews, with the grade attached to the specific claim rather than the compound:

Grade A. Multiple well-designed randomized controlled trials, long-term data, strong systematic-review evidence, or established standard-of-care with meaningful human outcomes.

Grade B. One or more randomized trials or strong review evidence, limited by sample size, duration, blinding, population, protocol variability, or lack of long-term replication.

Grade C. Smaller trials, observational studies, inconsistent protocols, or useful but less definitive evidence.

Grade D. Mechanistic rationale, weak clinical evidence, or cosmetic-only benefit; biologically plausible but not proven.

Grade E. No meaningful evidence for the claim, or claims that clearly outrun the evidence.

One point worth holding onto: a B isn’t bad evidence. It can mean a real clinical signal that deserves serious use or serious study. Whether something is “ready for prime time” depends on the claim, and for hair loss the endpoints aren’t interchangeable. A treatment can work by slowing loss, stabilizing miniaturization, raising hair count, raising density, thickening individual hairs, or improving global photos, and a man can have a treatment that’s genuinely working without ever growing back a teenage hairline.

The rest of this is organized around three blunt questions: Can we stop the loss? Can we regrow anything? And what’s mostly bullshit?

Question 1: Can We Stop the Loss?

Yes, sometimes, and the best-supported move is to intervene while follicles are still miniaturizing rather than gone. The core biology is androgen-driven miniaturization in genetically susceptible scalp. That doesn’t mean every man has to take a DHT blocker, but the honest discussion has to include it. The two main DHT-directed drugs are finasteride and dutasteride.

If a plan never addresses DHT, it isn’t really addressing the disease.

Finasteride

The claim: finasteride slows progression and can increase hair growth in men with androgenetic alopecia.

The evidence: it’s one of the best-studied medical treatments for male-pattern loss. The original randomized trials showed that 1 mg daily slowed loss and increased growth over two years, and five-year multinational data showed durable improvement in scalp hair while placebo-treated men kept losing ground. [1,2] The FDA-approved Propecia label adds the regulatory framing: oral finasteride 1 mg is approved for male-pattern loss, daily use for at least three months is generally needed before benefit shows, continued use is needed to maintain it, and efficacy at the bitemporal recession hasn’t been established. That last point matters, because the temples and frontal hairline are exactly what many men care most about, while the strongest classic evidence is vertex and mid-scalp.

The limits: response varies, the benefit depends on staying on it, and stopping usually means losing the maintained gain over time. The better-supported claim isn’t that finasteride restores a juvenile hairline; it’s that it slows progression and maintains or increases growth in many men while follicles are still alive. It doesn’t prove cosmetically obvious regrowth for everyone, it does nothing once follicles are gone, and it carries a real side-effect discussion that shouldn’t be waved off in either direction.

On that discussion: the debate is polarized between people who treat finasteride as harmless and people who treat a single tablet as causing permanent harm, and neither framing helps. Reported adverse effects include decreased libido, erectile dysfunction, ejaculatory changes, breast tenderness or gynecomastia, mood symptoms, and effects on semen parameters in some men, with the frequency and persistence of certain symptoms genuinely debated, especially around what’s called post-finasteride syndrome. Regulators have taken the mood signal seriously; the European Medicines Agency reviewed finasteride and dutasteride and confirmed suicidal ideation as a side effect of finasteride tablets while still judging that benefits outweigh risks for approved uses with risk-minimization measures. Sexual, mood, and fertility concerns are real and deserve a genuine conversation, and the existence of side effects doesn’t make the drug useless or categorically unsafe.

Evidence grade: A/B. Randomized trials, long-term data, FDA approval, objective endpoints, and decades of use put it near the top. I wouldn’t call every claim Grade A, because “regrowth” varies by region and cosmetic response, but for slowing loss and maintaining or increasing growth in the right men, the evidence is strong.

Finasteride is one of the few male hair-loss treatments with strong clinical evidence. It’s best understood as a progression-slowing, maintenance drug that increases growth in many men while follicles are still alive, not a hairline-restoration pill, and it deserves a real side-effect discussion.

Topical Finasteride

The claim: topical finasteride may improve hair count with less systemic exposure than the oral version.

The evidence: this category matters because it’s marketed everywhere as a safer, more “local” alternative. There’s legitimate evidence for specific studied formulations; a phase III randomized trial found that a topical finasteride spray improved hair count versus placebo with lower systemic exposure than oral finasteride. The catch is that this applies to the studied formulation and dose, not to every compounded product sold online. And in April 2025 the FDA alerted providers and consumers about compounded topical finasteride: there’s no FDA-approved topical product, compounded versions haven’t been reviewed for safety, effectiveness, or quality, and the agency had received reports of adverse events. Crucially, absorption through the skin into the bloodstream is expected, and the reported events, including erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido, and testicular pain, mirror oral finasteride. [3]

The limits: formulation, dose, vehicle, and application area all change the picture, systemic absorption still happens, and the long-term comparative data are less mature than for oral finasteride. None of this makes topical finasteride risk-free or proves zero absorption, and “topical” doesn’t mean a man can ignore the same sexual, mood, fertility, and pregnancy-exposure concerns. The compounded market is not equivalent to a standardized, reviewed product.

Evidence grade: B for studied formulations, C for the compounded market as a whole.

Topical finasteride has real evidence for improving hair count in the formulations that were actually studied, but topical doesn’t mean risk-free, and a compounded mixture from a telehealth platform shouldn’t be treated as if it cleared FDA review.

Dutasteride

The claim: dutasteride is often more effective than finasteride for male androgenetic alopecia.

The evidence: dutasteride blocks both type I and type II 5-alpha reductase while finasteride mainly hits type II, so it suppresses DHT more deeply. Comparative studies and reviews suggest that dutasteride 0.5 mg daily increases hair counts more than finasteride 1 mg daily, with a 2024 comparative review finding dutasteride 0.5 mg and 2.5 mg significantly more effective than finasteride 1 mg, and an evaluator-blinded randomized study supporting its superiority for regrowth and reversal of miniaturization. [4,5] More recent randomized work is also testing non-daily dutasteride against finasteride, including a 2025 trial comparing twice- or thrice-weekly dutasteride 0.5 mg with daily finasteride over 24 weeks. [6] None of this is biologically surprising, since deeper DHT suppression should do more.

The limits: in the US, dutasteride is FDA-approved for benign prostatic hyperplasia, not for hair loss, so hair-loss dosing is off-label and its hair-specific long-term dataset isn’t finasteride’s. It has a long half-life, and deeper DHT suppression makes the side-effect conversation more important rather than less. Stronger isn’t automatically the right first choice for every man, more suppression isn’t always better clinically, and it doesn’t remove the need for sexual, mood, fertility, gynecomastia, PSA, and long-half-life counseling.

Evidence grade: A/B for efficacy. Strong comparative efficacy, held back from a clean A by US regulatory status and the weight of patient selection and long-term safety discussion.

Dutasteride is more potent and often more effective than finasteride for hair-count outcomes, but stronger isn’t automatically better. Treat it as a stronger DHT intervention that should come with a more careful risk-benefit conversation.

Question 2: Can We Regrow Anything?

Yes, sometimes, but “regrowth” has to be defined honestly. Most treatments don’t conjure new follicles; they increase the size, thickness, density, or growth phase of hairs from follicles that are still alive. This is where minoxidil and combination therapy live.

The best candidates for regrowth are men with thinning, miniaturized areas, not bald ones.

Topical Minoxidil

The claim: topical minoxidil improves hair growth in men with androgenetic alopecia.

The evidence: it’s foundational. A major randomized trial compared 5% topical minoxidil, 2%, and placebo, and at 48 weeks the 5% was significantly better than both for change in nonvellus hair count and for patient and investigator ratings of scalp coverage, with a faster response than the 2%. [7] Current treatment reviews still list topical minoxidil alongside oral finasteride as standard evidence-based therapy. [8] It’s a real growth treatment, not just a cosmetic thickener, though the benefit isn’t universal and it does nothing to the androgen pathway.

The limits: it needs adherence and twice-daily application, scalp irritation is common with the propylene-glycol solutions, foam is often better tolerated, early shedding can happen, and benefit depends on staying on it. It doesn’t prove permanent benefit after stopping, doesn’t treat DHT biology, doesn’t regrow slick bald scalp, and on its own usually isn’t enough for progressive loss.

Evidence grade: A/B. Randomized trials, FDA approval, objective endpoints, decades of use.

Topical minoxidil is a genuine hair-growth treatment that improves count and coverage in some men, but it doesn’t touch the androgen signal, and any benefit lasts only as long as you keep using it.

Oral Minoxidil

The claim: low-dose oral minoxidil can help male androgenetic alopecia and may be easier than the topical.

The evidence: it’s popular because the topical is messy and adherence is poor, but oral minoxidil isn’t just the topical in pill form; it’s a systemic vasodilator. The key recent trial compared them head to head: a 2024 JAMA Dermatology randomized trial of oral minoxidil 5 mg daily versus topical 5% twice daily found that oral did not demonstrate superiority over topical after 24 weeks. [9] That should temper the online framing, where oral is implied to be a straight upgrade. It may be useful and easier to take and a good option for men who can’t tolerate or won’t use the topical, but the honest phrasing isn’t “oral is better.”

The limits: the trial ran 24 weeks at 5 mg, longer-term data are thinner, and it’s off-label with a systemic safety profile, including hypertrichosis, edema, lightheadedness, tachycardia, palpitations, headache, and blood-pressure effects, with rare but serious concerns like pericardial effusion at higher doses or in susceptible patients. It doesn’t prove superiority to the topical, doesn’t earn first-line status for every man, and isn’t “just a hair vitamin.”

Evidence grade: B. Real evidence and a legitimate off-label option, less mature than topical minoxidil and finasteride, and it needs systemic-medication counseling.

Oral minoxidil is a legitimate off-label choice, especially for men who can’t tolerate or won’t stick with the topical, but the best randomized trial didn’t show it beating the topical, and it’s a systemic drug, not a casual supplement.

VDPHL-01: Extended-Release Oral Minoxidil (2026 Update)

Added after original publication. In April 2026, Veradermics reported positive late-phase topline results for VDPHL-01, and it’s the most legitimate new pharmacologic development in this space in years, so it earns its own entry.

The claim: VDPHL-01, a new extended-release oral minoxidil, may produce stronger hair growth than standard oral minoxidil while lowering the cardiac risk that comes with the immediate-release version.

The evidence: this isn’t a new anti-androgen or a new pathway; it’s minoxidil, a drug that already grows hair, delivered differently. Veradermics built it as an extended-release formulation with a gel-matrix system meant to hold drug levels above the threshold that stimulates hair growth while avoiding the sharp peak plasma concentrations that drive minoxidil’s cardiovascular effects. [23] That design is the whole pitch: same proven drug, engineered pharmacokinetics. The readout that put it on the map is Study ‘302,’ announced in April 2026. It was Part A of a randomized, double-blind, placebo-controlled Phase 2/3 trial in 519 men aged 18 to 65 with mild-to-moderate androgenetic alopecia, randomized to VDPHL-01 8.5 mg once daily, 8.5 mg twice daily, or placebo, with co-primary endpoints of change in non-vellus target-area hair count by digital image analysis and a patient-reported “improved” or “much improved” rating on the Androgenetic Alopecia Impact Rating Scale, both at month 6. [24] The objective endpoint is the one to anchor on, and it was strong: hair count rose 30.3 hairs/cm² in the once-daily arm and 33.0 in the twice-daily arm, versus 7.3 for placebo, all at p<0.0001, with separation reported as early as month 2. [24] The patient-reported numbers were also high, 79.3% and 86.0% reporting improved coverage versus 35.6% on placebo, and those are better read as supportive than as definitive, because minoxidil causes body-hair growth that makes a hair-loss trial hard to keep fully blinded, and the softer the endpoint, the more expectancy can move it. On safety, the company reported a profile consistent with its Phase 2 data, with discontinuation rates lower than placebo and adverse-event-related discontinuation similar between drug and placebo; Veradermics also reported no cardiac adverse events of special interest through six months, which is the company’s own topline summary and worth confirming against the full release. [24] A second pivotal Phase 3 in men finished enrolling in early 2026, bringing the two Phase 3 trials to more than 1,000 participants combined, and if the program holds up, Veradermics is positioning VDPHL-01 as the first FDA-approved oral pill for pattern hair loss in nearly 30 years. [25]

The limits: this is a strong signal that hasn’t finished proving itself, and several things keep it short of settled practice. It’s topline, company-reported data, not a full peer-reviewed publication, so the complete adverse-event tables, pharmacokinetics, subgroup breakdowns, and dropout details aren’t public yet, and the safety statement above is the company’s own summary of its own data. The trial compared VDPHL-01 with placebo, not with topical minoxidil, immediate-release oral minoxidil, finasteride, or combination therapy, so it proves superiority to placebo, which isn’t the same as superiority to anything men already use; and the reminder there is that the 2024 randomized trial found ordinary oral minoxidil 5 mg no better than topical 5% over 24 weeks, so “oral and easier” shouldn’t slide into “oral and better.” [9] The dose deserves attention: 8.5 mg once daily, and 17 mg a day in the twice-daily arm, sits well above the 1.25 to 5 mg most men take off-label, and while peak concentration rather than total dose is what drives minoxidil’s cardiac risk, which is exactly what the extended-release design is meant to blunt, the serious problems like pericardial effusion track with higher doses, so the full pharmacokinetic and cardiac data aren’t a formality. [26] Six months is enough to show an early growth signal and not enough for a condition men manage for decades, the trial studied selected men with mild-to-moderate loss rather than older men with cardiac disease or women with female-pattern loss, and the drug isn’t FDA-approved. For the broader backdrop, a 2025 single-arm meta-analysis of 2,933 patients across 27 oral minoxidil studies found meaningful benefit alongside a pooled adverse-event rate around 27%, which is the kind of large-scale evidence oral minoxidil has mostly lacked and which VDPHL-01 is trying to generate properly. [27]

Evidence grade: B, provisional. The trial design is genuinely strong, randomized, double-blind, placebo-controlled, over 500 men, with an objective hair-count endpoint at p<0.0001, which is better than most of the oral minoxidil literature. It’s held below that by the fact that the data are topline rather than published, placebo-controlled rather than head-to-head, six months long, and not yet confirmed by the second Phase 3 or cleared by the FDA. If it publishes in full and the second trial holds, it moves up.

VDPHL-01 is probably the most legitimate new hair-loss drug in years, and it’s still investigational, not proven standard of care. The efficacy signal is strong and the early safety signal is reassuring, and the data we can actually interrogate is topline, six-month, company-reported, and placebo-controlled, so it doesn’t change today’s recommendations. It’s the right thing to watch closely, and not yet the thing to switch anyone to.

Combination Therapy

The claim: combining treatments is often more effective than monotherapy.

The evidence: it’s biologically rational, because the pieces hit different parts of the problem: a DHT blocker reduces miniaturization, minoxidil stimulates growth, microneedling may improve the minoxidil response, and PRP or laser may add follicular stimulation. A 2025 network meta-analysis of randomized trials found that combination approaches can outperform minoxidil alone and singled out strong performers like finasteride plus minoxidil in men. [10] The best-supported principle is that pairing a DHT-directed drug with a growth stimulant beats a growth stimulant alone in progressive loss. The caveat is that network meta-analyses lean on indirect comparisons and can overstate confidence when the underlying studies are small or mismatched.

The limits: combinations, doses, and formulations vary, some of the evidence is indirect, some studies are small and short, and a combined product makes it harder to tell which ingredient is doing the work or causing the side effect. It doesn’t prove every marketed combination spray or capsule stack works, doesn’t validate proprietary compounded mixtures, and doesn’t mean more ingredients equals better medicine.

Evidence grade: B for rational DHT-blocker-plus-minoxidil strategies; lower for combinations built on weak adjuncts or proprietary blends.

Combination therapy is often the right call, especially when it pairs DHT reduction with growth stimulation, but each combination stands or falls on its own evidence. More ingredients isn’t automatically better.

Microneedling

The claim: microneedling helps regrowth, especially combined with minoxidil.

The evidence: it creates controlled micro-injury, with proposed mechanisms around wound-healing signaling, growth-factor release, stem-cell activation, and better response to topical minoxidil. The evidence isn’t for microneedling alone; it’s for microneedling plus minoxidil. A 2025 systematic review and meta-analysis found that the combination significantly improved hair count and related outcomes versus minoxidil alone, and a review of 17 investigations totaling 911 men reported better hair parameters when microneedling was paired with 5% minoxidil, growth-factor solutions, or PRP, or introduced after a plateau. [11,12] The 2025 combination network meta-analysis points the same way. [10]

The limits: the trials are generally small and short, needle depth, frequency, and devices vary, home and professional use aren’t the same, blinding is hard because a man knows his scalp is being needled, and cosmetic significance can lag the statistics. The FDA also notes that microneedling devices aren’t approved to deliver topical products, drugs, or blood products into the skin, which matters since most hair-loss use is exactly that combination. The defensible claim is that microneedling may improve the minoxidil response, not that it’s a stand-alone treatment, treats DHT biology, or rescues follicles.

Evidence grade: C. A real adjunct signal, not foundation-level.

Microneedling may help some men respond better to minoxidil, and that’s the strongest honest claim. It shouldn’t be sold as a foundational therapy, a DHT treatment, or proven follicle rescue.

Platelet-Rich Plasma

The claim: PRP can improve hair density in androgenetic alopecia.

The evidence: blood is drawn, processed to concentrate platelets, and injected into the scalp, with growth-factor signaling as the proposed mechanism. The evidence is real but messy. A 2023 systematic review and meta-analysis found PRP increased hair density, with stronger effects in men, but didn’t clearly increase hair diameter; another 2023 meta-analysis found higher density at three and six months versus placebo while count and diameter didn’t differ significantly; and a 2023 randomized trial suggested PRP may beat 5% topical minoxidil in its study population, with the authors stressing that more work is needed. [13,14,15] The recurring signal is improved density; the signal for diameter and for beating standard therapy is weaker.

The limits: PRP isn’t one standardized thing. Preparation, platelet concentration, leukocyte content, activation, injection depth, number of sessions, and maintenance all differ, the cost is high, and durability is uncertain. That variability isn’t a footnote; a positive PRP study doesn’t validate the specific protocol a clinic down the street is selling. It doesn’t prove guaranteed or durable regrowth, doesn’t make all systems equivalent, and doesn’t justify spending thousands before using cheaper, better-supported options.

Evidence grade: C. A real density signal held back by protocol heterogeneity and cost.

PRP has a real but inconsistent effect, mostly on density, and it’s heavily overmarketed. It’s best treated as an adjunct or second-line option, not a guaranteed or foundational therapy.

Low-Level Laser Therapy

The claim: low-level laser therapy can improve hair density.

The evidence: this covers caps, combs, and helmets, with photobiomodulation as the proposed mechanism. There are sham-controlled randomized trials and meta-analyses suggesting benefit; a systematic review and meta-analysis of randomized trials found that LLLT significantly increased hair density, and others summarize improved outcomes while flagging device variation. [16,17] The signal is real but the effect is generally modest, and the practical problem is device quality and adherence.

The limits: wavelength, power, schedule, and duration vary, consumer devices may not match studied ones, cost can be high, long-term durability is unclear, and a statistical bump doesn’t always mean a visible one. It doesn’t prove large cosmetic benefit, doesn’t validate every laser cap on the market, isn’t equivalent to finasteride, dutasteride, or minoxidil, and doesn’t treat DHT.

Evidence grade: B/C. More evidence than people assume, including sham-controlled data, but device variation, modest effect, adherence, and real-world generalizability keep it below the top tier.

Low-level laser therapy has a modest effect supported by sham-controlled trials. But device quality, adherence, and effect size matter, so treat it as an adjunct, not a replacement for proven therapy.

Ketoconazole Shampoo

The claim: ketoconazole shampoo may help hair loss or improve the scalp environment.

The evidence: it’s an antifungal, anti-inflammatory shampoo used for seborrheic dermatitis and dandruff, and its direct role in male-pattern loss is much weaker. The commonly cited 1998 study reported that hair density, size, and the proportion of anagen follicles improved similarly with ketoconazole and minoxidil regimens, and a later review called it potentially promising while stressing that the evidence base is thin and larger trials are needed. [18,19] This isn’t in the same league as finasteride or minoxidil. What it can do is help scalp inflammation, seborrheic dermatitis, and dandruff, which matters for overall scalp health.

The limits: the hair-loss evidence is thin, the studies are old and small, protocols aren’t standardized, and it isn’t FDA-approved for androgenetic alopecia. It doesn’t prove meaningful stand-alone treatment of male-pattern loss, comparable modern efficacy to minoxidil, or any ability to stop miniaturization or rescue advanced loss.

Evidence grade: D for androgenetic alopecia, B/C for seborrheic dermatitis and dandruff.

Ketoconazole shampoo is a useful tool for scalp inflammation, dandruff, and seborrheic dermatitis. As a direct treatment for male-pattern hair loss it’s weak, and it belongs in the adjunct column at best.

Question 3: What’s Mostly Bullshit?

This is where most men waste money. Not every product is fake, but the marketing usually claims far more than the evidence supports.

Saw Palmetto

The claim: saw palmetto helps androgenetic alopecia through weak anti-androgenic effects.

The evidence: it’s the headline “natural DHT blocker.” There’s some signal; a systematic review of saw palmetto for hair disorders found five randomized trials and two cohort studies reporting positive effects of topical and oral saw-palmetto products on hair quality, count, density, and disease stabilization in some patients. [20] That’s better than nothing, but the review pooled varying formulations, doses, populations, and combination products, which makes it hard to isolate saw palmetto itself, and the effect is nowhere near prescription 5-alpha reductase inhibition. It doesn’t prove equivalence to finasteride, strong DHT suppression, reliable regrowth, or durable benefit, and it can’t replace prescription therapy in progressive loss.

Evidence grade: D. A weak adjunct signal, not treatment-level evidence.

Saw palmetto has weak signals and a plausible rationale, but it’s not a serious substitute for finasteride or dutasteride. The “natural DHT blocker” label is mostly marketing.

Pumpkin Seed Oil

The claim: pumpkin seed oil improves hair growth in men with androgenetic alopecia.

The evidence: it has one commonly cited randomized, double-blind, placebo-controlled study, in which 76 men took 400 mg of pumpkin seed oil daily or placebo for 24 weeks, and mean hair count rose 40% in the oil group versus 10% in placebo. [21] That’s a genuine positive signal, and it’s one trial: small, short, with formulation questions, an incompletely established mechanism, limited replication, and no head-to-head against finasteride, dutasteride, or 5% minoxidil. It doesn’t prove it’s a serious substitute for DHT-blocking medication, doesn’t prove durable benefit or benefit in advanced loss, and doesn’t earn the “natural finasteride” label.

Evidence grade: D. One positive RCT gives it more credibility than most supplements, not enough to sit beside evidence-based medical therapy.

Pumpkin seed oil has a small positive signal, but it’s a weak adjunct, not a replacement for finasteride, dutasteride, or minoxidil.

Rosemary Oil

The claim: rosemary oil improves androgenetic alopecia and is sometimes sold as equal to minoxidil.

The evidence: the most-cited study compared rosemary oil with 2% minoxidil over six months, and both groups showed increased hair count. [22] That result is heavily overused online, because the comparator was 2% minoxidil, not the more relevant 5%, there was no placebo arm, and it doesn’t build a broad evidence base. Performing similarly to 2% minoxidil in one study isn’t the same as matching evidence-based minoxidil therapy. It doesn’t prove equivalence to 5% minoxidil, benefit versus placebo, any effect on DHT, or meaningful long-term regrowth.

Evidence grade: D.

Rosemary oil rests on one small, overused study against 2% minoxidil, with no 5% arm and no placebo. It shouldn’t be sold as equivalent to evidence-based therapy.

Biotin

The claim: biotin helps hair growth.

The evidence: biotin deficiency can cause hair and nail problems, but true deficiency is uncommon, and the whole question turns on deficiency versus non-deficiency. Correcting a real deficiency is one thing; giving high-dose biotin to a man with ordinary male-pattern loss is another, and there’s little evidence for routine supplementation in non-deficient men. Biotin also has a real downside: it interferes with lab testing, including assays that matter clinically, such as thyroid and troponin. Most men taking hair gummies aren’t documented as deficient, and the multi-ingredient products make it hard to credit biotin for anything. It doesn’t prove high-dose biotin grows hair in non-deficient men, doesn’t prove gummies treat androgenetic alopecia, and isn’t even reliably harmless given the lab interference.

Evidence grade: E for routine use in non-deficient men, B for correcting true deficiency.

Biotin helps if you’re genuinely deficient. Most men with male-pattern loss aren’t, high-dose biotin can interfere with lab tests, and routine biotin for hair loss is mostly marketing.

Caffeine Shampoos, Peptide Serums, Exosomes, Stem Cells, and “Natural DHT Blockers”

The claim: these are sold as regrowth treatments, follicle activators, DHT blockers, or regenerative therapies.

The evidence: for most of them it’s weak, proprietary, cosmetic, mechanistic, or not specific to male-pattern loss. Some shampoos make hair look thicker, some products improve scalp feel, some ingredients have in-vitro plausibility, and some serums reduce breakage. None of that is the same as treating androgen-driven miniaturization. A thickening shampoo coats the shaft, a serum reduces frizz, a scalp product calms irritation; those can matter cosmetically and don’t regrow miniaturized follicles. Many of these products lack randomized trials and lean on before-and-after photos where lighting and styling do the work, with subjective endpoints, hidden doses, and claims extrapolated from mechanism rather than outcomes. None of it proves true regrowth, DHT control, follicle rescue, durable benefit, or equivalence to the proven options.

Evidence grade: mostly D/E.

A shampoo can clean the scalp, fight dandruff, or make hair look thicker for a few hours. It’s not a treatment for androgen-driven miniaturization, and most peptide, exosome, stem-cell, and “natural DHT blocker” marketing is far ahead of the evidence.

Hair Transplant Surgery

The claim: transplant surgery can restore cosmetic density and hairline appearance.

The evidence: surgery is a different category from medication. It doesn’t reverse miniaturization pharmacologically; it redistributes hair from donor areas to where it’s wanted, by strip surgery (FUT) or follicular unit extraction (FUE). A good transplant can rebuild a hairline, add density, and change how the hair frames a man’s face. But it’s operator-dependent, and outcomes ride on surgeon skill, donor supply, hair caliber and curl, the contrast between hair and scalp, hairline design, and graft survival. The central limitation is that it can be cosmetically powerful and it doesn’t stop androgenetic alopecia. A man who transplants while his native hair keeps miniaturizing can end up chasing progressive loss with repeated surgeries.

The limits: not everyone is a good candidate, donor hair is finite, poor design looks unnatural, overharvesting damages the donor area, shock loss and scarring can happen, and future procedures and medical stabilization are often part of the deal. It doesn’t create unlimited hair, doesn’t stop ongoing miniaturization, doesn’t remove the need for medical therapy in many men, and doesn’t rescue poor candidate selection.

Evidence grade: A/B for cosmetic redistribution in appropriate candidates. That’s not the same kind of evidence as a placebo-controlled drug trial, but as a procedure done well in the right patient, it’s one of the most powerful cosmetic interventions available.

Hair transplant surgery can produce a large cosmetic change, but it only moves hair; it doesn’t stop hair loss. Men who don’t stabilize ongoing loss end up chasing the disease with repeated procedures.

Red Flags for Hair-Loss Marketing

A few tells separate marketing from medicine. The company says “clinically proven” but never shows the trial; the before-and-after photos use different lighting; there’s no hair-count endpoint and no control group; the product is a “secret formula” that promises to “detox DHT” or deliver permanent regrowth after you stop using it; the pitch runs on influencer testimonials and the word “natural” as if natural means effective; and it claims to regrow hair on slick bald scalp or sells stem cells, exosomes, or peptides as if the science is already settled.

If a company can’t tell you which endpoint improved, in which study, against which control, over what time frame, you’re reading marketing, not medicine.

What a Rational Plan Looks Like

This is a general framework, not personal medical advice. For early thinning, the usual sequence is to confirm the diagnosis, take baseline photos under consistent lighting, discuss finasteride or dutasteride, add topical or oral minoxidil when appropriate, and reassess at six to twelve months rather than at six weeks. For moderate thinning, combination usually makes more sense, with a DHT blocker plus minoxidil as the foundation, microneedling as a reasonable adjunct, and PRP or laser as options when budget and expectations are sane; the transplant conversation usually waits until the pattern is stable or medically managed. For advanced baldness, medications may preserve what’s left and some miniaturized hair may improve, but a slick bald scalp won’t be restored by medication alone, and transplant surgery may be the only meaningful cosmetic option if donor supply allows.

Consistent monitoring matters: same lighting, same camera angle, same hair length and wet-or-dry status, photos every three to six months, and enough patience to let treatment work. Minoxidil can cause early shedding, finasteride and dutasteride often prevent loss before any visible regrowth shows, and stopping any of them usually means losing the maintained benefit.

Hair treatment is a long-term maintenance strategy, not a 30-day transformation.

Evidence Grade Summary

Foundation-level. Finasteride (A/B): strong evidence for slowing loss and maintaining or increasing growth, with a real side-effect discussion. Topical minoxidil (A/B): strong evidence for growth and coverage, but no effect on DHT and benefit only while used. Dutasteride (A/B for efficacy): often stronger than finasteride for hair count, with US regulatory caveats and a heavier risk-benefit conversation.

Legitimate but not automatically superior. Oral minoxidil (B): real and useful off-label, not clearly better than the topical, systemic drug. Topical finasteride (B for studied formulations, C for the compounded market): real evidence for specific formulations, not for every compounded version. Combination DHT blocker plus minoxidil (B): rational and supported, judged combination by combination.

Investigational, worth watching (2026 update). VDPHL-01, extended-release oral minoxidil (provisional B): a strong Phase 2/3 topline hair-count signal and reassuring early safety, still topline, placebo-controlled, six-month, and not FDA-approved, so promising and not yet a recommendation.

Adjuncts with real but messy signals. Microneedling plus minoxidil (C), PRP (C, mostly density), low-level laser therapy (B/C, modest effect with device and adherence caveats).

Scalp health and weak adjuncts. Ketoconazole shampoo (D for AGA, B/C for dandruff and seborrheic dermatitis), saw palmetto (D), pumpkin seed oil (D), rosemary oil (D).

Mostly marketing unless a deficiency exists. Biotin (E in non-deficient men, B for true deficiency, with lab-interference caveats), and most hair vitamins, peptide serums, “natural DHT blockers,” caffeine shampoos, oils, exosomes, stem-cell products, and influencer stacks (D/E): they may improve appearance or scalp feel without meaningfully treating miniaturization.

Bottom Line

Male-pattern hair loss has a real evidence hierarchy. At the top sit finasteride, dutasteride, and topical minoxidil, the treatments with the strongest evidence for slowing loss or improving growth. Oral minoxidil and topical finasteride are legitimate but need careful framing: useful and increasingly common and evidence-supported in specific ways, not magic upgrades. Microneedling, PRP, and low-level laser therapy have signals and belong in the adjunct column, not the foundation. Ketoconazole shampoo can help an inflamed scalp, which isn’t the same as treating baldness. And supplements, oils, shampoos, peptides, “natural DHT blockers,” and influencer stacks mostly live at the bottom unless they’re correcting a true deficiency or scalp condition.

The serious answer isn’t complicated: protect follicles early, address DHT when it’s appropriate, use minoxidil if you want growth stimulation, be honest about side effects, stay skeptical of cosmetic claims, use transplant surgery when redistribution is the goal, and don’t confuse weak adjunct signals with foundational evidence.

This article is for education only and is not personal medical advice. It does not create a physician-patient relationship. Medical decisions should be made with a qualified clinician who knows your history, labs, medications, risk factors, and goals.

References

1. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4):578–589.

2. Kaufman KD, Rotonda J, Shah AK, Meehan AG. Long-term (5-year) multinational experience with finasteride 1 mg in men with androgenetic alopecia. Eur J Dermatol. 2008;18(4):400–406.

3. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products. April 22, 2025.

4. Almudimeegh A, et al. Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in androgenetic alopecia: a review. 2024. PMC11694415.

5. Shanshanwal SJS, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized, open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol.

6. Efficacy and safety of twice- or thrice-weekly dutasteride 0.5 mg vs daily finasteride 1 mg for male androgenetic alopecia: a randomized study. 2025. PMC12547282.

7. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385.

8. Treatment of androgenetic alopecia: current guidance and evidence. PMC. 2023. PMC10239632.

9. Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(6):600–605. doi:10.1001/jamadermatol.2024.0284.

10. Relative efficacy of minoxidil in combination with other treatments for androgenetic alopecia: a network meta-analysis. Front Med. 2025;12:1638496.

11. Ahmed KMA, et al. Combined microneedling therapy versus topical minoxidil in androgenetic alopecia: a systematic review and meta-analysis. 2025. PMC11890238.

12. English RS Jr, Ruiz S. Microneedling and its use in hair loss disorders. Dermatol Ther (Heidelb). 2022. doi:10.1007/s13555-021-00653-2.

13. Effectiveness of platelet-rich plasma in androgenetic alopecia: a systematic review and meta-analysis. 2023. PMC10980625.

14. Platelet-rich plasma for androgenetic alopecia. J Cutan Med Surg. 2023. doi:10.1177/12034754231191461.

15. A randomized control trial comparing platelet-rich plasma and 5% topical minoxidil for androgenetic alopecia. J Drugs Dermatol. 2023.

16. Lueangarun S, et al. Comparative effectiveness of low-level laser therapy for androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. Lasers Med Sci. 2019. PMID 30706177.

17. A systematic review and meta-analysis of randomized controlled trials of light/laser devices for androgenetic alopecia. PMC. PMC8675345.

18. Piérard-Franchimont C, et al. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474–477.

19. Fields JR, et al. Topical ketoconazole for the treatment of androgenetic alopecia: a review. Dermatol Ther. 2020.

20. Evron E, Juhasz M, Babadjouni A, Mesinkovska NA. Natural hair supplement: friend or foe? Saw palmetto, a systematic review in alopecia. Skin Appendage Disord. 2020. PMC7706486.

21. Cho YH, et al. Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2014. PMC4017725.

22. Panahi Y, et al. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed. 2015. PMID 25842469.

23. Veradermics. VDPHL-01: non-hormonal oral therapeutic for hair regrowth (formulation and mechanism). veradermics.com.

24. Veradermics. Oral VDPHL-01 achieved early, consistent, and robust hair growth in positive Phase 2/3 ‘302’ clinical trial in male pattern hair loss. News release. April 27, 2026.

25. Veradermics. Veradermics completes enrollment in second pivotal Phase 3 clinical trial of VDPHL-01 for male pattern hair loss. News release. February 2026.

26. Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations. Front Pharmacol. 2025;16:1718208.

27. Liu C, Liu X, Shi T, et al. Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review. Front Pharmacol. 2025;16:1556705.

A subscriber to the Substack responded to our survey and asked specifically about infrared sauna and cold plunge. The specific questions were whether infrared sauna improves cardiovascular health, reduces inflammation, mimics a fever, or reduces the risk of colds and illness when symptoms first appear; and whether cold plunge has actual benefits.

The short answer is that both interventions are being marketed far beyond the evidence.

A physiologic response is not a clinical outcome. A body that reacts to heat or cold is not the same as a body that ends up healthier. That single confusion is the engine of this entire industry.

Infrared sauna has not been shown to prevent cardiovascular disease, reduce cardiovascular death, meaningfully treat hypertension, reduce clinically important inflammation, mimic a true fever, or prevent or treat colds. Cold plunge has better evidence for one narrow outcome: it can reduce short-term perceived muscle soreness after hard exercise. But most of the broader claims around cold plunge, including immunity, fat loss, hormones, metabolism, longevity, and chronic inflammation, are weak or unsupported.

The common marketing problem in both categories is that a small physiologic observation gets inflated into a large clinical claim. A change in heart rate becomes “cardiovascular conditioning.” Sweat becomes “detoxification.” Feeling less sore becomes “better recovery.” A temporary white blood cell change becomes “immune boosting.” A cold shock becomes “resilience.” None of those leaps are justified without real clinical outcome data.

Infrared Sauna

The first problem with the infrared sauna literature is that much of the marketing borrows from studies that are not actually infrared sauna studies. The most frequently cited sauna health studies are Finnish observational cohort studies on traditional sauna use. These are not randomized trials, and they are not studies of consumer infrared saunas. They are studies of a cultural lifestyle habit in Finland, where traditional sauna bathing is common and usually involves much higher temperatures than typical infrared sauna use.

The most famous example is the 2015 Laukkanen study in JAMA Internal Medicine. It followed 2,315 middle-aged Finnish men and found that the men who used saunas more often had lower rates of sudden cardiac death, fatal coronary heart disease, fatal cardiovascular disease, and death from any cause. Read the next two sentences carefully, because they are the ones the entire sauna industry hopes you will skip. The study found that sauna use was associated with fewer deaths. It did not find that sauna use caused them. Those are not the same claim, and the gap between them is where the marketing lives.¹

Here is what “associated with” actually means, in plain terms. It means two things were seen together in the same group of people. The men who sat in saunas more often were also the men who died less. That is the entire finding, and by itself it tells you nothing about why. Every summer, ice cream sales and drownings rise at the same time. Ice cream does not drown anyone. Hot weather simply drives both at once. When two things move together, there is almost always a third factor sitting underneath, and the first job of an honest scientist is to go looking for it.

With the sauna data, that third factor is not hard to find. The men were not assigned a sauna at random; they chose to use one. A man who owns a home sauna, has the free time to use it several times a week, and is healthy enough to sit in punishing heat without getting into trouble is, on average, already wealthier, fitter, less frail, and more socially connected than a man who does not. The sauna may be nothing more than a flag for the kind of man who was going to outlive his peers regardless. Researchers can try to adjust for some of this, but they can only adjust for what they thought to measure, and they cannot measure everything. This is called the healthy-user problem, and it sits underneath nearly every observational study of a voluntary lifestyle habit.

“Associated with” is not “caused by.” The men who used saunas the most were already healthier, wealthier, and fitter before they ever sat down. The sauna may simply be a marker of that life; it is not evidence that the heat itself did anything.

The study’s authors were honest about all of this. They reported the association, and they stated plainly that more research was needed to find out whether sauna was doing anything at all. That second half is the part the wellness ads quietly drop.

These are not infrared sauna studies. They are studies of traditional Finnish saunas, which run far hotter than the infrared units sold for home use. Even if the association did prove cause, which it does not, it would apply only to traditional saunas, not to the infrared units being marketed.

So here is the correct reading of the famous Finnish data. In a large group of Finnish men, the ones who used traditional saunas more often also lived longer, for reasons the study could not isolate. The marketing reading, that an infrared sauna will prevent your heart attack, does not follow from this study, and no other study has closed that gap.

The same pattern shows up in a series of other Finnish papers, this time linking sauna frequency to lower rates of hypertension, dementia, Alzheimer’s disease, and stroke. The hypertension paper reported less high blood pressure in frequent users;² the dementia paper reported lower rates of dementia and Alzheimer’s disease;³ the stroke paper reported fewer strokes.⁴ Read those results the same way you read the mortality data, because they share the identical flaw. None of these studies randomly assigned anyone to a sauna. They observed men who had already chosen how often to use one, and the men who used saunas the most were, again, the healthier, wealthier, and more active men to begin with. That is selection bias, and along with other uncontrolled differences between these men, it is the most likely explanation for every one of these associations.

Let me state this as plainly as possible, because the marketing depends on you missing it. These studies do not show that sauna use lowers your risk of dementia, Alzheimer’s disease, hypertension, or stroke. They do not show that the sauna caused anything at all. They show only that men who used saunas more often also happened to have less of these conditions, for reasons this kind of observational study cannot determine. Sitting in a sauna has not been shown to prevent any of these diseases, and the authors of these papers said the same, calling for controlled experiments before anyone reaches that conclusion. None of these were studies of infrared saunas in any case. They examined traditional Finnish saunas, which carry the same limitation and say nothing about the infrared units marketed for home use.

The more infrared-specific cardiovascular literature comes mostly from Japanese far-infrared “Waon therapy” studies. These are not wellness-spa studies. They used a structured medical protocol, often far-infrared dry sauna at about 60°C for 15 minutes followed by 30 minutes of bed rest under a blanket, usually in patients with chronic heart failure. In the WAON-CHF randomized trial, hospitalized heart-failure patients were randomized to Waon therapy or control for 10 days. The primary endpoint was the between-group difference in BNP before and after treatment, and the trial missed it; that difference did not reach statistical significance. BNP did fall within the Waon group, and some secondary measures improved, including NYHA class, six-minute walk distance, and cardiothoracic ratio. But a trial that fails to beat its own control on the one outcome it was built to test is not a green light for healthy people buying a sauna.⁵

That is not nothing, but it is also not what wellness marketers imply. A short-term intervention in hospitalized advanced heart-failure patients, using a structured medical protocol, does not prove that healthy people using infrared saunas prevent cardiovascular disease. It does not prove lower heart-attack risk, lower stroke risk, lower cardiovascular mortality, plaque regression, or reduced need for standard therapy. It is a narrow, disease-specific, short-term signal using surrogate and functional endpoints.

Earlier Waon therapy studies reported improvements in symptoms, cardiac function, or prognosis in chronic heart failure, but several were small, non-randomized, retrospective, or based on surrogate outcomes. A 2009 retrospective follow-up study reported fewer cardiac events in chronic heart-failure patients receiving Waon therapy, but retrospective treatment-selection bias is a major problem: patients who received Waon therapy may have differed from those who did not in adherence, disease severity, clinical monitoring, or background care.⁶ A 2018 systematic review concluded that infrared sauna was associated with short-term improvement in some heart-failure measures, including ejection fraction and BNP, while noting that the evidence for other measures was limited and inconsistent.⁷ Remember what those measures are: lab and imaging surrogates in patients who already have heart failure. They are not the same as living longer, and they say nothing about a healthy person buying a sauna to prevent disease.

The honest conclusion is narrow: structured Waon therapy has small, disease-specific heart-failure data using symptoms and surrogate markers. That does not validate infrared sauna as a cardiovascular prevention tool.

There are also small studies in people with coronary risk factors. Imamura and colleagues reported that two weeks of repeated sauna treatment improved impaired vascular endothelial function in patients with coronary risk factors.⁸ Masuda and colleagues reported that repeated sauna therapy lowered systolic blood pressure and urinary 8-epi-PGF2α, an oxidative-stress marker, after two weeks in patients with coronary risk factors.⁹ These findings are not strong enough to claim cardiovascular prevention. They are short-term, small, surrogate-endpoint studies. An endothelial-function marker or oxidative-stress marker is not a heart attack, stroke, death, coronary plaque progression, or clinical event.

This is where the wording matters. It is technically true that passive heat exposure can change heart rate, vascular tone, sweating, and sometimes blood pressure. But that should not be framed as a meaningful cardiovascular benefit. It is just a heat exposure response. The fact that the body responds to heat does not mean the response is beneficial, durable, or clinically useful.

Passive heat changes your heart rate, your vascular tone, and your sweat rate. So does standing outside in Tucson in July. A response to heat is not cardiovascular medicine.

A recent comparison study is useful here because it directly compared passive heating modalities. In young healthy adults, hot-water immersion produced the greatest thermoregulatory, cardiovascular, and immune responses, while far-infrared sauna was the least impactful on raising core temperature and the resulting cardiovascular and immune responses.¹⁰ It is one study in a small healthy sample, so it should not carry the whole argument, but it cuts directly against the idea that infrared sauna is uniquely powerful. If anything, far-infrared sauna appears to be a weaker heat stimulus than hot-water immersion or traditional sauna.

The blood-pressure claim needs a specific warning. Some studies report small short-term blood-pressure changes after sauna or repeated thermal therapy, but that is not hypertension treatment. A patient with high blood pressure should not interpret this as permission to avoid or stop medication. If someone has clinically meaningful hypertension, treatment remains weight loss when appropriate, sodium reduction, alcohol moderation, aerobic exercise, resistance training, sleep apnea treatment, and antihypertensive medication when indicated. Infrared sauna is not a substitute for blood-pressure therapy.

If you have high blood pressure, a sauna is not your treatment. Do not skip or stop your medication because you use a sauna. High blood pressure is treated with the things that actually lower it and prevent strokes.

The inflammation claim is also weak. Sauna marketing often cites lower CRP or inflammatory markers, but much of that evidence is observational Finnish sauna data, not infrared sauna intervention data. One study reported that sauna bathing frequency was associated with lower serum CRP, but this is exactly the same problem as the cardiovascular cohort literature: frequent sauna users may simply be healthier people.¹¹ Another Finnish cohort paper looked at inflammation, sauna bathing, and mortality, but again this was observational and cannot prove that sauna lowered inflammation in a clinically meaningful way.¹² An acute Finnish sauna study found that typical sauna bathing acutely increased IL-6 and IL-1RA in healthy middle-aged and older adults, which is the opposite of the simplistic marketing claim that sauna just “reduces inflammation.”¹³

So the inflammation answer is direct: infrared sauna is not proven to meaningfully reduce chronic systemic inflammation in a way that improves clinical outcomes. A marker change, especially in small or observational studies, is not enough. There is no good evidence that infrared sauna treats autoimmune disease, prevents cardiovascular events through inflammation reduction, prevents colds by reducing inflammation, or meaningfully lowers disease risk.

The “mimics a fever” claim is scientifically misleading. A fever is not simply being hot. Fever is a regulated immune response in which pyrogens raise the hypothalamic thermoregulatory set point, often through prostaglandin-mediated pathways. Hyperthermia from external heat exposure is different: the hypothalamic set point is not reset in the same way.¹⁴

A fever is a regulated immune response. A sauna is just being hot. Heating your skin does not reproduce the biology of fever, and even if it nudged your core temperature up, there is no evidence that prevents infection or shortens an illness.

An infrared sauna may heat the skin, cause sweating, and depending on the exposure, raise core temperature modestly. That is not the same as reproducing the immune biology of fever. More importantly, even if a sauna raises temperature, the clinically relevant question is whether that prevents infection or shortens illness. That evidence is not there.

There is an older 1990 trial on regular sauna bathing and common colds. It concluded that regular sauna bathing “probably” reduced common-cold incidence, but also stated that further studies were needed to prove the finding.¹⁵ That is a small, old, non-definitive study. It was not enough then, and it is not enough now, to claim that infrared sauna prevents colds. It also does not prove that going into a sauna when initial symptoms appear will stop an illness.

There are also acute immune-cell studies showing transient changes in white blood cells after sauna exposure, but those are not clinical outcomes. A temporary movement of immune cells in the bloodstream does not prove fewer infections, better viral clearance, shorter cold duration, or improved immune competence. The 2025 passive-heating comparison study also found far-infrared sauna produced the least core-temperature and immune response among the compared heat modalities.¹⁰

Direct Answer: Infrared Sauna

Infrared sauna does not have good evidence for meaningful cardiovascular prevention. It does not prevent heart attacks, strokes, cardiovascular death, or plaque progression. It does not replace exercise, weight loss, lipid lowering, blood-pressure medication, sleep apnea treatment, or any other evidence-based cardiovascular intervention.

There is no good evidence that infrared sauna prevents a single heart attack, stroke, or cardiovascular death. None. The burden is on the people selling it to prove otherwise, and after years of marketing, they still have not.

Infrared sauna is not a real treatment for hypertension. It may transiently change blood pressure in some settings because passive heat can alter vascular tone, but that is not the same as treating high blood pressure. Patients should not stop or avoid blood-pressure medication because they sit in a sauna.

Infrared sauna is not proven to reduce clinically important inflammation. The inflammation evidence is mostly observational, surrogate-based, acute, inconsistent, or not specific to infrared sauna. It does not show fewer inflammatory diseases or better clinical outcomes.

Infrared sauna does not truly mimic a fever. Fever is a regulated immune response involving a hypothalamic set-point change. Sauna is external heat exposure. Those are not the same thing.

Infrared sauna is not proven to reduce the risk of colds or stop an illness when early symptoms appear. The cold-prevention evidence is weak, old, not infrared-specific, and not strong enough to support that claim.

The honest conclusion is: infrared sauna may feel good, may relax some people, and may make people sweat, but the main wellness claims are not proven. It should not be presented as cardiovascular medicine, anti-inflammatory therapy, immune therapy, detoxification, or a substitute for actual medical care.

Cold Plunge

Cold plunge has a somewhat better evidence base than infrared sauna for one narrow use: short-term perceived recovery after strenuous exercise. But that is a narrow claim. It does not justify the much broader wellness marketing around immunity, metabolism, hormones, resilience, depression, fat loss, longevity, or inflammation.

The most defensible cold-plunge claim is that cold-water immersion can reduce delayed-onset muscle soreness after hard exercise. A Cochrane review concluded that there was some evidence cold-water immersion reduces delayed-onset muscle soreness compared with passive recovery.¹⁶ A 2012 meta-analysis in the British Journal of Sports Medicine also found that cold-water immersion can reduce muscle soreness after strenuous exercise.¹⁷

Cold plunge has exactly one honest benefit: you will probably feel less sore after a hard workout. That is real. Almost everything else being sold around it is not.

But even here, the benefit is easy to overstate. Reduced soreness is not the same as better tissue repair, better adaptation, improved fitness, greater strength, or improved long-term performance. Soreness is subjective, and cold immersion cannot be truly blinded. People know when they are sitting in cold water. That makes expectancy and placebo effects a major issue.

Broatch and colleagues directly tested this issue using a placebo-controlled recovery design. They found that post-exercise cold-water immersion benefits were not greater than the placebo effect; the recovery placebo was as effective as cold-water immersion and superior to thermoneutral water for some recovery outcomes over 48 hours.¹⁸ That does not mean cold-water immersion never helps. It means a large part of the recovery narrative may be perception, expectation, ritual, and altered soreness rather than true biological superiority.

When researchers built a fake “recovery” treatment and compared it to a real cold plunge, the placebo worked just as well. A large part of the cold plunge recovery story is ritual and expectation, not biology.

There is also an important downside for resistance training. The adaptation a lifter is chasing runs on stress and inflammation. The body has to endure that response and repair the muscle on its own, and that repair is the signal that tells it to grow back bigger and stronger. Cooling the tissue immediately afterward quiets that signal before it can do its work, and for strength training this blunting is real and well supported. Roberts and colleagues found that post-exercise cold-water immersion attenuated acute anabolic signaling and long-term adaptations in muscle after strength training.¹⁹ Fyfe and colleagues later reported that cold-water immersion attenuated anabolic signaling and skeletal muscle fiber hypertrophy after whole-body resistance training, although strength gain was not necessarily reduced.²⁰ A 2024 systematic review concluded that cold-water immersion immediately after resistance training may attenuate hypertrophic changes, while also noting limitations in the underlying studies.²¹ The timing is the actionable piece. This blunting shows up when the cold hits right after lifting, during the window when the muscle is mounting its growth response. Moving the plunge several hours away from the workout likely avoids it.

So for an athlete, cold plunge is not automatically “recovery.” If the goal is to compete again soon and feel less sore, cold-water immersion may be useful. If the goal is hypertrophy, strength adaptation, or maximizing the training signal from lifting, immediate post-lifting cold plunge may be counterproductive. Feeling less sore is not always the same thing as getting a better adaptation.

The immune claims are weak. A large randomized trial of cold showers found a 29% reduction in self-reported sickness absence from work, but not a reduction in actual illness days.²² That distinction is important. People missed fewer workdays, but they did not clearly get sick less often. That could mean they felt more willing to work through symptoms, had altered symptom perception, or were influenced by the behavior-change ritual. It does not prove improved immunity.

29% fewer self-reported sick days. Zero reduction in actual illness.
The best-known cold-shower trial did not show people getting sick less often. It showed them working through symptoms. That is not an immune system upgrade.

A 2025 systematic review and meta-analysis of cold-water immersion looked across inflammation, stress, immunity, sleep, and quality of life. That list of topics sounds impressive, so be precise about what a review like this does: it pools existing studies, and it can only be as good as the studies it pools. Here, the authors were blunt that the evidence was thin, built on a handful of small randomized trials with inconsistent protocols, narrow populations, and almost no long-term data. The “effects” they catalogued were short-lived and shifted depending on when they were measured, which is a polite way of saying the signal was unstable. The review did not establish that cold plunge strengthens immunity or improves health;²³ it described a small, low-quality literature and asked for better studies. It also restated the cold-shower result the way I just did: fewer reported sick days, no drop in actual illness.

The inflammation claim is mixed and not clinically proven. Cold exposure can acutely affect inflammatory markers, stress hormones, vascular tone, and autonomic output, but that does not prove chronic anti-inflammatory benefit. For general wellness consumers, there is no good evidence that cold plunge treats chronic inflammation, prevents autoimmune disease, reduces cardiovascular events, or improves long-term inflammatory disease outcomes.

The metabolic and fat-loss claims are also overextended. Cold exposure can activate brown adipose tissue and increase thermogenesis under certain conditions. A 2021 study of experienced winter-swimming men found altered brown-fat thermoregulation and enhanced cold-induced thermogenesis.²⁴ But winter swimmers are a highly selected population. They are not average sedentary consumers randomly assigned to a tub. Winter swimming also includes outdoor activity, cold exposure, swimming, social behavior, and long-term self-selection.

Cold-acclimation studies are sometimes used to claim metabolic benefit. One small study found that 10 days of cold acclimation at 14–15°C increased peripheral insulin sensitivity by about 43% in eight people with type 2 diabetes.²⁵ But this was not cold plunging. It was repeated cold-room acclimation, and the sample was tiny. A later single-arm study in nine patients with type 2 diabetes found that 10 days of mild cold acclimation without overt shivering did not improve insulin sensitivity, postprandial glucose or lipid metabolism, or intrahepatic lipid content; the authors suggested that some form of muscle contraction may be needed for metabolic benefit.²⁶

43% better insulin sensitivity — with shivering. No shivering, no benefit.
A 10-day cold-acclimation study raised insulin sensitivity in type 2 diabetics. A near-identical follow-up without shivering showed nothing. If the metabolic effect depends on shivering, the active ingredient is muscle activity, which is a form of exercise.

That is a key point. If the metabolic benefit requires shivering or muscle contraction, then the “cold” effect is partly an exercise-like muscle-activity effect. There is no good evidence that brief cold plunges cause meaningful fat loss, reverse insulin resistance, or substitute for exercise and diet.

The mood and mental-health claims are also not established. Cold immersion can create an acute arousal response. Some people feel better afterward. That is plausible. But acute mood improvement is not the same as treating depression, anxiety, PTSD, ADHD, or chronic stress. Much of the mental-health claim rests on small studies, subjective outcomes, open-water swimming culture, expectancy effects, and self-selection.

Cold plunge is also not risk-free. Cold-water immersion triggers the cold-shock response: rapid breathing, increased heart rate, increased blood pressure, and increased cardiac workload. The American Heart Association warns that sudden cold-water exposure can cause rapid increases in breathing, heart rate, and blood pressure, can produce involuntary gasping, and places stress on the heart.²⁷ Cold-water submersion can also create “autonomic conflict,” where sympathetic cold-shock responses and parasympathetic diving responses occur together, potentially provoking arrhythmias even in healthy volunteers.²⁸

Cold plunge is not free of risk. The cold-shock response spikes your breathing, heart rate, and blood pressure, and can trigger arrhythmias even in healthy people. If you have heart disease, high blood pressure, or unknown cardiac risk, this is not a casual purchase.

Direct Answer: Cold Plunge

Cold plunge has one fairly reasonable benefit: it may reduce perceived soreness after strenuous exercise. That may matter for athletes who need to compete or train again soon.

But cold plunge is not proven to improve long-term training adaptation. In resistance training, immediate post-workout cold plunge may blunt hypertrophy-related signaling and muscle growth adaptation. So it can be counterproductive depending on timing and goal.

Cold plunge is not proven to boost immunity. The best-known cold-shower trial reduced self-reported work absence, not actual illness days. That is not proof of fewer infections.

Cold plunge is not proven to reduce chronic inflammation in a clinically meaningful way. Acute changes in inflammatory markers or stress responses do not establish disease benefit.

Cold plunge is not proven to cause meaningful fat loss, reverse insulin resistance, improve testosterone, treat depression, treat autoimmune disease, or extend lifespan.

Cold plunge is not harmless. It acutely increases sympathetic and cardiovascular stress and can be risky for people with hypertension, coronary disease, arrhythmias, poor conditioning, breath-holding behavior, panic response, or unknown cardiac risk.

The honest conclusion is: cold plunge may help some people feel less sore after hard exercise and may create a short-term arousal or mood effect. Beyond that, most of the major wellness claims are unsupported or overstated.

References

1. Laukkanen T, et al. Sauna bathing and fatal cardiovascular and all-cause mortality events. JAMA Internal Medicine, 2015. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2130724

2. Sauna bathing and incident hypertension: a prospective cohort study. https://pubmed.ncbi.nlm.nih.gov/28633297/

3. Sauna bathing inversely associated with dementia and Alzheimer’s disease. https://pubmed.ncbi.nlm.nih.gov/27932366/

4. Sauna bathing and reduced risk of stroke in Finnish men and women. https://pubmed.ncbi.nlm.nih.gov/29720543/

5. Tei C, et al. Waon therapy for managing chronic heart failure (WAON-CHF). Circulation Journal, 2016. https://pubmed.ncbi.nlm.nih.gov/27001189/

6. Waon therapy improves the prognosis of patients with chronic heart failure (retrospective). Journal of Cardiology, 2009. https://www.journal-of-cardiology.com/article/S0914-5087(08)00328-6/fulltext

7. Effects of sauna bath on heart failure: a systematic review and meta-analysis, 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6489706/

8. Imamura M, et al. Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. https://pubmed.ncbi.nlm.nih.gov/11583886/

9. Masuda A, et al. Repeated sauna therapy reduces urinary 8-epi-PGF2α. Japanese Heart Journal. https://www.jstage.jst.go.jp/article/jhj/45/2/45_2_297/_article

10. Comparison of thermoregulatory, cardiovascular, and immune responses to passive heating modalities, 2025. https://pubmed.ncbi.nlm.nih.gov/40332494/

11. Sauna bathing and systemic inflammation. https://pubmed.ncbi.nlm.nih.gov/29209938/

12. Inflammation, sauna bathing, and all-cause mortality in middle-aged and older Finnish men. https://pmc.ncbi.nlm.nih.gov/articles/PMC9792415/

13. Impact of Finnish sauna bathing on circulating markers of inflammation. https://pubmed.ncbi.nlm.nih.gov/32951736/

14. Fever. Merck Manual, Professional Version. https://www.merckmanuals.com/professional/infectious-diseases/biology-of-infectious-disease/fever

15. Ernst E, et al. Regular sauna bathing and the incidence of common colds, 1990. https://pubmed.ncbi.nlm.nih.gov/2248758/

16. Bleakley C, et al. Cold-water immersion (cryotherapy) for preventing and treating muscle soreness after exercise. Cochrane. https://pubmed.ncbi.nlm.nih.gov/22336838/

17. Leeder J, et al. Cold water immersion and recovery from strenuous exercise: a meta-analysis. British Journal of Sports Medicine, 2012. https://pubmed.ncbi.nlm.nih.gov/21947816/

18. Broatch JR, et al. Postexercise cold water immersion benefits are not greater than the placebo effect. https://pubmed.ncbi.nlm.nih.gov/24674975/

19. Roberts LA, et al. Post-exercise cold water immersion attenuates acute anabolic signalling and long-term adaptations in muscle. https://pmc.ncbi.nlm.nih.gov/articles/PMC4594298/

20. Fyfe JJ, et al. Cold water immersion attenuates anabolic signaling and skeletal muscle fiber hypertrophy. Journal of Applied Physiology, 2019. https://journals.physiology.org/doi/full/10.1152/japplphysiol.00127.2019

21. Throwing cold water on muscle growth: a systematic review, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11235606/

22. Buijze GA, et al. The effect of cold showering on health and work. PLOS ONE, 2016. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161749

23. Effects of cold-water immersion on health and wellbeing: a systematic review and meta-analysis. PLOS ONE, 2025. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0317615

24. Altered brown fat thermoregulation and enhanced cold-induced thermogenesis in winter swimmers. Cell Reports Medicine, 2021. https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00266-4

25. Hanssen MJW, et al. Short-term cold acclimation improves insulin sensitivity in patients with type 2 diabetes. Nature Medicine, 2015. https://www.nature.com/articles/nm.3891

26. Metabolic responses to mild cold acclimation in type 2 diabetes. Nature Communications, 2021. https://www.nature.com/articles/s41467-021-21813-0

27. You’re not a polar bear: the plunge into cold water comes with risks. American Heart Association, 2022. https://www.heart.org/en/news/2022/12/09/youre-not-a-polar-bear-the-plunge-into-cold-water-comes-with-risks

28. Shattock MJ, Tipton MJ. “Autonomic conflict”: a different way to die during cold water immersion? Journal of Physiology. https://pmc.ncbi.nlm.nih.gov/articles/PMC3459038/

These compounds get described as “neuroplastic,” “neuroregenerative,” “anti-inflammatory,” “brain-repairing,” even “disease-modifying.” Some of those ideas are biologically interesting and worth studying seriously, and none of them are the same as proven clinical outcomes. A compound can acutely change brain-network connectivity, raise markers of synaptic plasticity in animals, lift mood, cut craving, and help someone engage in psychotherapy, and none of that automatically means it repairs neurons, reverses neurodegeneration, remyelinates axons, slows Parkinson’s, treats Alzheimer’s, or changes the biology of multiple sclerosis.

The strongest human evidence for psychedelic-assisted therapy is in psychiatric and addiction outcomes, not in proven neurologic disease modification.

That distinction is where the public conversation usually falls apart. People hear “neuroplasticity” and jump to “brain repair,” hear “less depression” and jump to “neurodegeneration treatment,” hear “changed brain connectivity” and jump to “disease modification.” Those aren’t the same claim.

Psilocybin-assisted psychotherapy has randomized trial evidence for alcohol-use disorder, tobacco cessation, and cocaine-use disorder. Ibogaine has intriguing but lower-quality observational evidence for addiction, plus a recent uncontrolled study in veterans with traumatic brain injury, and it carries uniquely serious cardiac risks. For Parkinson’s, Alzheimer’s, multiple sclerosis, traumatic brain injury, neuromuscular disease, and age-related cognitive decline, the evidence is early, incomplete, and mostly mechanistic or preclinical rather than clinically definitive. [2–8]

Here’s the shape of it before the details. The addiction evidence is the strongest part of the field, mostly Grade B for psilocybin-assisted therapy in selected substance-use disorders. The neurologic-disease evidence is mostly Grade C to D, and the disease-modification claims are Grade E. The whole issue is the gap between “psychiatric symptom improved” and “neurologic disease repaired.”

Subscribe now

The SITREP Evidence Scale

This isn’t a formal Cochrane or GRADE review, but it follows the same logic: human outcomes beat animal mechanisms, randomized trials beat observational reports, and disease-specific outcomes beat extrapolation.

Grade A. Multiple well-designed randomized controlled trials, replicated across groups, with clinically meaningful human outcomes.

Grade B. One or more randomized controlled trials in humans, peer-reviewed, with meaningful outcomes, but limited by sample size, blinding problems, short follow-up, narrow populations, or no replication.

Grade C. Human open-label, uncontrolled, observational, retrospective, or feasibility data. Useful signal, not definitive.

Grade D. Mechanistic, imaging, biomarker, animal, cellular, case-report, or theoretical evidence. Biologically interesting, not enough for clinical claims.

Grade E. No meaningful clinical evidence for the specific claim.

The grade attaches to the specific claim, not the compound. Psilocybin has a reasonable human signal for alcohol-use disorder, and that says nothing about whether it modifies Parkinson’s, Alzheimer’s, MS, TBI, or cognitive aging.

The Regulatory Reality

In the US, many of these compounds are still Schedule I under federal law, including psilocybin, psilocin, DMT, mescaline, peyote, and ibogaine. That doesn’t mean they have no scientific value; it means they aren’t broadly available as FDA-approved treatments, and their clinical use stays confined to research protocols, specific state-regulated programs, or settings outside the US.

The FDA has issued draft guidance for psychedelic drug development, which signals the field is being taken seriously, but guidance isn’t approval. The bar stays the same one used for any neurologic or psychiatric intervention: controlled trials, clinically meaningful outcomes, biomarker support when disease modification is claimed, careful adverse-event reporting, and replication. [1] This is regulatory context, not efficacy evidence, and it argues for caution rather than dismissal.

The Field at a Glance

Alcohol-use disorder. Best evidence is a randomized trial of psilocybin-assisted psychotherapy. It suggests reduced heavy-drinking days versus active placebo plus therapy. It doesn’t prove brain repair, an addiction cure, or disease modification.

Tobacco cessation. Best evidence is a pilot randomized trial of psilocybin-assisted therapy versus nicotine patch, both with CBT. It suggests higher biochemically confirmed abstinence at six months. It doesn’t prove durable broad addiction efficacy or neurologic disease modification.

Cocaine-use disorder. Best evidence is a small randomized trial of psilocybin-assisted therapy. It suggests more cocaine-abstinent days and lower lapse risk. It doesn’t prove long-term remission across broader populations without replication.

Opioid and polysubstance addiction. Best evidence is mostly observational ibogaine studies and systematic reviews. It suggests possible reduction in withdrawal and craving. It doesn’t prove safe, reliable, FDA-grade efficacy.

Traumatic brain injury. Best evidence is an uncontrolled observational ibogaine-magnesium study in veterans. It suggests improvements in disability, mood, PTSD, anxiety, and function. It doesn’t prove axonal repair, reversal of blast injury, or true neural regeneration.

Parkinson’s disease. Best evidence is a small open-label psilocybin safety and feasibility study. It suggests possible mood, nonmotor, motor, and cognitive improvements. It doesn’t prove slowing of dopaminergic neurodegeneration or disease modification.

Alzheimer’s disease and MCI. Best evidence is mostly preclinical work, recruiting trials, and isolated case-level material. It suggests mechanistic plausibility and possible future psychiatric-symptom applications. It doesn’t prove cognitive rescue, amyloid or tau modification, or slowed dementia.

Multiple sclerosis. Best evidence is mechanistic reviews and palliative or distress trials that may include MS patients. It suggests possible relevance to depression, anxiety, distress, and neuroimmune biology. It doesn’t prove remyelination, relapse reduction, MRI improvement, or disability modification.

Neuromuscular disease. Best evidence is no meaningful disease-specific clinical evidence. It suggests a possible future role in distress in serious illness. It doesn’t prove motor-neuron rescue, neuromuscular junction repair, or reversal of denervation.

Cognitive aging. Best evidence is mostly extrapolation from plasticity and depression studies. It suggests hypothesis-generating biology only. It doesn’t prove cognitive longevity, dementia prevention, or age-related disease modification.

The map is deliberately conservative. The best clinical evidence isn’t in neurodegeneration; it’s in addiction and psychiatric symptoms, and for neurologic disease modification most categories sit at Grade D or E.

Addiction and Substance-Use Disorders

This is where the evidence is most developed.

In a randomized trial of 93 adults with alcohol-use disorder, psilocybin-assisted psychotherapy cut the percentage of heavy-drinking days compared with an active placebo of diphenhydramine plus psychotherapy. Heavy-drinking days ran 9.7% in the psilocybin group versus 23.6% in the controls over post-treatment follow-up, with no serious adverse events among psilocybin recipients. It’s worth saying exactly what was tested: psilocybin plus structured psychotherapy, not psilocybin as a standalone supplement, a retreat experience, or a casual self-administered dose. [2]

Evidence grade: B. A peer-reviewed, double-blind randomized trial in JAMA Psychiatry, 93 participants, active placebo, manualized psychotherapy, 32 weeks of follow-up. It isn’t Grade A because it’s still a single major trial, psychedelic trials are vulnerable to functional unblinding, and the intervention bundled drug with psychotherapy.

The randomized evidence is widening. A 2026 cocaine-use-disorder trial gave a single moderate-to-high psilocybin dose with psychotherapy against diphenhydramine plus psychotherapy in 40 adults; the psilocybin group had more cocaine-abstinent days, higher complete abstinence, and lower lapse risk through 180 days. A separate 2026 tobacco pilot found higher six-month biochemically verified abstinence with psilocybin-assisted therapy than with nicotine patch, both with CBT. Promising, and still small, and best read as supporting further development rather than proving that psychedelics “cure addiction.” [3,4]

Evidence grade: B, lower end, for cocaine and tobacco. The cocaine trial was randomized, quadruple-blind, and placebo-controlled in JAMA Network Open, but only 40 adults, 36 completing the 180-day assessment, with urine-verified outcomes. The tobacco trial, also in JAMA Network Open, randomized 82 smokers, but it was a pilot and participants and investigators were unblinded, which matters when expectancy effects run strong.

Ibogaine is the other compound that dominates addiction discussion, especially for opioid-use disorder. The signal’s intriguing and the evidence is much less clean. Systematic reviews suggest ibogaine and its metabolite noribogaine may reduce withdrawal and craving in some patients, and the literature is mostly observational, uncontrolled, heterogeneous in dosing, and shadowed by real safety problems, including QT prolongation, arrhythmia, neurologic complications, and deaths. Ibogaine doesn’t belong in the same safety category as psilocybin; it has different pharmacology and a far more concerning cardiac profile. [5,6]

Evidence grade: C for possible addiction benefit, B for cardiac risk. The efficacy literature is mostly observational and often gathered outside conventional research settings. The cardiac-risk concern, by contrast, is backed by pharmacology, safety studies, and recurring reports of QT prolongation and malignant arrhythmias.

None of these studies prove structural neural repair. The benefits may come from some mix of the acute experience, greater psychological flexibility, reduced avoidance, network-level brain changes, stronger therapeutic engagement, and behavior change after the session. That’s Grade B for psilocybin-assisted therapy improving selected addiction outcomes, Grade C for ibogaine reducing addiction symptoms, and Grade E for any claim that either has proven structural neural repair in humans.

Psilocybin-assisted therapy has real randomized evidence in some substance-use disorders. Ibogaine has a weaker evidence base and much larger safety concerns, and the two shouldn’t be discussed as if they’re equal.

Traumatic Brain Injury

The most visible recent TBI study paired ibogaine with magnesium in 30 male US Special Operations veterans with mostly mild traumatic brain injury. It was a prospective observational study, not a randomized trial. Participants got ibogaine in a non-US setting along with other interventions, and the study reported improvements in disability, PTSD, depression, and anxiety immediately and at one month, with no serious adverse events in that cohort. [7]

Evidence grade: C for symptom improvement, E for neurorepair. It was published in Nature Medicine, which makes it a visible, credible signal, and the design is still uncontrolled and observational. There was no randomization, no placebo, no blinding, and no way to separate ibogaine from the magnesium, the psychotherapy, the retreat setting, expectancy, group effects, travel, or natural recovery. The authors themselves called for controlled trials. The outcomes were clinical and functional, not biomarkers of axonal repair, reduced neuroinflammation, better white-matter integrity, or reversed pathology. The clinical signal is worth studying; the neural-repair claim isn’t established.

Ibogaine may improve symptoms after TBI, especially the parts that overlap with PTSD, depression, and anxiety. There’s no evidence it repairs the injury itself, and its cardiac risk makes the unsupervised version genuinely dangerous.

Parkinson’s Disease

Parkinson’s is one of the areas where enthusiasm is most likely to outrun the evidence.

A recent open-label pilot tested psilocybin in 12 patients with mild-to-moderate Parkinson’s plus clinically significant depression or anxiety, giving two doses with psychotherapy support. There were no serious adverse events, no psychosis, and no worsening of Parkinson’s symptoms, alongside reported improvements in mood, nonmotor symptoms, motor scores, and some cognitive measures. [8]

Evidence grade: C for the short-term symptom signal, E for disease modification. A small, open-label pilot in Neuropsychopharmacology, useful for safety, feasibility, and signal. With 12 participants, no placebo, no blinding, and strong expectancy potential, it can’t establish efficacy, let alone disease modification. Parkinson’s rating scales move with mood, sleep, expectancy, motivation, attention, and rater effects, so a short-term MDS-UPDRS improvement doesn’t show that psilocybin protects dopaminergic neurons, reduces alpha-synuclein pathology, or slows progression.

The best read: psilocybin may eventually help depression, anxiety, demoralization, or nonmotor burden in Parkinson’s, and there’s no convincing human evidence it touches the underlying neurodegeneration.

A better mood and a steadier motor score for a few weeks isn’t the same as a slower disease. Nothing here shows psilocybin changes the course of Parkinson’s.

Alzheimer’s Disease, MCI, and Cognitive Decline

For Alzheimer’s and mild cognitive impairment, the evidence is mostly mechanistic, preclinical, or early-stage.

There are trials testing psilocybin for depression in MCI or early Alzheimer’s, and that’s different from proving cognitive rescue. Even a positive depression result wouldn’t mean reduced amyloid, reduced tau, preserved hippocampal volume, slower decline, or delayed conversion to dementia. [9] Preclinical work has explored effects on synaptic plasticity markers, neuroinflammation, and hippocampal or cortical signaling, which can justify more research and can’t be turned into a claim that psilocybin prevents Alzheimer’s or reverses dementia. Case reports of transient improvement after psilocybin-containing mushrooms are hypothesis-generating only; a single case can be moved by placebo, measurement noise, caregiver perception, arousal, sleep, mood, or delirium fluctuation. [10]

Evidence grade: D for mechanistic plausibility, E for clinical disease modification. The human trial landscape is early-phase and aimed at depression or quality of life, not proven dementia modification. The defensible conclusion: there’s no established clinical evidence that psychedelics prevent, reverse, or slow Alzheimer’s. At most there’s a plausible research path for mood, distress, and future biomarker-based trials.

There’s no established clinical evidence that psychedelics prevent, reverse, or slow Alzheimer’s disease. The interesting part is all upstream of that, in mechanism and mood.

Multiple Sclerosis, Neuroinflammation, and Neuromuscular Disease

Multiple sclerosis comes up because psychedelics may influence inflammatory signaling, microglial activity, cytokines, and stress-related immune pathways. That’s mechanistic plausibility, not clinical proof. Reviews have proposed relevance through anti-inflammatory, neuroplastic, or mood effects, and there’s no human data showing reduced relapse rate, better MRI lesion burden, lower neurofilament light chain, remyelination, or slowed disability. [11]

Some palliative-care trials include patients with serious neurologic illness such as ALS, atypical Parkinsonian disorders, or MS, and those are generally aimed at psychological distress, depression, anxiety, or existential suffering, which is a worthy endpoint and still not the same as treating the disease. [12]

For neuromuscular disease the evidence is thinner still. There’s no credible human evidence that psilocybin, DMT, 5-MeO-DMT, mescaline, or ibogaine restores motor neurons, improves neuromuscular junction function, reverses denervation, or changes ALS biology. These compounds may eventually be studied for distress in severe illness, and disease modification stays speculative.

Evidence grade: D for mechanistic plausibility, E for MS and neuromuscular disease modification. The MS literature is mainly mechanistic and review-based, and none of it proves relapse, MRI, remyelination, or disability benefit in humans.

The neuroimmune biology is a reasonable research lead. It’s nowhere near evidence that psychedelics remyelinate MS lesions or rescue motor neurons.

DMT and 5-MeO-DMT

DMT and 5-MeO-DMT show up in neurologic-repair discussions because they produce intense acute changes in consciousness and because preclinical models suggest neuroplastic and anti-inflammatory pathways. The human data, though, are mostly psychiatric.

A recent Phase IIa trial of intravenous DMT in major depressive disorder found rapid antidepressant effects versus placebo, and it was a depression trial, not a neurologic one. Randomized, double-blind, and placebo-controlled in Nature Medicine, with 34 participants. [13]

5-MeO-DMT has been studied as mebufotenin (GH001) in treatment-resistant depression. A Phase 2b randomized trial reported rapid antidepressant effects and high day-8 remission versus placebo, with no severe or serious adverse events during the placebo-controlled period. Again, that’s psychiatric therapeutics, not Parkinson’s, Alzheimer’s, MS, TBI repair, or cognitive longevity. This was a larger Phase 2b, double-blind, placebo-controlled trial across 16 European sites with 81 patients in JAMA Psychiatry; the endpoint was depression at day 8. [14]

Evidence grade: B for the short-term depression outcomes, E for neurologic disease modification. The psychiatric signal for 5-MeO-DMT is stronger than many early psychedelic studies, and the endpoint was depression, not neurologic repair. Both compounds are interesting in psychiatry, and their role in neurologic disease is unproven.

Mescaline, Peyote, San Pedro, and Related Phenethylamines

Mescaline has a long cultural and scientific history and a thin modern clinical base. A recent systematic review found reports of therapeutic effects across depression, well-being, nicotine dependence, alcohol-related outcomes, and obsessive symptoms, and the usable clinical evidence is small, heterogeneous, and often at serious risk of bias; the review concluded it’s insufficient for formal clinical decision-making without larger controlled trials. [15]

There’s no meaningful modern evidence that mescaline treats Parkinson’s, Alzheimer’s, MS, TBI, neuromuscular disease, or age-related cognitive decline, and claims about mescaline as a neurologic regenerative therapy aren’t evidence-based right now.

Evidence grade: C to D for psychiatric signal, E for neurologic disease modification. The 2026 review is useful for mapping the field and explicit about the limits: variable quality, many observational studies, small samples, older trials, and serious risk of bias.

Mechanisms: What’s Plausible

The common mechanistic argument is that psychedelics are “psychoplastogens,” compounds that may rapidly promote structural or functional neural plasticity.

In preclinical systems, serotonergic psychedelics promote neuritogenesis, spinogenesis, synaptogenesis-related signaling, and dendritic complexity, apparently through 5-HT2A signaling and downstream pathways that may include glutamatergic, BDNF/TrkB, and mTOR signaling. [16] The Ly et al. paper in Cell Reports is the heavily cited source, and it’s a mechanistic, preclinical study, not a human outcomes trial. It supports biological plausibility, not proof of human brain repair.

Human imaging shows psychedelics can acutely reorganize brain networks. Psilocybin, for instance, lowers within-network integrity of the default mode network and raises global connectivity across systems, which may help explain altered self-referential processing, emotional flexibility, and shifts in entrenched patterns. [17] But altered connectivity isn’t the same as improved outcome, neurogenesis, remyelination, or disease modification.

Here’s where the interpretation usually goes wrong. More plasticity isn’t automatically good. The brain isn’t improved just by becoming more plastic; plasticity can be adaptive or maladaptive, and a temporary rise in synaptic plasticity doesn’t prove neurogenesis, remyelination, reversed neurodegeneration, or durable cognitive gain. A recent systematic review of human studies found no evidence that psychoplastogens reliably raise peripheral BDNF in blood, which should cool the simple claim that these drugs “boost BDNF” in any meaningful way. The meta-analysis pooled 29 human studies; it doesn’t disprove central neuroplasticity, and it shows “raises BDNF” isn’t a clean human biomarker claim. [18]

There’s also preclinical evidence that psychedelics influence inflammatory signaling, including microglial function and cytokines. Interesting for neuroinflammatory disease hypotheses, still far from clinical benefit in MS, Alzheimer’s, Parkinson’s, TBI, or neuromuscular disease. Cell and animal models generate mechanism; they aren’t clinical outcomes. [11]

Evidence grade: D for clinical inference from mechanism, B for the negative peripheral-BDNF finding. The mechanistic biology is plausible enough to study and not strong enough to guide practice or support disease-modification claims.

Plasticity isn’t the same as repair, and “raises BDNF” doesn’t hold up as a clean human marker. The biology is a reason to run the trials, not a result that replaces them.

Symptom Improvement Versus Disease Modification

This distinction is the center of the whole discussion.

A Parkinson’s patient may have less depression, better sleep, lower anxiety, more motivation, and better engagement with physical therapy after a psychedelic-assisted intervention. That would matter, and it wouldn’t prove the intervention slowed Parkinson’s. A TBI patient may report better function, less PTSD, better mood, and better quality of life. That matters too, and unless the trial shows objective neurologic recovery beyond expectation, ideally with biomarkers, imaging, neuropsychological testing, and durability, it doesn’t prove neural repair.

Disease modification means something specific in each condition. For Alzheimer’s, slower cognitive decline on validated testing plus amyloid, tau, or MRI changes. For MS, reduced relapse activity, better MRI lesion metrics, lower neurofilament light chain, improved disability trajectory, or remyelination. For Parkinson’s, more than a short-term motor-score bump: altered progression, dopaminergic preservation, or alpha-synuclein-related biomarkers. None of that has been shown for any of these compounds.

Feeling better isn’t the same as being repaired. Addiction and psychiatric outcomes have real Grade B signals; neurologic symptom relief is mostly Grade C; mechanism is Grade D; disease modification is Grade E.

Where Enthusiasm Exceeds the Evidence

A handful of overclaims show up again and again.

The first is that psychedelics “repair the brain.” That isn’t established in humans. Dendritic spine growth, altered connectivity, or shifted plasticity markers in preclinical work don’t equal clinical neural repair.

The second is that they’re anti-aging cognitive enhancers. There’s no convincing evidence that any of these compounds slows cognitive aging or prevents dementia.

The third is that microdosing is a proven neurologic therapy. It’s popular, and popularity isn’t evidence; placebo, expectancy, selection bias, and publication bias all run heavy here.

The fourth is that ibogaine is a safe reset button for addiction or TBI. It’s pharmacologically interesting and medically risky, with QT prolongation, arrhythmias, drug interactions, electrolyte problems, opioid-related risks, and deaths on the record. Its addiction evidence is mostly Grade C and the safety concern is more substantial, so possible benefit doesn’t erase plausible serious harm. [5,6]

The fifth is that depression trials extrapolate to neurodegenerative disease. A positive treatment-resistant-depression trial doesn’t prove benefit in Alzheimer’s, Parkinson’s, MS, ALS, or TBI.

Safety

Classic serotonergic psychedelics like psilocybin look reasonably well tolerated in carefully screened clinical-trial settings, and that sentence carries several qualifiers. Participants are screened. Dosing is supervised. Psychological support is provided. People at risk for psychosis or mania, with unstable cardiovascular disease, or on certain interacting medications are often excluded.

Acute effects can include anxiety, panic, headache, nausea, vomiting, transient blood-pressure elevation, dizziness, fatigue, and psychologically distressing experiences. Serious psychiatric adverse events look uncommon in modern supervised trials, and the studied populations aren’t the general population. A 2024 meta-analysis of randomized double-blind trials found therapeutic psilocybin doses produced acute effects like headache, nausea, anxiety, dizziness, and blood-pressure changes, generally tolerable and time-limited. That’s Grade B for short-term tolerability in supervised, screened settings, and it doesn’t prove safety in unscreened real-world use, repeated use, medically complex patients, bipolar or psychosis-risk patients, or unsupervised settings. [19]

Ibogaine needs separate treatment. It isn’t just another classic psychedelic; it has complex pharmacology and a clearer link to QT prolongation and potentially fatal arrhythmias. Any discussion that skips cardiac screening, medication interactions, electrolyte management, monitoring, and the limits of nonmedical retreat settings is incomplete. Even with efficacy uncertain, the cardiac-risk signal is clinically real, and it matters most because ibogaine is often used in medically fragile addiction populations where electrolyte abnormalities, opioid exposure, co-ingestions, and drug interactions are common. [5,6]

Screened, supervised psilocybin trials are one thing; unscreened real-world use is another. Ibogaine’s cardiac risk puts it in a different category entirely.

Practical Clinical Interpretation

The evidence-based position is neither dismissal nor hype.

These compounds are scientifically interesting. Psilocybin-assisted therapy has credible evidence in several substance-use disorders and psychiatric conditions. DMT and 5-MeO-DMT are in development for mood disorders. Ibogaine has intriguing signals in addiction and TBI-related symptom burden, with weaker evidence and much greater safety concerns. Mescaline stays underdeveloped.

For neurologic disease, the current evidence supports research, not routine clinical claims. These compounds may eventually earn a role as adjuncts for depression, anxiety, demoralization, PTSD symptoms, existential distress, addiction, or behavioral rigidity in patients who also have neurologic disease. That would be valuable, and it’s different from saying they modify Parkinson’s, reverse Alzheimer’s, remyelinate MS lesions, regenerate neurons after TBI, or slow neurologic aging.

The next studies have to be more rigorous: randomized, blinded where possible, active placebo comparators, measured expectancy, long-term follow-up, careful adverse-event tracking, and disease-relevant biomarkers when disease modification is the claim. For Parkinson’s, validated motor and nonmotor outcomes plus progression biomarkers. For Alzheimer’s, cognitive outcomes plus amyloid, tau, or MRI. For MS, relapse rates, MRI lesions, disability, and neurofilament light chain. For TBI, objective neuropsychological testing, imaging, functional metrics, and durability past the immediate post-retreat window.

Bottom Line

Psychedelic and entheogenic medicine is a legitimate area of investigation. It isn’t a proven neurologic repair platform.

The best current human evidence is in addiction and psychiatric outcomes, especially psilocybin paired with structured psychotherapy. Ibogaine is promising and medically risky and rests on weaker evidence. For Parkinson’s, Alzheimer’s, MS, TBI, neuromuscular disease, and cognitive aging, the evidence is early and largely speculative.

The field doesn’t get one grade, because the grade attaches to the claim. Addiction outcomes in alcohol, tobacco, and cocaine are roughly Grade B: real randomized trials that are still small, hard to blind, and not broadly replicated. Neurologic symptom relief is mostly Grade C. The mechanistic biology, including plasticity, network changes, BDNF pathways, and anti-inflammatory hypotheses, is Grade D, interesting and indirect. Disease modification, meaning slowing Parkinson’s, reversing Alzheimer’s, remyelinating MS, repairing TBI, neuromuscular rescue, or cognitive longevity, is Grade E. Ibogaine sits in its own box: a possible Grade C benefit for addiction and TBI symptoms against a stronger Grade B cardiac-risk concern, a very different risk-benefit profile from psilocybin.

Graded like a college course: psilocybin for certain addictions earns a B; ibogaine for addiction and TBI symptoms earns a C with a safety warning in red ink; the mechanistic biology earns a C-minus to D, interesting but indirect. And on the question everyone actually cares about, whether these compounds modify neurologic disease, repair the injured brain, slow Parkinson’s, reverse Alzheimer’s, remyelinate MS, or prevent cognitive decline, the grade is an E.

The point isn’t that psychedelics are useless; it’s that the evidence swings hard depending on the claim. Addiction and psychiatric symptoms have real human data behind them, and neurologic repair and disease modification, so far, don’t. This field is worth studying seriously, and it hasn’t earned the right to make neurologic repair claims. Not yet, and maybe not ever.

This article is for education only and is not personal medical advice. It does not create a physician-patient relationship. Medical decisions should be made with a qualified clinician who knows your history, labs, medications, risk factors, and goals.

Know someone who is hearing too many men’s health claims from podcasts, influencers, supplement companies, or social media? Share this with them.

Share

References

1. U.S. Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations. Draft Guidance. June 2023.

2. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(10):953–962.

3. Johnson MW, Naudé GP, Hendricks PS, Garcia-Romeu A. Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. JAMA Network Open. 2026;9(3):e260972.

4. Hendricks PS, Lappan SN, Shelton RC, et al. Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial. JAMA Network Open. 2026;9(5):e2611029.

5. Köck P, Froelich K, Walter M, Lang U, Dürsteler KM. A systematic literature review of clinical trials and therapeutic applications of ibogaine. Journal of Substance Abuse Treatment. 2022;138:108717. doi:10.1016/j.jsat.2021.108717.

6. Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction. 2022;117(1):118–128.

7. Cherian KN, Keynan JN, Anker L, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. 2024;30:373–381. doi:10.1038/s41591-023-02705-w.

8. Bradley ER, Sakai K, Fernandes-Osterhold G, et al. Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial. Neuropsychopharmacology. 2025;50(8):1200–1209. doi:10.1038/s41386-025-02097-0.

9. ClinicalTrials.gov. Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer’s Disease (trial registry listing). [Insert NCT number before publication.]

10. Zheng S, et al. Psilocybin for the treatment of Alzheimer’s disease (narrative review). 2024. [Confirm exact journal and volume before publication.]

11. Anchesi I, et al. Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair. Cells. 2025.

12. ClinicalTrials.gov. Psilocybin Therapy for Psychological Distress in Palliative Patients (trial registry listing; populations include COPD, ALS, MS, and atypical Parkinsonian disorders). [Insert NCT number before publication.]

13. Erritzoe D, Barba T, James E, et al. A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Nature Medicine. 2026. doi:10.1038/s41591-025-04154-z.

14. Cubała WJ, Bajbouj M, Bauer M, et al. GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026. doi:10.1001/jamapsychiatry.2026.0096.

15. Shaw J, Yong A, Lee J, et al. The Ethnopharmacological Use of Mescaline for Psychiatric Disorders: A Systematic Review. International Journal of Molecular Sciences. 2026;27(7):3081.

16. Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. 2018;23(11):3170–3182.

17. Gattuso JJ, Perkins D, Ruffell S, et al. Default Mode Network Modulation by Psychedelics: A Systematic Review. International Journal of Neuropsychopharmacology. 2023;26(3):155–188.

18. Calder AE, et al. Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor in humans: a systematic review and meta-analysis. Molecular Psychiatry. 2025.

19. Yerubandi A, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-analysis. JAMA Network Open. 2024. See also Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024.

Know someone who is hearing too many men’s health claims from podcasts, influencers, supplement companies? The Men’s Health SitRep is a physician-led review of men’s health, longevity, and wellness claims. Subscribe free to receive future reports. Paid supporters receive deeper reviews, additional content, and the ability to submit topics or claims for future evidence review.

Subscribe now

If this report helped clarify something, share it with someone who wants evidence instead of marketing.

Share The Men's Clinic For Wellness and Vitality

Subscribe free to receive every Men’s Health SitRep, or upgrade to unlock premium research, bonus content, and the ability to request future SitRep topics.

Subscribe now

Start Here

Testosterone is one of the most misunderstood topics in men’s health, and one of the most heavily marketed. Podcasts, wellness clinics, online hormone companies, and influencers tell men that fatigue, weight gain, low motivation, low libido, poor recovery, and getting older are signs they probably need testosterone. That message is easy to sell. It’s also incomplete, and a lot of the time it’s wrong.

This piece is long because the topic is complicated. To understand testosterone in men over 40, you have to separate true hypogonadism (the medical term for genuinely low testosterone caused by a real problem in the system that makes it) from a low-normal lab value, and you have to account for the things that lower testosterone without the testes having failed: sleep apnea (where breathing repeatedly stops and restarts through the night), obesity, insulin resistance, alcohol, poor sleep, chronic stress, under-recovery, and certain medications. It’s written for the man who wants to understand what’s actually happening in his own body.

The central point is simple, and everything else builds on it. The question to start with isn’t “Do I need TRT?” (TRT means testosterone replacement therapy, the gels or injections men go on.) If you have symptoms, the first question is “Why do I have these symptoms?” Fatigue, poor recovery, weight gain, low libido, erectile dysfunction, poor sleep, and low motivation all have many possible causes, and testosterone is only sometimes the main one. There’s a real condition in which a man has persistent, properly documented hypogonadism after a genuine evaluation, and for that man testosterone therapy can be appropriate. That’s a different situation from the common one: a man who’s tired, carrying too much visceral fat (the deep fat packed around your organs), sleeping badly, metabolically unhealthy, and being told that an injection will fix all of it.

What follows is not my opinion. After decades of practicing medicine and reading the science, the conclusion on this question is where all of the evidence points, and on the specific question of who needs testosterone and who doesn’t, the data is clear-cut. That won’t be true of every SITREP; some topics are genuinely equivocal and the evidence doesn’t hand us a clean answer. This isn’t one of them. So as you read, understand that I’m reporting what the data shows, not what I happen to believe.

Some of you will hit a section that contradicts what you’ve been told, or what a wellness influencer keeps repeating. Some of you read widely online and think of yourselves as well-informed on this, and that’s fine; if you’ve genuinely done the homework and weighed the real research, you’ve arrived at the same conclusions this document reaches. If you read this and disagree, the burden is on you to produce evidence that overturns the mountain of it pointing the other way. You won’t be arguing with me, because none of this is my opinion. I’m only telling you what the data says.

The mistake isn’t asking about testosterone; it’s starting there. The first question is why the symptoms exist, and testosterone only earns a place in the answer once that question has been taken seriously.

The Short Version: Common Questions

Why are men over 40 suddenly so focused on testosterone?
Because it’s been marketed heavily as the explanation for fatigue, weight gain, low drive, and aging itself. Many men are asking about TRT because they’ve been taught to wonder whether it’s the missing piece.

Is testosterone important?
Yes, and true hypogonadism is a real medical condition. The point isn’t that testosterone doesn’t matter; it’s that symptoms deserve a real evaluation before testosterone becomes the answer.

Should my first question be “Do I need testosterone?”
No. The first question is “Why do I have these symptoms?” Start with the root cause of the fatigue, poor recovery, low libido, and weight gain, not with the prescription. More often than not testosterone is NOT the cause.

Age and the Decline Question

Does testosterone decline with age?
Yes, but gradually and unevenly. Men don’t go through a hormonal collapse like menopause, and age by itself doesn’t mean you need TRT. The decrease is also much less than wellness influencers want you to believe.

Is it true that men today have lower testosterone than past generations?
Not necessarily. That question has conflicting data, and it’s not settled. Some large studies show a decline, and others show none once you account for obesity and changes in how testosterone is measured. Even if averages have shifted, that doesn’t make testosterone the cause of “fatigue.”

What Counts as a Real Problem

What’s the difference between primary and secondary hypogonadism?
Primary means the testes are failing despite proper signaling from the brain; testosterone is low and LH and FSH (the two hormones the brain sends to tell the testicles to make testosterone and sperm) are high. Secondary means the brain isn’t signaling the testes properly; LH and FSH are low or inappropriately normal. Secondary can be real pituitary disease, but it’s often functional suppression from obesity, sleep apnea, medications, or under-recovery, which is potentially reversible.

What actually counts as hypogonadism?
It takes symptoms or signs of androgen deficiency (androgens are the male hormones, and testosterone is the main one, so this just means a real shortage of male-hormone effect) plus repeatedly low testosterone, measured correctly. A tired, overweight man with a low-normal level doesn’t automatically have hypogonadism; that picture only becomes a diagnosis after the other causes are ruled out, and when it does, it’s usually secondary, meaning the testosterone is being suppressed by something like obesity, sleep apnea, or poor sleep rather than by the testes failing. A single low value isn’t enough to justify lifelong treatment.

Is a low-normal level automatically a problem?
No. A man in the low range may have true deficiency, or his system may simply be suppressed by something else, like sleep apnea, excess weight, or alcohol. For the second group the fix is correcting what’s suppressing it, not reflexively injecting.

How much does testosterone normally fluctuate in most men?
A lot. In my own review of patients I’ve treated who were not on TRT, their total testosterone (the full amount in the blood) fluctuated a median of about 34% from peak to trough and free testosterone (the smaller, active portion your body can actually use) about 42%, while the group’s average start-to-finish change was essentially zero. A man can read 400 one month and 530 two months later without any supplement deserving the credit. That’s simply how the body works. Ups and downs are normal.

Are symptom checklists reliable?
No. They can flag who deserves evaluation, but they can’t prove testosterone is the cause. The symptoms most specific to low testosterone are sexual: reduced morning erections, fewer sexual thoughts, and erectile dysfunction. Fatigue and mood are much less specific.

How common is true late-onset hypogonadism?
Less common than the marketing implies. Using a strict definition, the European Male Aging Study put it around 2.1% of men.

When It Isn’t Testosterone

I’m tired. Doesn’t that mean my testosterone is low?
Usually not. Fatigue is one of the least specific symptoms there is; it tracks with poor sleep, sleep apnea, excess weight, alcohol, and depression far more reliably than with testosterone.

If I’m tired, overweight, and have sleep apnea, and my testosterone is low-normal, isn’t that the cause?
That’s probably backwards. In that man the low testosterone is usually a downstream signal of impaired physiology, and injecting it won’t treat the sleep apnea, the belly fat, or the metabolic problems driving how he feels. In untreated sleep apnea it can actually make things worse.

Does testosterone melt fat?
No. It isn’t a weight-loss drug. In genuinely hypogonadal men it can add lean mass and modestly reduce fat, but that’s not the same as treating obesity, and it won’t do the work of nutrition, training, sleep, and cutting back on alcohol.

Why does obesity matter so much here?
Excess visceral fat is one of the strongest drivers of low testosterone, partly through SHBG (a protein in the blood that grabs testosterone and holds onto it so your body can’t use it) and estrogen, and partly by suppressing the brain-to-testicle signaling. In many men the weight is part of the cause of the low number, not proof that injections are needed.

Why does everyone keep mentioning sleep apnea?
Because it’s common, frequently missed, and tied directly to fatigue, poor recovery, sexual dysfunction, heart and metabolic risk, and low testosterone. Much of a man’s daily testosterone is produced during sleep, so when breathing fragments that sleep night after night, the number drops. A man with untreated sleep apnea shouldn’t be routed straight to TRT. In fact, a man with untreated sleep apnea on TRT has a worse risk profile and can worsen his sleep apnea.

Can poor sleep or high stress lower testosterone on their own?
Yes. A week of short sleep can drop daytime testosterone measurably in healthy young men, and extreme stress like military field training or deployment suppresses it sharply, with recovery afterward. That’s the system responding to under-recovery, not the testes failing.

Treatment, Risks, and What to Do First

Does testosterone reliably fix low energy?
No. The Testosterone Trials showed real benefit for sexual function but not for vitality on the primary measure, which is why “I’m tired” is a poor reason to start.

What does testosterone do to fertility?
Exogenous testosterone (testosterone you take, rather than make) shuts down LH and FSH, drops the testosterone inside the testes, and can suppress sperm production heavily, sometimes to zero. It’s not a casual decision if you may want children. Testicles shrink too, like peanuts in many cases.

Is testosterone FDA-approved as an anti-aging treatment?
No. It’s approved for low testosterone tied to specific medical conditions, not for aging, fatigue, or low motivation.

So what should a man over 40 do first?
Stop leading with the idea that you have “Low T” and need TRT. If you have symptoms, get them evaluated: sleep and snoring, daytime sleepiness, blood pressure, waist and visceral fat, fatigue, alcohol, diet, medications, mood, stress, and fertility goals. Treat the reversible causes first, and if your testosterone is still clearly low afterward and you have real symptoms of deficiency, then it’s a conversation worth having, as a medical treatment rather than a wellness upgrade. Testosterone will not fix those root causes.

The Full Picture

Why “why” comes first

A reader asked me to take on this topic of testosterone in men over 40 (even though I recently did a very comprehensive SITREP, “Stop Letting the Internet Diagnose Your Testosterone,” which covers a lot of this). So here we go again.

The marketing pitch is always the same: if you’re over 40 and tired, softer in the middle, less driven, and less interested in sex, you have “low T,” and testosterone will fix it. It’s persuasive because it compresses a complex physiologic problem into a simple fix. But the marketing claim is incomplete, very incomplete. Some men genuinely have hypogonadism (low testosterone) and do well on properly prescribed testosterone, but many more are being taught to believe that the ordinary effects of poor sleep, excess fat, metabolic dysfunction, stress, deconditioning, alcohol, and aging are proof of a hormone deficiency, and that isn’t what the evidence says. Evidence-based science defines testosterone deficiency as a clinical and biochemical diagnosis, not a tired man with a lab value he doesn’t like. [1,2]

So the better question isn’t “should men over 40 take testosterone.” It’s “why does this man have these symptoms, what’s his actual testosterone physiology, and is the testosterone the problem or a signal of a different one?” In many men a low or low-normal testosterone level isn’t the root cause; it’s a marker of impaired health. Raise the number with an injection and you’ve changed the lab without touching the physiology. [1,2,13-22]

A low testosterone level is a clue, not a diagnosis. Treating the number while ignoring why it’s low isn’t treating the man.

“Men have lower testosterone now” — what the data actually shows

Testosterone does tend to fall with age, but slowly and unevenly, and nothing about it resembles the abrupt transition of menopause. Some men hold normal levels into old age and others drop earlier, and age alone doesn’t explain the difference; body composition, sleep, chronic disease, medications, alcohol, and activity all feed into it. [1,2,13-15]

You’ll also hear that men today have lower testosterone than their fathers did. That deserves a careful look. Several studies do report age-independent declines over calendar time: the Massachusetts Male Aging Study, Danish and Finnish population surveys, a large Israeli health-system dataset, and a NHANES analysis of younger men. [6-10] At a glance, that looks like a settled downward trend.

But in fact it isn’t, because these are observational population datasets rather than experiments, vulnerable to shifts in assay methods, sample handling, who’s in the sample, obesity, smoking, disease burden, medications, and testosterone prescribing itself. The Danish data make the point well: across more than 5,300 samples, total testosterone looked lower in more recent men, but after adjusting for body weight the cohort effect on total testosterone lost significance, and there was no significant change in the active free testosterone. [7] That matters because total testosterone tracks heavily with SHBG, and a drop in total testosterone isn’t the same as a drop in the testosterone your body can actually use. The U.S. NHANES comparison from 1988–91 to 1999–2004 found essentially no change in total testosterone, free testosterone, or SHBG after adjustment, and concluded there was no evidence of a decline in that period. [11]

Men today are more likely to be overweight than men a generation ago, and excess weight lowers testosterone on its own. Once you adjust for that, much of the apparent decline shrinks or disappears, and the active, usable portion of testosterone often hasn’t fallen at all. The popular claim rests on weaker ground than it first appears.

Other studies do support a decline, with caveats. MMAS found an age-independent drop not explained by measured changes in obesity or smoking. [6] The Finnish data held up after weight adjustment. [8] The Israeli dataset found a decline but drew on men referred for testing, so referral patterns confound it. [9] The younger-men NHANES analysis found lower levels in later cycles but flagged confounders and changing lab methods. [10] Add the measurement problem, where the type of assay, calibration, fasting, and time of day all move the result, and cross-decade comparisons get hard to trust. [12]

The honest conclusion is cautious. Some credible studies suggest age-matched testosterone has fallen in certain populations, but others do not; the evidence isn’t uniform, the causes are unclear, and it’s not a basis for prescribing testosterone to every middle-aged man who complains of fatigue. It should prompt a better question: what’s changed in modern life, from body composition and sleep to activity, diet, medications, and metabolic health, that could be shaping testosterone biology?

Even if men’s average testosterone has fallen, a population trend can’t diagnose a person. It’s an argument for fixing modern health, not for writing testosterone prescriptions.

What hypogonadism actually means

Definitions matter here. Hypogonadism isn’t a testosterone level you’d like to be higher, and it isn’t being tired or being over 40. It’s symptoms or signs of androgen deficiency together with repeatedly low testosterone, measured correctly, and a single random value shouldn’t diagnose anyone or justify long-term treatment. The responsible approach is early-morning testing, a repeat measurement to confirm, and an evaluation of the whole system that runs from the brain down to the testicles. [1,2]

Primary hypogonadism means the testes aren’t producing enough despite proper signaling, so testosterone is low and LH and FSH are usually high, because the brain is calling louder and louder for a response that isn’t coming. Secondary means the brain isn’t sending the signal adequately, so testosterone is low and LH and FSH are low or inappropriately normal. The distinction is clinical: primary points toward testicular failure, while secondary points toward pituitary disease, high prolactin, medications, obesity, sleep disorders, illness, under-fueling, overtraining, or other functional suppression. [1,2,14-22]

Then there’s the gray zone, where most of the confusion sits. Plenty of men fall inside the normal reference range but in its lower portion. Harmonized data in healthy nonobese men aged 19 to 39 put the total testosterone range at roughly 264 to 916 ng/dL, which is a wide span. A man in the low 300s isn’t the same as a man at 800, but he also isn’t automatically diseased; he may have true deficiency, or one of the reversible causes already mentioned. The number only means something in context. [1-5,13-22]

“Low testosterone” and “hypogonadism” are not the same thing. One is a number; the other is a diagnosis that needs symptoms, repeat testing, and a reason the number is low.

Why your testosterone number bounces around

Testosterone fluctuates a lot in every man, and this is where a lot of marketing finds its opening. Levels swing over the day, with afternoon values materially lower than morning ones, especially in younger and middle-aged men, and ordinary biological variation means repeat measurements differ even when nothing about your health has changed. That’s why the guidelines call for repeat morning testing before any diagnosis. [1,2,4,5]

My own practice data show it plainly. In a review of untreated men I followed over time, men not on testosterone, not on hormone-modifying drugs, not on GLP-1s, not losing major weight, not preparing for competition, and not selected for heavy alcohol use or untreated sleep apnea, testosterone moved a lot anyway. Over an average of about 16.4 months, the median peak-to-trough swing in total testosterone was 34.4%, and free testosterone swung even more, a median of 41.8%. And the group wasn’t trending in either direction; from first lab to last, average total testosterone changed by −0.4% and free testosterone by −0.8%. The group was essentially flat while individual numbers moved up and down the whole way through.

That has a direct clinical consequence. Check testosterone monthly for six months and the values will wander; a man might read 400 ng/dL one month and 520 to 540 a few months later with no supplement, protocol, or “hack” responsible. In that same review, total testosterone commonly moved 15 to 20% from one draw to the next, and the typical high-to-low spread over the full period was close to a third of the value. One man went from 401.6 to 539.9 ng/dL, a 34.4% rise. Another went from 478.8 to 723, a 51% swing. Another’s free testosterone went from 62.7 to 119 pg/mL, an 89.8% swing. Place a supplement label between any of those two draws and the testimonial writes itself, but it wouldn’t prove a thing.

This is why a before-and-after lab pair proves so little. Catch a man at a relative low, retest at a relative high, and the second number can be nothing more than normal variation, the natural drift back toward average, better sleep, different timing, a different training load, different calories, or less stress. So when someone says their testosterone jumped 30% on a supplement, the right reaction is skepticism; that much movement happens on its own, and the real question is whether it exceeds normal variation under controlled conditions.

Testosterone naturally swings by about a third on its own, so a before-and-after comparison can’t prove a supplement did anything. The lower starting number and the higher follow-up are exactly what normal fluctuation looks like.

Why symptom checklists mislead

Symptom checklists for low testosterone have the same problem. The usual list, including fatigue, low energy, low motivation, reduced strength, low mood, low libido, erectile dysfunction, more body fat, and poor recovery, is real, but most of it isn’t specific to testosterone. The same symptoms show up with all the usual suspects: poor sleep, sleep apnea, excess weight, depression, alcohol, and being out of shape. A questionnaire can tell you who deserves a look; it can’t tell you testosterone is the cause. [1,2,13]

The European Male Aging Study is useful here because it separated the generic symptoms from the ones that actually track with low testosterone, and the ones that did were sexual: reduced morning erections, fewer sexual thoughts, and erectile dysfunction. Physical and psychological symptoms were far less specific. With a strict definition, requiring at least three sexual symptoms plus low total and free testosterone, the prevalence of late-onset hypogonadism came out around 2.1%. That’s a long way from the marketing picture, where nearly every tired man over 40 is treated as deficient. [13]

Under a strict definition, true late-onset hypogonadism showed up in about 2.1% of men. The marketing treats it as if it’s nearly everyone.

Fatigue is the wrong place to start

Fatigue is the most common trap. A man is tired, gaining fat, not recovering, not himself; his testosterone comes back low-ish; the easy read is that low testosterone did it. Sometimes that’s true, and often it isn’t. If that same man sleeps badly, snores, wakes unrefreshed, has untreated sleep apnea, carries excess belly fat, drinks most nights, doesn’t train, and eats poorly, the low number is more likely a downstream signal than the cause, and those very habits are the likelier drivers. [13-22]

That’s why injecting testosterone into that man usually won’t fix why he feels bad. It won’t treat the sleep apnea or restore normal sleep, it won’t strip belly fat in any reliable way, and it won’t undo the damage of poor food, no exercise, and nightly alcohol. In a man with untreated sleep apnea it can make things worse, worsening the breathing at night, thickening the blood, and adding to heart risk. That’s the core error of the hormone-first model: it treats the number and ignores why the number is low. The likely result is a man stuck on long-term testosterone, with his own production now shut down, his fertility impaired, his testicles shrunken, and a monitoring burden on top of it, while the original causes of his fatigue sit exactly where they were. [1,2,14-22,26-28]

Injecting testosterone into a tired man with untreated sleep apnea and visceral fat raises a lab value and leaves the actual problem untouched. Sometimes it makes the problem worse.

Testosterone doesn’t melt fat

This is one of the biggest places the marketing oversells. Testosterone gets promoted as if it burns off belly fat and resets metabolism on its own, and that isn’t what happens in the clinic. In truly hypogonadal men, testosterone can add muscle and modestly reduce fat, and some trials show favorable body-composition effects, especially alongside a calorie-restricted diet or a lifestyle program. That’s a real effect, and it still isn’t a weight-loss drug or a treatment for obesity. In day-to-day practice, men on testosterone don’t automatically shed visceral fat; many stay overweight and out of shape if they don’t change food, training, sleep, and alcohol. [23]

There’s a related point worth one line: a man with a round middle, thin arms and legs, easy bruising, wide purplish stretch marks, and hard-to-control blood pressure or diabetes may have a cortisol problem (a different hormone disorder) rather than low testosterone, and that picture needs a real endocrine workup, not an injection. [29]

Testosterone is not a fat-loss drug. In the right patient it nudges body composition; it doesn’t replace food, training, sleep, and cutting back on alcohol.

Obesity and the testosterone number

Obesity is one of the strongest drivers of a low or low-normal number. Excess fat, the deep belly fat in particular, lowers total testosterone partly by lowering SHBG and partly by suppressing the brain-to-testicle signaling, and in many men that low testosterone is functional and at least partly reversible; weight gain tends to push it down and weight loss tends to bring it up. That doesn’t mean every heavy man can normalize through weight loss alone, but it does mean body composition belongs at the center of the evaluation rather than as an afterthought. [14,15]

The sleep apnea problem

Obstructive sleep apnea (OSA) is worth its own section, because it’s one of the most common and most commonly missed reasons a man over 40 shows up tired, unrecovered, sexually flat, at cardiac and metabolic risk, and low-normal on testosterone. Testosterone production is tied closely to sleep; the normal overnight rise depends on enough sleep and intact sleep stages, so when the repeated breathing pauses of sleep apnea fragment and shorten sleep night after night, the body’s ability to make testosterone gets suppressed. In that man the testes may not be the problem at all; the sleep apnea is choking off normal production. [16-20]

The mechanism is clear. Men make a meaningful share of their daily testosterone during sleep, and sleep apnea fragments sleep, cuts into the deepest stages, starves the body of oxygen in repeated dips, and keeps it on high alert all night. Studies in men with sleep apnea show reduced overnight testosterone signaling, and reviews pooling many studies find that the worse the apnea, the lower the testosterone tends to be. Severe apnea, obesity, and aging tend to occur together, which makes the causal web complicated, but sleep apnea belongs high on the list in any man with fatigue, low libido, erectile dysfunction, poor recovery, high blood pressure, belly fat, and a borderline number. [16-18]

So the move is direct: a man with untreated sleep apnea doesn’t need a hormone-first workup; he needs the sleep disorder found and treated, whether that’s CPAP (a machine that keeps the airway open at night), an oral appliance, weight loss, or some combination, usually alongside cutting back on alcohol and getting more exercise, because these factors feed each other. [16-20]

Will testosterone reliably rise once the apnea is treated? No, and the literature is mixed; some studies show a rise after treatment and others, pooling many trials, don’t show a consistent average increase across all men on CPAP. That doesn’t make sleep apnea irrelevant to testosterone; it makes the relationship real but variable. Some men improve hormonally when sleep improves, some get better energy, sexual function, and blood pressure without much testosterone change, some need weight loss on top of CPAP, and some have true hypogonadism that persists after the apnea is handled. [16-19] What shouldn’t happen is skipping the apnea and going straight to testosterone, because if untreated apnea is feeding the low number, testosterone doesn’t fix the upstream problem and can worsen the apnea in some men. It’s generally avoided or used with real caution in untreated severe apnea, where it can worsen the breathing at night and thicken the blood on top of risk that’s already elevated. [1,2,20,21,26-28]

Sleep apnea is the most commonly missed reason a man over 40 is tired and low on testosterone. Treat the breathing first; in untreated apnea, testosterone can make things worse.

Sleep, stress, and recovery

Even without apnea, short sleep alone lowers testosterone. In healthy young men, cutting sleep to about five hours a night for a week drops daytime testosterone by roughly 10 to 15%. That isn’t testicular failure; it’s the body responding to inadequate recovery. [20] The same logic runs through severe stress and food shortage: military field-training studies, including Army Ranger School, show large temporary drops in testosterone under sustained stress, sleep deprivation, and heavy workload, with recovery once the stressor lifts. The lesson isn’t that those men need testosterone; it’s that testosterone tracks the state of the body, and a man who’s underfed, under-slept, over-stressed, and under-recovered will often read low for that reason. [22]

A low number can simply mean an under-recovered body. A man who’s under-slept and over-stressed may need sleep and recovery, not a prescription.

What testosterone actually does, and doesn’t

None of this means testosterone is useless, and some men clearly benefit. Men with true primary or secondary hypogonadism, or persistent symptomatic deficiency after a real workup, deserve a serious treatment conversation, and in properly selected men testosterone can improve sexual desire and function, correct certain anemias, support bone density, and add lean mass. That’s legitimate medicine. [1,2,24]

But the benefits are narrower than the marketing, especially for age-related low testosterone with nonspecific symptoms. The Testosterone Trials in older men found real improvements in sexual activity, desire, and erectile function, and yet testosterone didn’t significantly improve vitality on the primary measure of energy and well-being. The American College of Physicians guideline for age-related low testosterone recommends considering it mainly for sexual dysfunction and specifically doesn’t support starting it to improve energy, vitality, physical function, or cognition. That distinction is the important one: testosterone can help sexual symptoms in selected low-testosterone men, and it’s not a reliable fix for feeling tired. [24,25]

The best trial in older men found testosterone helped sexual function but not vitality. It is not a reliable treatment for “I’m tired,” and the ACP guideline says so.

The risks and the fine print

There are real risks and long-term consequences. Testosterone you take from outside shuts down the brain’s signal to the testicles, which lowers the testosterone made inside them and can cut sperm production sharply, sometimes to zero, so it’s not a casual decision for a man who wants children. It can also thicken the blood, cause acne and fluid retention, bring on breast tissue in susceptible men, shrink the testicles, raise blood pressure, and commit a man to ongoing monitoring of his symptoms, testosterone, blood count, blood pressure, prostate, sleep apnea status, and heart risk. [1,2,26-28]

On heart safety, the picture should be stated accurately in both directions. The TRAVERSE trial was reassuring; in middle-aged and older men with documented low testosterone and elevated heart risk, testosterone was no worse than placebo for major cardiac events like heart attack and stroke, and on the strength of that the FDA removed the old boxed warning about cardiovascular risk in early 2025. That finding matters, and it isn’t a blanket approval. TRAVERSE studied symptomatic men with documented low testosterone, not healthy men using it for general aging, and the testosterone group still had higher rates of an irregular heartbeat (atrial fibrillation), blood clots in the lungs, and acute kidney injury. In the same round of changes the FDA kept the language saying it isn’t approved for age-related low testosterone and added blood-pressure warnings across testosterone products, after monitoring studies confirmed a class-wide rise in blood pressure. [26,27]

And the approved use is narrower than most men assume. Testosterone is approved for low testosterone tied to specific medical conditions, not as a general anti-aging treatment for a number that’s lower because of age or because a man feels off. Treating a disease and enhancing a healthy man aren’t the same thing, and the label still reflects that. [27]

TRAVERSE was reassuring on heart attacks and strokes, which is why the FDA dropped the old cardiac boxed warning. It still isn’t a green light, and the same drug raised atrial fibrillation, clots, and blood pressure.

What a man over 40 should actually do

First, stop treating testosterone as a standalone explanation for how you feel. It matters, but it’s one part of a larger system, and a man who’s tired, softening, losing fitness, sleeping poorly, drinking too much, and feeling flat shouldn’t assume the diagnosis is testosterone. [1,2,13]

Second, if you have symptoms, get evaluated properly. And do not go to a testosterone clinic. They only want to convince you that you need it, and they will. A proper evaluation means a real look at sleep and snoring, witnessed breathing pauses, daytime sleepiness, nighttime urination, morning headaches, blood pressure, waist and belly fat, exercise and strength, alcohol, diet quality, medications including opioids and any anabolic steroid use, depression, chronic stress, other illness, and fertility goals. These aren’t footnotes; they’re how you tell whether testosterone is the cause or just a marker. [1,2,13-22,28]

Third, if testosterone is measured, measure it correctly: in the morning, when you’re well, rested, and not acutely sleep-deprived, ill, overtrained, or starving yourself, and repeat it if it’s low or borderline. Interpret total testosterone alongside SHBG and free testosterone where appropriate, use LH and FSH to separate testicular failure from a brain-signaling or functional cause, and check the pituitary further in selected cases. [1-5]

Fourth, address the reversible causes first when they’re present. Treat the sleep apnea, lose the belly fat, and stop the nightly drinking; build aerobic fitness and lift weights; eat well, get enough protein, and sleep enough; repair the under-recovery, address depression, review medications, and treat metabolic disease. None of this replaces testosterone when true hypogonadism exists, but it’s the actual treatment when the low number is a downstream marker of poor health. [1,2,13-22]

Fifth, if testosterone stays clearly low after all that and you have real symptoms of deficiency, then it’s a reasonable conversation, and it should cover the expected benefits and their limits, fertility suppression, blood thickening, blood pressure, prostate monitoring, sleep apnea, route, dose, monitoring, and the likelihood that treatment is long-term. It should be presented as a medical treatment, not a wellness upgrade. [1,2,24-28]

The bottom line

Testosterone in men over 40 matters, and it’s widely misunderstood. A low level can mean true hypogonadism, and it can just as easily mean one of the everyday causes that suppress it: excess weight, sleep apnea, poor sleep, metabolic problems, stress, medications, overtraining, alcohol, or depression. The job is figuring out which. Many men are being pushed to chase a number before anyone has asked why it’s low, and that order is backwards. Understand the physiology first; if it’s true hypogonadism, treat it, and if it’s one of those reversible causes, treat that first. Raising testosterone while ignoring why it’s suppressed isn’t comprehensive care.

Testosterone can be a useful therapy or a convenient distraction. The difference is whether your doctor is treating a diagnosis or treating a lab value.

This article is for education only and is not personal medical advice. It does not create a physician-patient relationship. Medical decisions should be made with a qualified clinician who knows your history, labs, medications, risk factors, and goals.

References

1. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FCW, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715-1744.

2. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. Journal of Urology. 2018;200(2):423-432.

3. Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. Journal of Clinical Endocrinology & Metabolism. 2017;102(4):1161-1173.

4. Brambilla DJ, O’Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual Variation in Levels of Serum Testosterone and Other Reproductive and Adrenal Hormones in Men. Clinical Endocrinology. 2007;67(6):853-862.

5. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The Effect of Diurnal Variation on Clinical Measurement of Serum Testosterone and Other Sex Hormone Levels in Men. Journal of Clinical Endocrinology & Metabolism. 2009;94(3):907-913.

6. Travison TG, Araujo AB, O’Donnell AB, Kupelian V, McKinlay JB. A Population-Level Decline in Serum Testosterone Levels in American Men. Journal of Clinical Endocrinology & Metabolism. 2007;92(1):196-202.

7. Andersson AM, Jensen TK, Juul A, Petersen JH, Jørgensen T, Skakkebaek NE. Secular Decline in Male Testosterone and Sex Hormone Binding Globulin Serum Levels in Danish Population Surveys. Journal of Clinical Endocrinology & Metabolism. 2007;92(12):4696-4705.

8. Perheentupa A, Mäkinen J, Laatikainen T, Vierula M, Skakkebaek NE, Andersson AM, Toppari J. A Cohort Effect on Serum Testosterone Levels in Finnish Men. European Journal of Endocrinology. 2013;168(2):227-233.

9. Chodick G, Epstein S, Shalev V. Secular Trends in Testosterone: Findings From a Large State-Mandate Care Provider. Reproductive Biology and Endocrinology. 2020;18:19.

10. Lokeshwar SD, Patel P, Fantus RJ, Halpern J, Chang C, Kargi AY, Ramasamy R. Decline in Serum Testosterone Levels Among Adolescent and Young Adult Men in the USA. European Urology Focus. 2021;7(4):886-889.

11. Nyante SJ, Graubard BI, Li Y, McQuillan GM, Platz EA, Rohrmann S, Bradwin G, McGlynn KA. Trends in Sex Hormone Concentrations in U.S. Males: 1988-1991 to 1999-2004. International Journal of Andrology. 2012;35(3):456-466.

12. Vesper HW, Wang Y, Vidal M, Botelho JC, Caudill SP. Serum Total Testosterone Concentrations in the US Household Population From the NHANES 2011-2012 Study Population. Clinical Chemistry. 2015;61(12):1495-1504.

13. Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. New England Journal of Medicine. 2010;363(2):123-135.

14. Camacho EM, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, et al. Age-Associated Changes in Hypothalamic-Pituitary-Testicular Function in Middle-Aged and Older Men Are Modified by Weight Change and Lifestyle Factors: Longitudinal Results From the European Male Ageing Study. European Journal of Endocrinology. 2013;168(3):445-455.

15. Fernandez CJ, Chacko EC, Pappachan JM. Male Obesity-Related Secondary Hypogonadism: Pathophysiology, Clinical Implications and Management. European Endocrinology. 2019;15(2):83-90.

16. Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L, Lavie P. Decreased Pituitary-Gonadal Secretion in Men With Obstructive Sleep Apnea. Journal of Clinical Endocrinology & Metabolism. 2002;87(7):3394-3398.

17. Luboshitzky R, Lavie L, Shen-Orr Z, Herer P. Altered Luteinizing Hormone and Testosterone Secretion in Middle-Aged Obese Men With Obstructive Sleep Apnea. Obesity Research. 2005;13(4):780-786.

18. Su L, Meng Y, Zhao H, et al. Association Between Obstructive Sleep Apnea and Male Serum Testosterone: A Systematic Review and Meta-Analysis. Andrology. 2022;10(2):223-231.

19. Cignarelli A, Castellana M, Castellana G, Perrini S, Brescia F, Natalicchio A, et al. Effects of CPAP on Testosterone Levels in Patients With Obstructive Sleep Apnea: A Meta-Analysis Study. Frontiers in Endocrinology. 2019;10:551.

20. Leproult R, Van Cauter E. Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy Men. JAMA. 2011;305(21):2173-2174.

21. Hoyos CM, Killick R, Yee BJ, Grunstein RR, Liu PY. Effects of Testosterone Therapy on Sleep and Breathing in Obese Men With Severe Obstructive Sleep Apnoea: A Randomized Placebo-Controlled Trial. Clinical Endocrinology. 2012;77(4):599-607.

22. Henning PC, Scofield DE, Spiering BA, Staab JS, Matheny RW Jr, Smith MA, et al. Recovery of Endocrine and Inflammatory Mediators Following an Extended Energy Deficit. Journal of Clinical Endocrinology & Metabolism. 2014;99(3):956-965.

23. Fui MNT, Prendergast LA, Dupuis P, Raval M, Strauss BJ, Zajac JD, Grossmann M. Effects of Testosterone Treatment on Body Fat and Lean Mass in Obese Men on a Hypocaloric Diet: A Randomized Controlled Trial. BMC Medicine. 2016;14:153.

24. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of Testosterone Treatment in Older Men. New England Journal of Medicine. 2016;374(7):611-624.

25. Qaseem A, Horwitch CA, Vijan S, Etxeandia-Ikobaltzeta I, Kansagara D, for the Clinical Guidelines Committee of the American College of Physicians. Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine. 2020;172(2):126-133.

26. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. 2023;389(2):107-117.

27. U.S. Food and Drug Administration. FDA Issues Class-Wide Labeling Changes for Testosterone Products. February 28, 2025.

28. Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone Is a Contraceptive and Should Not Be Used in Men Who Desire Fertility. World Journal of Men’s Health. 2019;37(1):45-54.

29. Juszczak A, Morris D, Grossman A, Nieman LK. Cushing’s Syndrome. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth, MA: MDText.com, Inc.; updated 2024.

That distinction carries the entire article, so it’s worth being precise about it up front. A peptide is just a short chain of amino acids, and some of the most important drugs in medicine are peptides. Insulin is a peptide. The GLP-1 medications transforming obesity care are peptide-based. Oxytocin is a peptide. The category isn’t the problem, and nobody serious doubts that peptides can be medicine. The problem is that the word “peptide” is being used to borrow the credibility of insulin and semaglutide and lend it to compounds that have never been tested properly in a single human being. This article is about how to tell those two groups apart, and it starts by teaching you to read evidence rather than by listing molecules.

It’s worth being honest about who tends to read something like this, because you might be exactly the person the marketing was built for. Maybe you watched a podcast where a lean, confident guy credited his recovery and his physique to a peptide stack, and some part of you thought that might be the missing piece, the shortcut that finally turns your effort into the body and the energy you’re after. That instinct is human, and I’m not going to try to talk you out of wanting it. I’m going to ask you to hold it loosely. You can believe whatever you like about these compounds; the evidence will keep saying exactly what it says regardless of what any of us hope, and the whole point of what follows is to teach you how to hear it clearly. Wanting something to be true is one of the most dependable ways people end up paying for things that aren’t, and the more a claim flatters the hope you walked in with, the more carefully it deserves to be checked before you put it in your body.

Peptides can absolutely be real medicine. The real question is never the category; it’s whether the specific one in the syringe has ever been proven in a human.

Part I: How to Read the Evidence

Why a Result in Animals Tells You Almost Nothing About Humans

Most peptide marketing rests on animal studies, and most readers don’t know how weak that foundation is. The honest number is sobering: roughly nine out of ten drug candidates that are good enough to enter human trials still fail, and one large analysis found that 95% of candidates failed during clinical development, which works out to 19 of every 20 projects being abandoned.¹ When researchers ask why, the leading reason is simply that the drug doesn’t work in people; lack of efficacy accounts for 40 to 50% of clinical failures, with unexpected toxicity close behind.² These are compounds that already cleared the animal bar. They looked terrific in mice and rats, and then most of them did nothing useful, or caused harm, once they reached humans.

This happens for reasons that apply directly to peptides. Rodent studies often use doses that would never be practical in a person, delivered by routes that differ from how the compound is actually sold. They use animals bred to be genetically identical and housed in controlled conditions, which strips out the variability that makes real patients hard to treat. And they usually measure a disease model deliberately induced in the lab, not the lived condition a human walks in with. A peptide that accelerates tendon healing in a rat with a surgically created injury is telling you something genuinely interesting; it’s telling you the compound is worth the cost and trouble of a proper human trial. It isn’t telling you the compound works in humans, and treating those two statements as the same is the central error the marketing depends on.

Why Testimonials Are Worth Less Than People Think

Start with who’s giving the testimonials, because it explains most of their weakness. The people injecting these peptides are, almost by definition, people who went looking for them; they’re drawn to the idea of optimizing the body, they’ve already spent money and effort to get the vial, and they badly want the experience to be real. That’s close to the worst possible audience to ask whether something works, because the wanting itself changes what they feel. This is the placebo effect, and it’s neither imaginary nor a sign of a weak mind. When a person genuinely expects to improve, the brain can produce real, measurable changes in pain, energy, mood, and the sense of recovery, and those changes happen with an inert shot of salt water about as readily as with the active compound. A biohacker who has already decided a peptide will transform him will very often feel transformed, and his honest report of feeling incredible is a measure of his expectations far more than of the drug.

Layer the other distortions on top and it gets worse, so it’s worth knowing each one by name. People improve on their own all the time; injuries heal, stress passes, a rough stretch ends, and whatever you happened to be taking when the upswing arrived gets the credit even though you’d have recovered anyway. Statisticians call that regression to the mean, and it’s why people swear by a remedy they started on their worst day. Then there’s confirmation bias, the very human habit of noticing and remembering whatever fits what you already believe while quietly letting the rest fall away; the morning you felt strong becomes proof the peptide is working, and the three flat days get forgotten. There’s selection bias in what you even hear about, because the guy who felt nothing stops posting and cancels his next order, while the true believer makes the videos, so the testimonials that reach you have already been filtered down to the converts before you see a single one. And there’s publication bias in the research itself, where studies that find a positive result tend to get written up and celebrated while the ones that find nothing sit unpublished in a drawer. Any one of these, on its own, can manufacture the appearance of a working drug out of a compound that does nothing at all. Stack them together in an audience that desperately wants to be convinced, and they can make almost anything look like a miracle. That’s not a knock on the people sharing their stories; it’s the reason medicine stopped trusting stories a long time ago and built something more reliable in their place.

The Hierarchy of Evidence

Here’s the idea the whole field rests on, stated as plainly as I can put it. Feeling different isn’t the same thing as being helped, and one person getting better isn’t the same thing as a treatment working. Your body is noisy; it shifts from day to day for dozens of reasons that have nothing to do with what you took, and your mind quietly assembles a story to explain how you feel. So to actually know that a compound does something, you can’t lean on any single person’s sense that it helped, and that includes your own. The effect has to show up again and again, across groups of people, under conditions built specifically to rule out chance and wishful thinking, and it has to still be there when a different research team runs the same test. That property, repeatable under controlled conditions and confirmed by people with no stake in the answer, is what the word “proven” actually means in medicine. Everything below is just a way of ranking how close a given piece of evidence gets to that bar.

Picture it as a ladder. At the bottom sits work in cells and test tubes, then studies in animals, then a single case report of one patient, then a case series of a handful, then observational studies that follow groups over time without controlling who gets what. Higher up sits the randomized controlled trial, where people are assigned purely by chance to the drug or to a placebo, and neither they nor the people measuring them know which they got, because that design is the only one that reliably separates the drug’s real effect from the placebo response, the natural healing, and the biases just described. Above any single trial sits the systematic review and meta-analysis, which pool many good trials into one stronger answer, and at the very top sit the clinical guidelines built from all of it. Each rung carries more confidence than the one beneath it. When you hear a peptide claim, the only question that matters is which rung it’s actually standing on, and for most of what gets sold, the honest answer is one of the bottom two.

The Standard This Article Holds

Every compound below is judged against the same explicit rules, and I’m stating them so you can hold me to them. Human evidence outranks animal evidence. Randomized controlled trials outrank observational studies. Sound systematic reviews outrank single trials. Large, well-run Phase II and III trials count for far more than small pilots. Mechanistic, cell, and animal work is treated as a reason to investigate, never as proof. Statistical significance is kept separate from a benefit large enough to matter to a real patient. FDA-approved uses are kept separate from off-label use and from marketing claims. And absence of evidence is distinguished from evidence of no effect, because many of these peptides aren’t proven harmful; they simply have never been studied adequately in humans, which is its own kind of answer.

To make that standard visible, every compound ends with the same scorecard: biological plausibility, the quality of human efficacy data, the state of long-term safety data, FDA approval status, and an overall grade. The same five lines for a research peptide and for a blockbuster drug. That’s the point.

Part II: The Compounds

BPC-157

The claims. This is the flagship of the recovery-peptide world, sold as a near-universal repair compound: heals tendons, ligaments, muscle, nerve, and gut, accelerates recovery from training, and pushes back on aging.

The evidence. The animal literature is genuinely large; more than 200 peer-reviewed studies have examined BPC-157, almost all in rodents.³ The human literature is close to empty. **There are only three published human studies, all from a single research group, totaling fewer than 30 people, and not one is a completed randomized controlled trial.**⁴ The most-cited human study gave 12 people with knee pain an injection with no control group, no blinding, and no imaging; about 87% reported feeling better, which tells you nothing about whether the peptide caused it.⁵ The first properly designed trial, a placebo-controlled study in hamstring strains, only began recruiting in February 2026 and has no results yet.⁶ Decades of rat data and three tiny uncontrolled human reports is exactly the evidence profile the rest of this article is teaching you to recognize.

Evidence Scorecard — BPC-157
Biological plausibility: High · Human efficacy data: Very low · Long-term safety data: None · FDA approval: None · Overall: Experimental; not supported for clinical use

TB-500 (Thymosin Beta-4)

The claims. Marketed alongside BPC-157 as its partner in injury repair, with added claims around inflammation, flexibility, and cardiac and hair benefits.

The evidence. The same pattern, a step weaker. The mechanism is real and the preclinical work is suggestive, but there are no completed controlled human trials supporting the uses it’s sold for. What’s marketed as “TB-500” in the gray market is also frequently a fragment that differs from the thymosin beta-4 actually studied, so even the preclinical rationale doesn’t cleanly transfer to the product in the vial.

Evidence Scorecard — TB-500
Biological plausibility: Moderate · Human efficacy data: None of usable quality · Long-term safety data: None · FDA approval: None · Overall: Experimental; not supported for clinical use

CJC-1295, Ipamorelin, and Sermorelin

The claims. These growth-hormone-releasing peptides are sold as a gentler path to the benefits people want from growth hormone: more muscle, less fat, better sleep, faster recovery, a younger body.

The evidence. This group is more interesting, because the surrogate effect is real and the outcome data isn’t. CJC-1295 has been shown in humans to raise growth hormone and IGF-1 over time;⁷ the trouble is that raising a hormone level on a lab report isn’t the same as making a healthy adult healthier, stronger, or longer-lived, and that second step has never been demonstrated. Ipamorelin’s human record is limited to preclinical work and small investigational studies, with no large efficacy trials.⁸ Sermorelin was FDA-approved years ago for pediatric growth hormone deficiency, but the branded adult product was discontinued in 2008, and adult use today is essentially all off-label with no visceral-fat-specific evidence behind it.⁹ There’s also a reason to be cautious rather than merely unconvinced. Chronically raising growth hormone and IGF-1 isn’t free: growth hormone drives insulin resistance, which can push blood sugar toward diabetes, and the same axis brings fluid retention and joint complaints, with a longer-term cancer concern on top. The safety section takes those up in detail. This is the cleanest teaching case in the article, because it shows how a real biological effect on a number gets sold as a proven clinical benefit it has never earned.

Evidence Scorecard — GH-releasing peptides (CJC-1295 / Ipamorelin / Sermorelin)
Biological plausibility: High · Human efficacy data: Surrogate markers only, no outcomes · Long-term safety data: Limited; insulin resistance and theoretical IGF-1 cancer concerns · FDA approval: None for adult anti-aging use · Overall: Raises a lab value; unproven clinical benefit, with real metabolic downside

MK-677 (Ibutamoren)

A necessary aside, because this one isn’t even a peptide. MK-677 is an orally active compound sold in the same channels and stacks, and it does reliably raise growth hormone and IGF-1. But its larger human trials, including studies in older adults and in frailty, failed to deliver the functional benefits people are chasing, and it can worsen insulin sensitivity and cause fluid retention. It’s a useful reminder that the “peptide” label gets stretched over whatever the market wants to sell next.

Evidence Scorecard — MK-677
Biological plausibility: High · Human efficacy data: Raises hormones; functional trials largely negative · Long-term safety data: Concerns (glucose, fluid) · FDA approval: None · Overall: Not recommended

AOD-9604

The claims. A fragment of the growth hormone molecule sold as a targeted fat-loss peptide.

The evidence. This one had its proper test and failed it. Developed as an obesity drug, it did not beat placebo for weight loss in human trials, after which it was repurposed into the supplement and gray markets where the original failure goes unmentioned.

Evidence Scorecard — AOD-9604
Biological plausibility: Low · Human efficacy data: Negative trials · Long-term safety data: Limited · FDA approval: None · Overall: Not recommended

GHK-Cu (Copper Peptide)

The claims. Sold for skin rejuvenation, wound healing, hair growth, and as an injectable anti-aging compound.

The evidence. Worth splitting in two. Topical GHK-Cu in cosmetics has some small human studies on skin appearance, which is the legitimate end of its story. The injectable systemic “anti-aging” use that the peptide world promotes has essentially no human outcome data, and the leap from a copper peptide improving the look of skin in a cream to injecting it for whole-body rejuvenation is unsupported.

Evidence Scorecard — GHK-Cu
Biological plausibility: Moderate (topical) · Human efficacy data: Limited cosmetic data topically; none for injection · Long-term safety data: Limited · FDA approval: None as a drug · Overall: Cosmetic topical use only; injectable use unsupported

Epitalon

The claims. One of the boldest in the category: lengthens telomeres, resets aging, extends lifespan.

The evidence. The supporting studies come largely from a single line of older research and are methodologically weak by modern standards, with the kind of design problems that place them near the bottom of the evidence ladder. There’s no rigorous, independently replicated human trial showing it does anything to human aging or lifespan.

Evidence Scorecard — Epitalon
Biological plausibility: Low to moderate · Human efficacy data: Very low, poor quality · Long-term safety data: None · FDA approval: None · Overall: Not supported

MOTS-c

The claims. A “mitochondrial” peptide sold for metabolism, fat loss, endurance, and longevity.

The evidence. Scientifically interesting and almost entirely preclinical. The compound is among those the FDA flagged for limited data, and **it has no completed human efficacy trials behind the marketed claims.**¹⁰ The mitochondrial biology is real; the human therapeutic story is hypothesis, not result.

Evidence Scorecard — MOTS-c
Biological plausibility: Moderate · Human efficacy data: None of usable quality · Long-term safety data: None · FDA approval: None · Overall: Experimental

Melanotan II

The claims. Sold for tanning and for libido, and it genuinely does both.

The evidence. This is the case where the effects are real and that’s precisely the problem. Melanotan II works, which is why its safety signals matter: it has been associated with changes in moles and concerns about melanoma, with prolonged erections, with nausea, and with other effects, all from an unapproved, unregulated product of unknown purity. Real activity plus no oversight is a worse combination than no activity at all.

Evidence Scorecard — Melanotan II
Biological plausibility: High · Human efficacy data: Effects real but safety poorly characterized · Long-term safety data: Concerning · FDA approval: None · Overall: Not recommended; safety concerns

Selank and Semax

The claims. Russian-origin nootropic peptides sold for anxiety, focus, and cognition.

The evidence. Most of the supporting work comes from a narrow research base outside the standards used elsewhere in the world, with little in the way of large, blinded, replicated trials. Interesting, under-studied, and nowhere near a clinical recommendation.

Evidence Scorecard — Selank / Semax
Biological plausibility: Moderate · Human efficacy data: Very limited, narrow source · Long-term safety data: None · FDA approval: None · Overall: Experimental

Thymosin Alpha-1

Why this one gets nuance. Unlike the recovery peptides, thymosin alpha-1 has a real clinical research history. It’s used and approved in a number of countries as an immune modulator, mainly around chronic hepatitis and as an adjunct in certain immune contexts, and it has been studied in serious settings including sepsis. That history makes it the most defensible of the immune-modulating peptides. The honest caveats still apply: it isn’t FDA-approved, the trial evidence is mixed rather than decisive, and none of its legitimate investigation supports the general “boost your immune system” use it gets sold for in wellness clinics. It belongs in a different conversation from BPC-157, and it’s still not a proven product for a healthy person.

Evidence Scorecard — Thymosin Alpha-1
Biological plausibility: High · Human efficacy data: Genuine but mixed; specific indications · Long-term safety data: Better characterized than most here · FDA approval: None in the US (approved in some countries) · Overall: Legitimate investigational/approved-abroad agent; not for general wellness use

SS-31 (Elamipretide)

The single best illustration of how high the bar is. Elamipretide is sold in the gray market as a mitochondrial anti-aging peptide, and its real story is a lesson in itself. It targets cardiolipin in the mitochondrial membrane, it has a serious investigational program, and in September 2025 the FDA granted it accelerated approval, as FORZINITY, for Barth syndrome, an ultra-rare genetic mitochondrial disease.¹¹ Here’s the part that matters. **The randomized, placebo-controlled portion of its pivotal trial did not meet its primary endpoints; the apparent benefit emerged later, in an uncontrolled open-label extension of roughly ten patients,**¹² and the approval covers a disease affecting only about 150 people in the United States, with a confirmatory trial still required.¹³ So even for a legitimate, mechanistically elegant peptide with a real company and a real trial, the controlled human data came back negative, and approval rested on weaker uncontrolled data for a tiny population. That’s the actual standard. The version sold to healthy adults for “mitochondrial optimization” is running miles ahead of anything the science has shown.

Evidence Scorecard — SS-31 / Elamipretide
Biological plausibility: High · Human efficacy data: Approved for one ultra-rare disease; controlled endpoints missed · Long-term safety data: Emerging · FDA approval: Yes, narrow (Barth syndrome) · Overall: Legitimate drug for a rare disease; wellness use unsupported

Tesamorelin

Why this matters: indication creep in plain sight. Tesamorelin is the one growth-hormone-releasing peptide that did the work. It’s FDA-approved as Egrifta, on the strength of Phase III trials showing roughly a 15% reduction in visceral fat, but the approval is specifically for HIV-associated lipodystrophy.¹⁴ Watch what happens next. Because off-label prescribing is legal, anti-aging and weight-loss clinics now prescribe tesamorelin off-label for general belly fat, a use it was never approved for and never tested against.¹⁵ A genuine, FDA-validated result for one specific patient population gets quietly stretched into a general anti-aging product. That stretch, from a narrow proven indication to a broad marketed one, is one of the most common moves in this entire field, and tesamorelin lets you watch it happen with a drug that actually works.

Evidence Scorecard — Tesamorelin
Biological plausibility: High · Human efficacy data: Strong, for one indication · Long-term safety data: Reasonable, within indication · FDA approval: Yes (HIV-associated lipodystrophy) · Overall: Proven for its approved use; off-label anti-aging use unproven

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)

This is what real evidence looks like. End here on purpose, because after walking down the ladder it’s worth seeing the top rung clearly. These are peptide-based drugs, the same broad category as everything above, and the contrast is total. The SELECT trial randomized 17,604 adults with obesity and established heart disease, without diabetes, across hundreds of sites in 41 countries, double-blind and placebo-controlled.¹⁶ **Semaglutide cut major adverse cardiovascular events by 20%, and the same trial showed lower kidney-disease risk and a sharp reduction in new diabetes.**¹⁶ These are hard endpoints, the outcomes that actually matter: heart attacks, strokes, kidney function, death. Tens of thousands of patients, multiple Phase III trials, independent replication, cardiovascular and renal outcome data.

Set that beside BPC-157’s three uncontrolled studies in fewer than 30 people, and you have the whole article in a single comparison. Same category of molecule. Opposite ends of the evidence universe. The lesson isn’t that peptides don’t work; it’s that proof in humans is a specific, expensive, achievable thing, and you should ask to see it before you pay for it.

Evidence Scorecard — GLP-1 agonists
Biological plausibility: High · Human efficacy data: Extensive, hard endpoints · Long-term safety data: Strong and growing · FDA approval: Yes · Overall: Evidence-based for approved indications

Retatrutide

The frontier, and a lesson in patience. Retatrutide is the compound to watch, and it makes the point of this entire article better than almost anything else on the list. It’s an Eli Lilly peptide that activates three receptors at once, GLP-1, GIP, and glucagon, and it’s the first triple agonist to reach late-stage testing.¹⁷ The weight-loss results are the largest ever recorded for a drug. In its pivotal Phase 3 obesity trial of 2,339 people, randomized and placebo-controlled, the studied doses produced average weight loss in the range of roughly 28 to 30% over 80 weeks and met their primary endpoints.¹⁸ In an earlier Phase 3 trial, close to 59% of participants lost at least a quarter of their body weight, approaching what bariatric surgery achieves.¹⁹ This is the rigorous human evidence the gray-market peptides never have, generated across a program that has enrolled thousands of patients in large controlled trials.

And here’s the discipline the rest of this article keeps coming back to. With all of that, retatrutide still isn’t approved for anything, anywhere; it’s investigational, its full Phase 3 program is still reporting out, and a filing with the FDA isn’t expected until late 2026.²⁰ It also carries a real tradeoff rather than a free lunch; side effects skew gastrointestinal, and at the highest dose about 11% of patients stopped treatment because of them, versus roughly 5% on placebo.²¹ Despite none of this being finished, unapproved “research” retatrutide is already being marketed online to people who don’t want to wait, which is the trap of this whole field in a single example. Even the most promising peptide ever tested is something you get through a proven, regulated channel once the evidence and the safety data are actually complete, not something you inject from a gray-market vial tonight because a video told you it’s the future. The excitement here is earned; the shortcut around it still isn’t.

Evidence Scorecard — Retatrutide
Biological plausibility: High · Human efficacy data: Strong and growing (large Phase 3) · Long-term safety data: Still being established; GI tradeoff · FDA approval: None yet (investigational) · Overall: Genuinely promising; unapproved, and not a shortcut to chase early

Part III: The Bigger Picture

Peptides and the Wellness Economy

It helps to step back and see where peptides actually sit, because they didn’t arrive in your feed by accident. There’s an enormous wellness economy now, and from a business standpoint every part of it is hunting for the next thing to sell, because selling is how it makes money. Peptides are close to perfect for that role; they sound scientific, they come in a syringe, they carry the promise of transformation, and until recently almost nobody outside of medicine had heard of them. That combination is gold for marketing, and the same machinery that sold you the last trend has simply moved on to this one.

Most of what that machine sells is harmless and close to useless, and it’s worth saying so plainly, because it sets up the part that matters. Take the supplement aisle. More than half of American adults take a dietary supplement, most often for general health and wellness,²² and when researchers actually test them the payoff barely shows up. **The U.S. Preventive Services Task Force reviewed the evidence and concluded that vitamin and mineral supplements provide little to no benefit in preventing cancer, cardiovascular disease, or death in healthy adults,**²³ and it recommended against beta-carotene and vitamin E outright.²⁴ Or take red light therapy, the panels people stand in front of every morning, convinced they’re reversing age. The honest read sits between marketing and cynicism; there’s real evidence for a specific use, like pattern hair loss, and very little behind the sweeping promises of energy, fat loss, and whole-body renewal.²⁵ The shared feature of both is that the worst case is usually a lighter wallet. Red light, used properly, is external and low-risk, with no evidence that it causes cancer,²⁶ and a multivitamin that does nothing still won’t hurt you, so the only thing you’ve lost is money.

That’s the assumption peptides quietly break, and it’s why they can’t be filed under harmless wellness theater. With a supplement or a light panel, “probably useless” comes packaged with “probably safe,” so the cost of being wrong is small. With most of these peptides we don’t get to make that second assumption, and the rest of this section is about why.

Why So Many Clinics Offer the Unproven Ones

If the evidence behind so many of these compounds is this thin, the obvious question is why so many clinics offer them anyway, and a lot of the answer is structural rather than sinister. The unproven peptides carry a product margin that an ordinary visit doesn’t; they’re dispensed through compounding pharmacies that run under different rules than FDA-approved manufacturing, and because most of them aren’t approved for anything, they sit in a regulatory gray zone where off-label prescribing is legal and oversight is light. Patient demand, manufactured by the same social media engine described earlier, runs hard in one direction, and clinicians see the patients who feel better and remember them, which is the same confirmation bias that affects everyone. To be clear about what isn’t the problem: charging for your expertise and prescribing therapies that actually work is ordinary medicine, and there’s nothing wrong with it. The concern is narrower, and it’s the incentive to offer compounds nobody has shown to be effective or safe; I’ll come back to where that crosses the line. For now the practical point holds: the incentives lean toward offering these things, almost nothing pushes back, and that’s exactly why the burden of asking for evidence falls on you.

That gray zone is unusually visible right now. In April 2026 the FDA removed BPC-157, TB-500, and CJC-1295 from its Category 2 list, but pointedly did not move them to the approved Category 1 list, leaving them neither prohibited nor authorized.²⁷ An FDA advisory committee is scheduled to review several of these peptides, including BPC-157, on July 23 and 24, 2026.²⁸ And federal health leadership has been publicly pushing to return roughly 14 of 19 flagged peptides toward compounding eligibility.²⁹ The marketing is already reading all of this as vindication, which is the misread to watch for; reclassification governs whether a pharmacy may compound a substance, and it confers no FDA approval, no validated dose, and no proof that the compound works, because the Phase I through III evidence still doesn’t exist.²⁹ A peptide becoming easier to obtain isn’t the same as a peptide becoming proven, and the gap between those two ideas is where a lot of money is about to change hands.

What About Safety?

Here’s the distinction that should drive the whole decision. The wellness products in the last section are mostly safe even when they’re useless, so being wrong about them costs you money. Peptides are different, because for most of them we genuinely don’t know the safety, and being wrong could cost you far more than money.

A useless supplement costs you money. An unproven peptide can cost you something you won’t see for ten or twenty years.

Start with the good news, because it’s real. A handful of these compounds have been through enough rigorous human testing that we can speak about their safety with some confidence. The GLP-1 drugs have been studied in tens of thousands of patients over years, with their benefits and their risks characterized in detail,¹⁶ and tesamorelin carries a known safety profile within its approved use. When a peptide has cleared that bar, it has earned the right to be called reasonably safe, because the work was actually done. That’s the entire point of the standard; it’s how safety gets established in the first place.

The trouble is that the large majority of the peptides being sold have never been near that bar. There’s no long-term human safety data for them, because the long-term human studies were never run, and you can’t reassure yourself about a risk that nobody has measured. This matters most over time. A compound can feel fine for months or even years and still be doing something you won’t see until much later, and the kind of harm that surfaces at ten, twenty, or thirty years is exactly the kind that short, uncontrolled experience can’t catch. The people injecting these peptides today are running that experiment on themselves, with no control group and no one tracking the outcome, and they won’t have an answer until it may be too late to use it.

The growth-signal peptides deserve a specific mention, because they carry a downside that gets almost no airtime in the marketing. The growth-hormone secretagogues raise growth hormone and IGF-1 on purpose, and that gets sold purely as a benefit, but that axis is metabolically double-edged. Growth hormone works against insulin, so raising it chronically drives insulin resistance and can push blood sugar in the wrong direction.³⁰ The clearest picture of where that road leads is acromegaly, the disease of long-term growth-hormone excess, and it’s a sobering model. Depending on the study, somewhere between 15% and 40% of acromegaly patients develop diabetes, and the condition brings hypertension, an enlarged and stiffened heart, abnormal lipids, sleep apnea, and roughly double the expected mortality.³¹ A peptide user isn’t reaching acromegaly-level hormone concentrations, and that distinction is fair to make. The point is the direction of travel; these compounds nudge the body toward the same signaling whose extreme form is a defined disease of metabolic and cardiovascular harm.

The cancer concern sits alongside that, driven by the same axis. IGF-1 is a growth factor, which means it tells cells to multiply and not to die, and it helps build the new blood vessels that growing tissue needs, which are the same tools a tumor uses to grow and spread.³² In human studies, higher IGF-1 levels are linked to greater risk of several cancers, including prostate, breast, and colorectal,³³ and acromegaly again provides the natural example, since chronically high growth hormone comes with elevated cancer rates as well as the metabolic toll.³¹ This doesn’t prove that any given peptide causes cancer; the associations are modest and not uniform across every cancer type,³⁴ and that honesty cuts both ways. It does mean that deliberately driving these growth signals upward, for years, in a body that may already be carrying a few abnormal cells nobody has found yet, is a real and biologically grounded concern, and no one has the long-term data to wave it away.

This is the place to deal with one of the most common arguments you’ll hear, and it does more quiet damage than any single influencer claim: a peptide is just a protein, something your body already makes, so it can’t really hurt you. The people who say this usually aren’t physicians or scientists or pathologists; they’re confident voices who have mistaken a simple-sounding fact for a safety guarantee.

“It’s just a protein, your body already makes it, so it can’t hurt you.” This is the most dangerous sentence in the entire peptide conversation.

That claim is worth taking apart, because it proves almost nothing. A peptide is a chemical signal, a short sequence that fits into a receptor the way a key fits a lock, and what it does depends entirely on which lock it fits and what that lock is wired to control. Your body runs on thousands of these signals, and they do opposite things. Insulin lowers blood sugar and glucagon raises it, and both are peptides; one signal can tell a cell to multiply while another tells it to die, and one can tighten a blood vessel while another relaxes it. So the word “peptide” doesn’t describe a safety level any more than the word “molecule” does; it’s a category that holds both medicine and poison, and the label alone tells you nothing about which one you’re holding.

Once you see peptides that way, the danger stops being abstract.

What makes a peptide harmful isn’t that it’s a protein. It’s the specific switch it flips, and where in the body it flips it.

Take the proteins your own body and nature already make. Insulin is a protein your pancreas produces every single day, and a modest overdose drops blood sugar low enough to kill within hours. Botulinum toxin is a protein too, and it blocks the signal nerves use to fire muscles, so a vanishingly small amount, a few billionths of a gram, can paralyze the diaphragm and stop your breathing. Snake venom is largely peptides; some unravel red blood cells, some stop the heart. None of these is dangerous for being a protein; each is dangerous because of the precise job it does and the place it does it. And here’s what the “it’s just a protein” crowd has backwards: the recovery and longevity peptides don’t earn a pass for being inert, because they were never inert to begin with. They were chosen precisely because they act on real biology, telling tissue to grow and hormones to surge, and that is the selling point and the warning in the same breath. A compound strong enough to change how your tissue grows is, by definition, strong enough to change it in ways nobody intended, especially taken for years, and especially when nobody has fully mapped which switches it’s hitting or how cleanly. “It’s just a protein” is the most dangerous reassurance in this whole space, because it takes a powerful, barely-studied signal and makes it sound like nothing.

The practical safety problems sit on top of all of that. Most of these compounds come from gray-market sources with no purity guarantee, and that isn’t hypothetical. When independent labs have tested peptides bought online, they’ve repeatedly found products that aren’t what the label claims: one analysis in the journal Drug Testing and Analysis found that about 30% contained the wrong amino acid sequence and roughly two-thirds carried bacterial endotoxin above safety limits,³⁵ and anti-doping testing of black-market peptides found more than 20% mislabeled or contaminated.³⁶ Endotoxin matters because it can trigger fever and a dangerous immune reaction on its own, before the peptide does anything at all. The dose can vary from one vial to the next, and because these aren’t approved drugs under active monitoring, there’s no system collecting adverse events, so even when something does go wrong it tends to stay invisible. You’re trusting an unregulated manufacturer to have put exactly what the label claims into the vial, at the stated dose, free of contaminants, with nothing in place to catch it if they didn’t.

A Word About Prescribing the Unproven

Before I say the hard part, let me draw the line carefully, because it matters. None of what follows is about charging for legitimate medicine. A physician who prescribes a proven, FDA-approved therapy and earns a living doing it is doing exactly what the job is. A physician who prescribes a GLP-1 is being paid for training, time, and the judgment to use a drug that tens of thousands of patients have shown to be effective and safe, and there’s nothing wrong with earning a living that way; it’s the basis of the profession. The problem isn’t profit, and it isn’t peptides as a category. The problem is prescribing the unproven and the unstudied for the markup. Hold that distinction, because everything below depends on it.

With that line drawn, here’s the standard I hold, stated without softening. A doctor’s job is to act on evidence in the patient’s interest, and that obligation is the whole reason a medical license means anything. Prescribing a patient a compound whose benefit is unproven and whose long-term safety is unknown, and profiting from doing it, isn’t a gray area of the obligation; it’s a breach of it. It isn’t practicing medicine; it’s commerce dressed up in a white coat, and the older name for it, snake oil, still fits. A physician who hands a patient an experimental compound for the margin has stopped being a clinician and started being a salesman, and the license on his wall is doing nothing but lending false authority to the pitch. Conduct like that should put a license in jeopardy, because protecting what the license stands for is one of the few things that actually protects the patient.

A prescription pad is not a revenue strategy. Charging for evidence-based care is the job; selling unproven compounds under the authority of a medical license is the betrayal of it.

The objection writes itself: the patient wanted it, and he’s an adult who can choose. That defense fails, and a comparison shows why. If a patient walked in and asked his doctor for methamphetamine or heroin, no ethical physician would write the prescription, no matter how badly the patient wanted it or how much he’d pay, because we know with certainty those drugs would harm him. The experimental-peptide case isn’t identical, and the difference is the whole point; with these compounds, we don’t have certainty in either direction, because the long-term safety was never studied. A doctor who would refuse to hand over a known poison should refuse just as firmly to hand over an unknown one, because the duty was never to give patients whatever they ask for; it’s to protect them from the things they don’t yet know to fear. Wanting something and being owed it by your physician are not the same thing.

This is also where it stops being abstract, because the market sorts patients toward exactly the wrong doctors. A man who’s decided he wants the latest unproven peptide will keep looking until he finds someone willing to prescribe it, which means demand flows steadily toward the least scrupulous clinicians in the system, the ones whose judgment is most easily bought. The careful physician who says no loses that patient to the one willing to prescribe it. That isn’t a market correcting itself; it’s a market rewarding the people who should be trusted least, and the patient, convinced he’s finally found a doctor who gets it, has actually found the one who was willing to put a price ahead of his safety. The only thing being optimized in that exchange is revenue, and it was never the patient’s.

The Scientific Bottom Line

Held to one standard, the field sorts itself cleanly. A small number of peptide-based drugs are backed by exactly the kind of large, rigorous, replicated human evidence medicine should demand, and they’re approved and appropriate for their proven uses. A few more are legitimate investigational or narrowly approved agents being sold far beyond what their data supports. And the bulk of what’s marketed for recovery, fat loss, and longevity rests on animal studies and testimonials, which is to say on the two weakest rungs of the ladder. The skepticism in this article isn’t a starting opinion; it’s where the evidence lands once you apply the same rules to everyone.

Here’s the entire field on one scorecard, sorted by how much human evidence actually stands behind each one.

Proven, FDA-approved, evidence-based

• GLP-1 agonists (semaglutide, tirzepatide) — Extensive human evidence, hard endpoints. Approved and appropriate for their indications.

• Tesamorelin — Strong evidence, but only for its one approved use (HIV-associated lipodystrophy). Off-label anti-aging use is unproven.

• SS-31 / Elamipretide — A real, FDA-approved drug for one ultra-rare disease (Barth syndrome). Wellness use is unsupported.

Promising but not there yet

• Retatrutide — Strong Phase 3 data, still investigational and unapproved. Wait for approval; it isn’t a shortcut to chase early.

• Thymosin alpha-1 — Genuine but mixed human data; approved in some countries, not the US. Legitimate in specific settings, not for general wellness use.

Raises a number, with no proven benefit and real downside

• CJC-1295 / Ipamorelin / Sermorelin — Raises growth hormone and IGF-1 on a lab report, with no proven clinical benefit and a real metabolic downside. Not adult-approved.

• MK-677 — Raises hormones, but the functional trials were largely negative, with glucose and fluid concerns. Not recommended.

Little or no credible human evidence

• BPC-157 — Very weak human evidence. Not recommended outside a clinical trial.

• TB-500 — Very weak human evidence. Not recommended.

• AOD-9604 — Failed its human weight-loss trials. Not recommended.

• MOTS-c — No usable human efficacy data. Experimental.

• Epitalon — Very weak, low-quality evidence. Not supported.

• Selank / Semax — Very limited evidence from a narrow research base. Experimental.

• GHK-Cu — Limited evidence for topical cosmetic use only; injectable use is unsupported.

Real effects, but unapproved and a poor safety profile

• Melanotan II — The effects are real, which is the problem; unapproved, unregulated, with genuine safety concerns. Not recommended.

The next time someone sells you on a peptide, you don’t need to know the molecule. You need to ask one question, the same question for all of them: where is the human evidence, and what rung of the ladder does it stand on? For most of this list, the honest answer is that the evidence is still in the rats, and the rest is a sales pitch.

References

1. The (misleading) role of animal models in drug development. Frontiers in Drug Discovery, 2024. https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2024.1355044/full

2. Sun D, et al. Why 90% of clinical drug development fails and how to improve it. Acta Pharmaceutica Sinica B, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/

3. BPC-157: the first controlled human trial is now recruiting. PeptIQ, 2026. https://peptiq.io/blog/bpc-157-first-controlled-human-trial-recruiting

4. BPC-157 and the difference between an evidence gap and a cover-up. WellFounded, 2026. https://wellfounded.health/insights/bpc-157-and-the-difference-between-an-evidence-gap-and-a-cover-up

5. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/

6. BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547). ClinicalTrials.gov, 2026. https://clinicaltrials.gov/study/NCT07437547

7. Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295. J Clin Endocrinol Metab, 2006.

8. Sermorelin alternatives: an evidence-based comparison (CJC-1295, ipamorelin, tesamorelin). TrimRx, 2026. https://trimrx.com/blog/sermorelin-alternatives-evidence-based/

9. Tesamorelin vs Sermorelin: a medical provider’s comparison. Perfect B, 2026. https://www.perfectb.com/tesamorelin-vs-sermorelin/

10. FDA mulls compounding for peptides previously flagged over safety risks. BioSpace, 2026. https://www.biospace.com/fda/fda-mulls-compounding-for-peptides-previously-flagged-over-safety-risks

11. FDA approves drug for treatment of rare mitochondrial disorder (elamipretide/FORZINITY). Johns Hopkins Medicine, 2025. https://hub.jhu.edu/2025/09/25/fda-approves-barth-syndrome-treatment/

12. Reid Thompson W, et al. Phase 2/3 randomized trial of elamipretide in Barth syndrome (TAZPOWER). PMC, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC7935714/

13. FDA approval for the mitochondrial therapeutic elamipretide (Stealth BioTherapeutics; ~150 US patients). 2025. https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/

14. Falutz J, et al. Tesamorelin (Phase 3 trials) for HIV-associated lipodystrophy. N Engl J Med, 2007. (Egrifta label and pivotal trials)

15. Tesamorelin protocol and off-label use. The Peptide Guides, 2026. https://thepeptideguides.com/protocols/tesamorelin-protocol

16. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271387/

17. Lilly’s triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial. Eli Lilly (PR Newswire), 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html

18. Retatrutide Achieves up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial. AJMC, 2026. https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial

19. Retatrutide TRIUMPH-4 Phase 3 results (≥25% weight loss in ~59%). Eli Lilly, 2025. https://www.retaweightloss.com/article/retatrutide-clinical-results-how-effective-is-the-new-triple-hormone-drug

20. Retatrutide Phase 3 program and regulatory timeline. Parahealth, 2026. https://parahealth.com/blogs/blog/retatrutide-phase-3-triumph-program

21. Lilly’s triple-G agonist triumphs in Phase III trial, but AEs noted. Clinical Trials Arena, 2026. https://www.clinicaltrialsarena.com/news/eli-lilly-retatrutide-phase-iii-triumph-1-study-results/

22. Vitamin, Mineral, and Multivitamin Supplementation to Prevent CVD and Cancer (recommendation). US Preventive Services Task Force, 2022. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-supplementation-to-prevent-cvd-and-cancer-preventive-medication

23. O’Connor EA, et al. Vitamin and mineral supplements for the primary prevention of CVD and cancer: USPSTF evidence review. JAMA, 2022. https://www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/vitamin-supplementation-to-prevent-cvd-and-cancer-preventive-medication

24. USPSTF recommends against beta-carotene and vitamin E for CVD and cancer prevention. American College of Cardiology, 2022. https://www.acc.org/Latest-in-Cardiology/Articles/2022/06/21/21/45/USPSTF-Recommends-Against-Use-of-Beta-Carotene

25. Comparative effectiveness of low-level laser therapy for adult androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. Lasers in Medical Science, 2019. https://pubmed.ncbi.nlm.nih.gov/30706177/

26. Is red light therapy right for your skin? American Academy of Dermatology. https://www.aad.org/public/cosmetic/safety/red-light-therapy

27. Regulatory updates on compounded peptides. New Drug Loft / VLS Pharmacy, 2026. https://newdrugloft.com/recent-regulatory-updates-on-compounded-peptide-injections/

28. BPC-157 legal status: FDA PCAC review scheduled July 2026. Loti Labs, 2026. https://lotilabs.com/resources/bpc-157-legal-status-2026-fda-update/

29. The peptide reclassification: what RFK Jr’s announcement actually means. Pharmacy Times, 2026. https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means

30. Vila G, et al. Insulin Resistance in Patients With Acromegaly. Frontiers in Endocrinology, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6683662/

31. Katznelson L, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2014. https://academic.oup.com/jcem/article/99/11/3933/2836347

32. The IGF System in Cancer. PMC, 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3614012/

33. IGF-1 and Risk of Morbidity and Mortality From Cancer (EPIC-Heidelberg). J Clin Endocrinol Metab, 2023. https://academic.oup.com/jcem/article/108/10/e1092/7124430

34. Larsson SC, et al. IGF-1 and site-specific cancers: a Mendelian randomization study. Cancer Medicine, 2020. https://onlinelibrary.wiley.com/doi/10.1002/cam4.3345

35. Mislabeling and endotoxin contamination in online peptides (analysis reported in Drug Testing and Analysis: ~30% with incorrect amino acid sequence, ~two-thirds with endotoxin above safety limits). Reported via New Regeneration Orthopedics / Regenexx, 2025. https://newregenortho.com/the-hidden-risks-of-bpc%E2%80%91157-what-patients-need-to-know-about-contamination-and-safety/

36. USADA testing of black-market peptides (>20% mislabeled or contaminated), 2017. Reported via New Regeneration Orthopedics / Regenexx, 2025. https://newregenortho.com/the-hidden-risks-of-bpc%E2%80%91157-what-patients-need-to-know-about-contamination-and-safety/

I watched a respected physician praise, on camera, a documentary that misleads patients, and I decided someone ought to put the evidence on the table. What follows is a claim-by-claim review of that film, The Cholesterol Code: I take its central arguments one at a time and hold each against the published evidence. Not my opinion, not what I want the answer to be, not what fits some belief about diet, cholesterol, statins, or the pharmaceutical industry. Just what the research shows, what it does not, and where the film takes something true and stretches it into a conclusion the evidence does not support.

The film centers on Dave Feldman, an engineer who reportedly reversed prediabetes with a low-carbohydrate diet, then developed very high LDL cholesterol, which led him into self-experimentation, citizen science, and eventually coronary imaging studies in ketogenic “hyper-responders.”[2,3] Its pitch is that one man’s health journey “could upend” what we know about cholesterol and heart disease, and it asks whether we have been “fighting the wrong enemy.”[2,3] I came to it through a YouTube interview in which Dr. Eric Westman, speaking after an early screening, praised the film and walked through its themes: ketogenic diets, LDL, coronary CT scans, citizen science, statins, and pharmaceutical influence.[1] He is a physician, he sounds confident, and the patients in this story feel better, some with low triglycerides, high HDL, and clean scans. None of that, by itself, makes the conclusion true.

That is what makes this film effective, and dangerous. Its claims do not start as lies; they start as facts. A man loses weight, his blood sugar improves, his triglycerides fall, he feels better, all real. Then the film stacks a much larger conclusion on top of those real observations than they can bear. That is the move to watch in every section that follows, and it is harder to catch than an outright falsehood precisely because the first half of each argument is true.

One distinction has to be clear before any of it makes sense, because the film leans on the confusion between two things. LDL-C is the amount of cholesterol riding inside LDL particles, and it wobbles, with diet, with fasting, with weight change. ApoB is closer to the number of artery-damaging particles in circulation, and that number is what actually drives atherosclerosis, because the disease begins when those particles lodge in the arterial wall and build plaque.[10,11] You can move the first without moving the second, which is why a changing LDL-C tells you far less than the film wants you to think.

So the real question is not whether LDL-C fluctuates, whether keto improves metabolic markers, or whether a single scan can look clean. All of those can be true at once. The real question is whether sustained exposure to a high number of these particles is harmless over years and decades, and that is the question the film implies it has answered when it has not. Here are its claims, one at a time, measured against what we actually know.

Claim 1: Ketogenic Diets Have Unique Disease-Reversing Properties

The problem is not that everything the film says is wrong. Low-carbohydrate and ketogenic diets can improve weight, glycemic control, triglycerides, HDL-C, and medication burden in selected patients, especially type 2 diabetes.[4,5] But many of those benefits are not unique to ketosis. They are mediated by reduced energy intake, weight loss, loss of visceral and hepatic fat, higher protein, less ultra-processed food, and better adherence, and when calories drop people improve across many dietary patterns. In a year-long Stanford trial called DIETFITS, which randomly assigned more than 600 overweight adults to either a healthy low-fat or a healthy low-carbohydrate diet, the two groups lost roughly the same amount of weight.[6] In POUNDS LOST, a two-year trial that put more than 800 adults on diets differing in their fat, protein, and carbohydrate proportions, people lost comparable weight no matter which macronutrient the diet emphasized.[7] And in a tightly controlled metabolic-ward study, where every calorie was supplied and measured, switching to a ketogenic diet at matched calories did not increase body-fat loss.[8] So the fair conclusion is not that keto has unique disease-reversing powers that override lipid biology; it is that carbohydrate restriction is one useful tool, and many of its broader benefits are shared by other calorie-controlled, high-quality diets.

This is the template for everything that follows: a true observation stretched into an unsupported conclusion. When someone says “keto reverses diabetes” without noting how much of that is calorie reduction, weight loss, and adherence, they are handing you a partial truth, and partial truths mislead more effectively than obvious falsehoods because they sound scientific. A Mediterranean pattern has the kind of hard evidence keto lacks: in a large Spanish trial called PREDIMED, which randomly assigned roughly 7,400 high-risk adults to a Mediterranean diet supplemented with olive oil or nuts versus a lower-fat comparison diet, the Mediterranean groups had fewer heart attacks, strokes, and cardiovascular deaths. (PREDIMED was itself retracted in 2018 over irregularities in how some participants were assigned to groups, then reanalyzed and republished with the benefit intact, the errors being correctable, which is the opposite of a paper withdrawn because its errors could not be fixed.) That pattern is built on vegetables, legumes, nuts, olive oil, and fish, not high saturated fat.[9] If it produces weight loss, better insulin sensitivity, lower blood pressure, and lower triglycerides without driving ApoB upward, why treat a high-saturated-fat approach that does drive ApoB up as superior?

Bottom line: Keto is a tool, not a miracle. Every benefit the film credits to ketosis — the weight loss, the steadier glucose, the lower triglycerides — has been matched by low-fat, Mediterranean, and high-protein diets in head-to-head randomized trials, because the active ingredient is calorie reduction, weight loss, and adherence, not ketosis itself. “Keto reversed my diabetes” proves it worked, not that it is superior, and the high-saturated-fat version does the same job the alternatives do while driving ApoB up, where they do not. Matching the others on benefit and losing to them on risk is not a breakthrough.

Claim 2: LDL-C Fluctuates, So Lipid Risk Can Be Dismissed

Westman describes Feldman measuring cholesterol repeatedly and noticing LDL-C moves with diet and timing,[1] implying that because LDL-C is dynamic, physicians have been too rigid. Yes, LDL-C fluctuates. That does not mean lipid risk can be dismissed. The correct question is whether someone with chronically elevated ApoB-containing lipoproteins is exposing the arterial wall to more atherogenic particles over time. Atherosclerosis is not caused by one LDL-C value; it is driven by cumulative exposure to ApoB particles that enter the intima, are retained, undergo modification, recruit macrophages, and build plaque.[10,11] That biology does not vanish because triglycerides are low or the patient feels good.

The pathophysiology here is not speculative. When coronary arteries are opened and examined histologically, plaque is built around retained cholesterol-rich ApoB particles, which then drive inflammation, foam-cell formation, fibrous cap development, necrotic core, calcification, and eventually rupture. As a heart surgeon, this is not an abstract biomarker debate to me; it is a structural disease of the artery wall, and ApoB particles are the necessary substrate around which it forms. Inflammation, blood pressure, diabetes, smoking, Lp(a), kidney disease, and genetics all modify the rate and the danger, but none of them erase that central role.

This is why LDL-C and ApoB are not interchangeable. They usually move together, but when they are discordant, ApoB is the more relevant measure, because the wall is exposed to particles, not to a cholesterol-mass number. I have seen this directly: a patient did a 40-day fast and his LDL-C fell roughly 50%, while his ApoB dropped only about 10%. That is not a controlled trial, and I do not present it as one, but it shows the point exactly: LDL-C can swing because the cholesterol content per particle changes, while the number of atherogenic particles barely moves. A patient who fasts or shifts lipid trafficking and sees a big LDL-C change with little ApoB change has not made the process benign; he has shown that LDL-C alone was never the complete marker. So the dynamic nature of LDL-C is an argument for measuring ApoB, not for dismissing lipid risk. And measuring ApoB in a short imaging study still does not establish long-term safety; it cannot replace pathology, genetics, prospective epidemiology, discordance analyses, and randomized outcome trials.[10-14]

Bottom line: A number that moves is not a number that stops mattering. LDL-C fluctuates because it measures cholesterol cargo, not particle count, which is the reason to track ApoB, not the reason to dismiss cholesterol, and the film has it exactly backwards. The disease is built by the total number of atherogenic particles striking the artery wall over a lifetime, and pointing at a wobbling LDL-C does nothing to lower that count. Fluctuation is an argument for measuring ApoB, not for ignoring it.

Claim 3: Metabolic Health Improvements Neutralize Lipid Risk

The film frames the LDL-C rise as “one little detraction” against everything else getting better.[1] That sets up a false tradeoff, as if we must choose between valuing metabolic health and valuing ApoB risk. That is not how ASCVD works. Diabetes, obesity, hypertension, smoking, inflammation, and ApoB do not cancel each other out; they layer, interact, and add to lifetime risk.

This is settled epidemiology. The Framingham models and other long-term cohort studies use multiple simultaneous risk factors because risk is multifactorial.[17] In the United Kingdom Prospective Diabetes Study, a long-running study that followed people with type 2 diabetes for years, coronary disease tracked with higher LDL-C, lower HDL-C, higher HbA1c, higher systolic pressure, and smoking; even in diabetics, LDL-related risk remained relevant alongside glucose and blood pressure.[18] So improving insulin resistance does not make ApoB harmless. If a patient improves A1c, triglycerides, HDL-C, and blood pressure but drives ApoB very high and keeps it there, that is a separate exposure. And lipid lowering still reduces events in this exact population. The Cholesterol Treatment Trialists’ Collaboration, an ongoing academic effort that pools the raw, patient-level data from dozens of statin trials rather than leaning on any single one, looked specifically at more than 18,000 people with diabetes across 14 trials and found a 21% drop in major vascular events for each roughly 39 mg/dL (1 mmol/L) reduction in LDL, the same effect seen in people without diabetes.[19]

The correct clinical question is not whether some markers improved, but whether the total risk profile improved. Triglycerides down with ApoB sharply up is not automatically a net win. The goal is metabolic health together with a low ApoB: improve insulin sensitivity, cut visceral fat, normalize blood pressure, build fitness, treat sleep apnea, stop smoking, and bring a high ApoB down to limit cumulative arterial exposure.

Bottom line: Risk factors add up; they do not cancel out. Lowering your glucose, triglycerides, and weight is real progress, and none of it earns a pass on a high ApoB, because lipid lowering cuts heart attacks even in people whose diabetes is already controlled. A diet that fixes the markers you can see while doubling the particle count you cannot has not made you safer; it has traded a visible risk for a hidden one, and the artery wall still collects.

Claim 4: A Clean CCTA Proves Long-Term Safety

The film’s most persuasive-to-a-layperson claim is that coronary CT angiography shows these high-LDL patients are “fine.”[1] It is the strongest-sounding moment in the documentary, and it rests on a misunderstanding of how the disease actually develops.

CCTA is genuinely valuable. A trained reader can assess the lumen, grade stenosis, locate plaque, and characterize it as calcified, noncalcified, or mixed, and high-risk features like positive remodeling, low-attenuation plaque, and the napkin-ring sign carry higher event risk.[20,21,22] In the right patient it can find disease before a stress test turns abnormal and identify who needs aggressive prevention, and when the arteries are clean, it is reassuring.

But everything turns on what a scan can and cannot tell you, and that depends on the natural history of the disease. Atherosclerosis is not a fast process. The pathology is remarkably consistent across populations: it develops over roughly fifty years, beginning in the early teenage years, as cholesterol-carrying particles are retained in the artery wall and provoke inflammation at the site.[41] The landmark autopsy work that examined the arteries of young people who died in accidents found the first fatty streaks already present at 15 to 19 years of age, narrowing the coronary by only about 2% at that stage, with fibrous plaques appearing in the 25-to-34 age band; over the following decades those plaques expand to cover a fifth to nearly half of the coronary surface.[41,42] And the entire process is silent. People feel nothing for decades, which is why advanced coronary atheroma turns up in as many as one in five men in their early thirties who never knew anything was wrong.[42] So at any single early checkpoint, the visible change over a year is necessarily tiny, even in arteries that will eventually fail. A one-year scan is one frame of a forty-year film, and it cannot certify the decades still to come. Lifetime risk is the integral of particle exposure over time, which is why the European Atherosclerosis Society consensus — the field’s formal summary of the genetic, population, and trial evidence — calls LDL and ApoB causal, dose-dependent, and cumulative, and why genetic data show lifelong lower exposure yields several times the risk reduction of the same reduction begun late.[10] A clean scan in a young, lean person mostly reflects their favorable starting point and their age, not the safety of the exposure they are now running.

Now the actual studies, because the film leans on them and they do not say what is claimed. A study called the KETO Trial, published in 2024, compared 80 metabolically healthy people on ketogenic diets against matched comparison subjects with lower LDL drawn from an existing Miami research cohort.[23] These were not minor elevations. In the follow-up cohort from the same group, ApoB — the particle count that actually drives the disease — ran a median of 178 mg/dL, with even the lowest quarter of the group above 149, against an optimal target under 80 and a high-risk threshold near 130.[27,37] In plain terms, the typical participant was carrying roughly twice the optimal load of atherogenic particles. The cross-sectional trial found no significantly greater plaque than the comparison group at the time of imaging,[13] which is worth studying but proves nothing about safety: it is a single snapshot of a small, hand-picked group, with no randomization, no clinical outcomes, and a fraction of the disease’s natural history. And there is a structural reason similar plaque is exactly what you would expect rather than a surprise. These are people whose LDL was presumably normal for the decades before they adopted the diet and high only for the few years since, so their arteries at scan time mostly reflect the low-exposure years they banked, not the high-ApoB exposure they have only begun to run.

Here is the part the framing hides: their own data show the disease underway, not absent. After a mean of only about five years on the diet, most of these people already had plaque — 85% of the follow-up cohort had detectable coronary plaque before the study year even began.[37] These are lean, fit, insulin-sensitive, non-diabetic, non-smoking people whose only meaningful abnormality is that particle count, and most of them had already started building plaque. Then, over the one year they were watched, the plaque grew. They did not find “no change”; the median noncalcified plaque volume rose. A minority regressed, but the group as a whole moved in the wrong direction, at a rate at or above what large imaging studies see in metabolically normal people. In a cohort lacking every other risk factor, which should therefore be progressing slower than average, the one variable left to explain plaque accumulating at the rate of ordinary people is the one the film insists is harmless. That cuts against the protective story, not for it.

The follow-up study, known as KETO-CTA, is where the overreach became indefensible, and it failed on its own terms twice over. First, the framing: its headline was that the amount of ApoB didn’t predict which arteries progressed — but every participant already had sky-high ApoB, the lowest quartile still above 149, and there was no comparison group of people with normal ApoB anywhere in the study. You cannot detect what ApoB does to arteries in a group where everyone’s ApoB is extreme; the absence of a within-group correlation is a consequence of who they enrolled, not a finding about the particle. It is the two-pack-a-day problem: study only heavy smokers, watch them a year, and the heaviest won’t look dramatically worse than the merely heavy, but that tells you nothing about whether cigarettes cause cancer. Second, the reporting: the study had pre-registered the change in noncalcified plaque volume as its primary outcome, and when the results came in the authors de-emphasized that number and promoted percent atheroma volume — a secondary endpoint that sounded smaller — which independent reviewers flagged as selective reporting after the fact.

And then they retracted it. The single study at the center of this film’s “your cholesterol is fine” message — the one claiming particle count doesn’t predict plaque — was pulled from the medical literature at the request of its own authors, because the journal and the authors agreed the methodological errors were too severe to correct. Read that twice. The people asking you to bet your arteries on this finding could not stand behind it themselves. When the researchers making an extraordinary claim have to withdraw the evidence for it, the claim does not become merely unproven. It becomes a warning.

JACC: Advances, the journal that published it, withdrew the paper at the request of both the authors and the editors, stating that concerns about the methodology affected the reliability of the data and that the errors were too great to correct.[15,24] The authors have since re-run the primary endpoint as a preprint, a manuscript posted publicly but not yet peer-reviewed,[37] and even there they concede the analysis had no proper control group, that their measurement methods are unreliable at the low plaque burdens that dominated the cohort, and that answering the actual risk question needs far longer follow-up with real cardiac events. They are right.

One more point, because it gets misread: baseline plaque predicting future plaque is unremarkable and says nothing about ApoB. People who already have plaque have demonstrated susceptibility and progress faster; existing plaque is among the strongest predictors of future plaque in every population, which is why imaging is useful for staging an individual. It does not displace causal biology. Imaging tells you where someone is on the road; it does not repeal the exposure that built it.

Bottom line: A clean scan is one frame of a forty-year film, and you cannot clear a lifetime disease from a single frame. The film’s own study makes the point against itself twice: it watched these people for one year, far too short to see a process that unfolds over decades, and it enrolled only people with sky-high ApoB, so by design it could never detect what ApoB does to an artery in the first place. And what it did see was not reassurance — most already had plaque after five years, and it grew over the year they were watched, in people too healthy in every other respect for it to be growing. The strongest-sounding evidence in the documentary is the weakest possible design for the question it claims to answer, and the only peer-reviewed version of it was retracted.

Claim 5: High HDL-C and Low Triglycerides Do Not Cancel Out High ApoB

The favorable lipid pattern is central to the hyper-responder argument. First, the precision: not everyone on keto develops high HDL-C, which is substantially heritable, with estimates around 40-60%.[25] So the claim should not be that keto reliably produces high HDL-C. The specific point is that the lean-mass-hyper-responder phenotype was defined around markedly elevated LDL-C, high HDL-C, and low triglycerides,[26] and the 2024 trial selected on it (LDL-C ≥190, HDL-C ≥60, triglycerides ≤80).[13] The favorable pattern is not an incidental finding; it is the entry criterion.

Low triglycerides and high HDL-C are favorable markers, often reflecting better insulin sensitivity. But favorable is not the same as protective enough to cancel high ApoB. The artery wall does not care whether an ApoB particle came from a patient with low or high triglycerides; if it enters the intima and is retained, it can drive atherosclerosis.[10,11] The National Lipid Association’s expert consensus makes the parallel point: ApoB improves risk assessment beyond LDL-C precisely because it counts atherogenic particles.[27] If ApoB is very high, the wall is being exposed to many of them, and a good triglyceride/HDL pattern does not erase that.

HDL-C is the most misunderstood piece. It is not “good cholesterol” in any protective sense; it is a cholesterol-content measurement, and association is not causation. Mendelian randomization, a method that uses the gene variants people inherit at birth as a kind of natural, lifelong randomized experiment, has challenged the idea that genetically higher HDL-C itself lowers heart attack risk.[16] And several drugs built specifically to raise HDL-C were tested in large trials and failed: torcetrapib raised HDL-C but increased events and death,[28] dalcetrapib raised it with no event reduction,[29] and evacetrapib produced large HDL-C increases and lower LDL-C yet still failed to reduce outcomes.[30] HDL particles may have real functions, but HDL-C is not a reliable target and should never serve as a permission slip for high ApoB.

Bottom line: High HDL and low triglycerides describe a healthier metabolism; they do not build a wall around your arteries. We know this because drugs that raised HDL dramatically were tested in large trials and failed to prevent heart attacks, and one increased deaths. The pattern the film treats as protection is the very pattern it selected its subjects for, which makes it a description of the group, not evidence of its safety. A good HDL says something reassuring about your metabolism and nothing about the particles already entering your artery wall.

Claim 6: LDL Is Not the Disease, Heart Disease Is the Disease

“LDL is not the disease, heart disease is the disease” sounds reasonable, and technically a lab value is not a heart attack. But it is a misleading way to frame prevention, which is the whole point of catching this early. Prevention means treating causal exposures before they cause irreversible injury. Hypertension is not a stroke, but we treat it to prevent one; smoking is not lung cancer, but we intervene before the cancer appears; hyperglycemia is not kidney failure, but we treat diabetes before dialysis. ApoB is not plaque rupture, but ApoB particles are central to building the plaque. The exposure not being the final event does not make it irrelevant.

This is where the film’s logic becomes dangerous. Convince people that the disease only counts once it is visible or symptomatic, and you have abandoned prevention. Atherosclerosis is silent for years, and the first presentation can be myocardial infarction, sudden death, or stroke; waiting for symptoms is not sophisticated, it is late. A good physician does not confuse detection with causation. CCTA, calcium scoring, stress testing, and angiography stage disease and guide intensity; none of them make ApoB irrelevant, and the absence of visible plaque today does not mean the process cannot progress tomorrow.

Bottom line: Yes, ApoB is not a heart attack, and blood pressure is not a stroke, and a cigarette is not lung cancer. We treat all three anyway, because prevention means acting on the cause before the event, not waiting for it. “LDL is not the disease” is a play on words, and followed to its conclusion it tells you to do nothing until the damage is done and irreversible. That is not sophistication; it is an argument for late medicine, and with this disease the first symptom is often the fatal one.

Claim 7: Statins and Lipid-Lowering Therapy Are the Problem

The recurring theme is that statins and lipid-lowering therapy are the problem, with physicians reflexively prescribing under guideline pressure or pharmaceutical influence. There are real grains of truth: some medicine is lazy, some patients are medicated without a serious lifestyle conversation, companies have incentives, and guidelines get applied poorly. None of that makes lipid-lowering therapy a scam.

The correct position is not that everyone with an elevated LDL-C needs a statin tomorrow; absolute benefit depends on baseline risk, age, sex, blood pressure, smoking, diabetes, Lp(a), kidney function, family history, plaque burden, and exposure time. But the opposite claim is also false. The Cholesterol Treatment Trialists’ pooled analyses (the same patient-level project introduced earlier) showed statins cut major vascular events in proportion to the dose, roughly a one-fifth reduction for each 39 mg/dL (1 mmol/L) drop in LDL.[14] A low-risk person gets a small absolute benefit and a high-risk person a large one, and any single trial understates the lifetime benefit, because these trials run a few years while the exposure runs for decades.

The signal was strong enough to become an ethical problem. Several landmark trials were never allowed to finish, because their independent data and safety monitoring boards judged the treatment arm to be benefiting so clearly that withholding the drug from the placebo group was indefensible. ASCOT-LLA, a trial of a statin against placebo in patients with high blood pressure, was stopped at a median of about three years against a planned five.[38] CARDS, which tested a statin against placebo in people with type 2 diabetes, was halted roughly two years early for the same reason.[39] JUPITER, a trial of a statin in people with elevated inflammatory markers but unremarkable LDL, was planned for four years and stopped at a median of 1.9.[40] When a trial has to end early because it is unethical to keep withholding the drug, that is not marketing; it is the strength of the effect forcing the trial to close.

I will be honest about the one fair objection, because honesty about it is what makes the rest hold. Trials stopped early for benefit can overestimate the size of the effect, and statistically minded critics have said exactly that about JUPITER. It does not rescue the keto position. The statin-versus-placebo trials that ran their full planned course, among them landmark studies known as 4S, the Heart Protection Study, LIPID, and WOSCOPS, are large, long, and consistent, and the totality is confirmed by the pooled patient-level analyses and, independently, by Mendelian randomization, the genetic method described above, which needs no drug company at all. Discount every early-terminated trial and the conclusion does not move.

And the evidence is not statin-specific, which is the part the detractors cannot answer. Ezetimibe lowers LDL-C by blocking cholesterol absorption in the gut and improved outcomes in IMPROVE-IT, a trial that added it to standard statin therapy in patients who had recently had a heart attack or unstable angina.[31] Evolocumab, a PCSK9 inhibitor given by injection, produced large LDL-C reductions and cut events in FOURIER, a trial in patients with established cardiovascular disease.[32] Bempedoic acid reduced major adverse cardiovascular events in statin-intolerant patients in a trial called CLEAR Outcomes.[33] Four drugs, four mechanisms, one shared action: they lower atherogenic particle burden, and the benefit per unit of LDL lowered is consistent across these mechanistically unrelated agents, which is what you would see only if the particle-lowering itself were the active ingredient rather than some drug-specific side effect. Mendelian randomization confirms the same causal effect with no drug, and therefore no off-target effects, involved at all.

So here is the question I would put to anyone arguing that cholesterol is not the problem and statins are a scam: explain the trials. Explain why a statin, a cholesterol-absorption blocker, an injectable PCSK9 inhibitor, and bempedoic acid, agents that share almost nothing except the lowering of ApoB-containing particles, all reduce heart attacks and strokes against placebo in tens of thousands of randomized patients. A coincidence does not repeat itself across four unrelated mechanisms. The one thing they share is the one thing the documentary insists does not matter. There is no honest counter to that, which is why you will not hear one.

Bottom line: Four drugs that share nothing but the lowering of atherogenic particles — a statin, a gut-absorption blocker, an injected antibody, and a pill in a separate class entirely — all cut heart attacks and strokes in large randomized trials. That is not coincidence, not pharma mythology, and not a shared side effect, because the drugs have no side effects in common; the only thing they share is the one thing the film insists is irrelevant. Several of those trials were stopped early because it became unethical to keep the placebo group off the drug. You can dislike statins and still owe this evidence an answer the film never gives.

Claim 8: Pharmaceutical Influence Refutes Lipid Biology

A related move points at pharmaceutical influence: because companies profit from cholesterol drugs, the cholesterol model itself is suspect. Influence and conflicts of interest are real, but a conflict-of-interest critique is not a biological rebuttal. Insulin makers profit from diabetes without making hyperglycemia harmless; antihypertensive makers profit without making hypertension safe. Financial incentives can distort how care is delivered without changing causal biology.

And the argument does not run one way. The low-carbohydrate ecosystem is itself a large commercial enterprise: books, paid speaking, coaching programs, branded supplements and exogenous ketones, the ketone-measurement industry, conferences, subscription media, and a documentary that needs a marketable thesis. If a financial stake discredited a conclusion, it would discredit that side first. It does not, because funding source is not what makes a result true; the methods are. And the evidence for ApoB-mediated atherosclerosis comes from far more than industry trials: pathology, arterial biology, animal models, human genetics, prospective epidemiology, discordance analyses, imaging, and randomized outcomes.[10-14,27] Mendelian randomization in particular needs no company at all and points the same direction. When independent evidence streams converge, dismissing the field as pharma influence is intellectually lazy.

It is also worth separating the cholesterol model from the statin market. ApoB biology does not require a statin specifically: ezetimibe, bempedoic acid, and PCSK9 inhibitors all lower atherogenic particle burden through different mechanisms. What ApoB does not respond to reliably is diet. Lifestyle change moves LDL-C modestly and particle number even less, and it rarely normalizes a genuinely elevated ApoB. The target is atherogenic particle exposure, and for someone who actually has a high particle count, the realistic lever is pharmacologic. People confuse institutional criticism with scientific refutation: “pharma has influence” may be true, but “therefore ApoB does not cause atherosclerosis” does not follow.

Bottom line: Follow the money and it leads to the keto side too: the books, the supplements, the ketone meters, the conference circuit, the film itself. That is the point — a financial motive is something every party here has, which is exactly why it settles nothing. Money can bend how medicine is sold; it cannot bend whether ApoB lodges in an artery wall, and the genetic evidence that it does was funded by no drug company at all. A conflict of interest is a reason to check the methods, never a reason to assume the conclusion is false.

Claim 9: Citizen Science Can Settle Long-Term Risk

Citizen science is the engine of the whole story. Feldman’s work is framed as an outsider’s challenge: an engineer notices an unusual cholesterol pattern, runs self-experiments, raises money, and generates research the academy supposedly would not. Stated that way, none of it is objectionable. Self-experimentation generates hypotheses, patient-driven inquiry surfaces overlooked patterns, and medicine should never dismiss an observation merely for its origin. I will give the model its due: it identified a real, reproducible phenotype, and that is a genuine contribution.

But generating a hypothesis is not proving one, and this is where the film performs its central sleight of hand. Citizen science can say, here is an interesting phenotype, this deserves formal study. What it cannot do, what no amount of curiosity or funding can do, is settle long-term cardiovascular risk. That takes careful phenotype definition, adequate sample size, real controls, sufficient follow-up, prespecified outcomes, blinded analysis, and hard endpoints, and it takes separating selection effects from biology. Enthusiasm does not solve those problems. Discipline does.

And here the film collides with a fact it never reckons with: the citizen-science program did partner with credentialed academics, ran its studies through a real institution, and submitted them to peer review, and the flagship longitudinal paper was still retracted for methodological errors too severe to correct. Sit with that. The apparatus the film treats as an obstacle, the slow, skeptical, credentialed machinery of academic medicine, is exactly what caught the error and pulled the paper. The system it asks you to distrust worked as designed. That is not an argument against outsiders contributing; it is an argument against what the film is actually selling, that an outsider’s conviction can stand in for that machinery rather than submit to it.

I have written about this pattern at length, because it is not unique to cholesterol. There is a particular kind of man who mistakes information for judgment and familiarity for expertise. In the digital age he can consume enough content to convince himself he has mastered a subject as complex as human physiology, and what he lacks is not data but exposure to consequence, to error, to the weight of decisions that have to work in the real world. He has “done his research,” so he resists proven guidance, convinced he is thinking critically when he is really selecting the arguments that protect what he already believed. This posture is dangerous in direct proportion to how intelligent the man is, because intelligence in one domain is exactly what lets him build a sophisticated case for being wrong in another. Success in engineering, business, software, or finance is real and non-transferable; it does not confer the competence to overturn a field built on pathology, physiology, and the accumulated consequence of clinical decisions made on real patients over decades.

Follow the film’s logic to the end. If a man brilliant in another field can, by force of that brilliance, decide that the settled science of lipidology is wrong and his own read is right, then what is the point of any of it? What is the point of the decade in training, the years in pathology learning what disease looks like in tissue, the study of physiology and pathophysiology, the long apprenticeship of being accountable when the decision is wrong and a patient is harmed? If clever-in-something-else were a substitute, we could close the medical schools, dissolve the residencies, and let anyone with a successful career and a glucose monitor rewrite the standard of care. We do not, and we should not, because some domains cannot be reasoned into from the outside by analogy; they have to be earned through the exposure to consequence the internet researcher has never had. The claim that a citizen scientist can do what we do because he succeeded elsewhere is not humility about institutions; it is a category error dressed as independence, and it has to be named as such.

The phenotype is also vulnerable to selection. The people who show up in forums, volunteer for studies, and become public examples are not a random sample of high-ApoB ketogenic dieters; they are likelier to be leaner, more adherent, more metabolically pristine, and more likely to already have reassuring scans. That does not make their data worthless, but it means the data describe a curated population. A movement built around people who feel fine and look fine on a scan is structurally incapable of seeing the people who did not.

So the right response is neither mockery nor surrender. It is the unglamorous work the film skips: larger cohorts, real controls, serial imaging over years rather than months, full lipid and genetic characterization, and eventually hard outcomes. Until then, the claim that high ApoB is harmless in this phenotype is a hypothesis, and a hypothesis with a retracted flagship paper behind it is on thin ice.

Bottom line: An outsider’s sharp observation is where science starts, not where it ends, and the film sells the starting line as the finish. Curiosity can find a phenotype; it cannot prove that phenotype safe over a lifetime, which takes controls, time, and hard endpoints the film never produced. And the irony is total: when these researchers finally did submit to the system they ask you to distrust, that system read their flagship paper and retracted it. Brilliance in engineering or business does not become expertise in lipidology by force of will. That is not the brave outsider correcting the experts; it is the unteachable man mistaking confidence for competence.

Claim 10: Ketones Are Inherently Protective Against Atherosclerosis

The final claim is mechanistic: maybe ketosis itself protects, maybe beta-hydroxybutyrate’s anti-inflammatory effects offset high ApoB. This is the most sophisticated-sounding argument because there is real biology behind parts of it. Beta-hydroxybutyrate is not just fuel; it has signaling properties, and laboratory work shows it can inhibit the NLRP3 inflammasome, a key driver of sterile inflammation.[34] The strongest version is a 2021 mouse study in which oral 3-hydroxybutyrate reduced atherosclerosis, even alongside a high-fat diet, by promoting cholesterol efflux from immune cells in the artery wall.[36] I will not pretend the claim is biochemically empty. The mechanism is real.

But notice what that study actually tested. The ketones were delivered as a once-daily oral supplement that raises beta-hydroxybutyrate without raising ApoB. Taken at face value, it is an argument for a ketone supplement while keeping particle burden low; it is not an argument for a high-saturated-fat diet that drives ApoB to twice the optimal level. Their strongest mechanistic paper quietly separates the ketones from the lipid elevation the documentary exists to defend.

And mechanistic plausibility is not outcome evidence, which is the deeper distinction. This work is in cell culture, mice, or short-term physiology, much of it about brain inflammation rather than coronary arteries; plenty looks promising at that level and never becomes a proven clinical strategy. The question is not whether beta-hydroxybutyrate affects inflammatory signaling, but whether sustained ketosis prevents ApoB particles from being retained in the human arterial wall over decades. That has not been shown. And the protective inference was actually tested in the very population the film champions: these hyper-responders were in sustained, measured ketosis, the exact condition the argument valorizes, and the cohort still showed net plaque progression over the follow-up studied. Whatever anti-inflammatory tone the ketones provided did not abolish progression in the people the film is built around.

Inflammation and ApoB are not competing explanations anyway; they are both part of atherosclerosis, with ApoB particles providing the retained substrate and inflammation shaping how plaque progresses and ruptures. We already know inflammation matters: a trial called CANTOS showed that canakinumab, a pure anti-inflammatory drug that does nothing to cholesterol, reduced cardiovascular events in heart-attack survivors.[35] But it proved the opposite of the simplistic framing, that atherosclerosis has multiple interacting causal pathways; lowering inflammation helps, so does lowering ApoB, so does treating blood pressure, diabetes, and smoking, and they are not mutually exclusive. A patient can have lower glucose, lower triglycerides, higher beta-hydroxybutyrate, and still have very high ApoB exposing the wall to many particles over time. The burden of proof is on whoever claims ketosis neutralizes that, and that proof does not exist. There is also a composition problem: “keto” built on olive oil, fish, nuts, and unsaturated fat is not the same diet as one built on butter, cream, fatty meat, and coconut oil, and if ApoB rises dramatically on the high-saturated-fat version, “but ketones are anti-inflammatory” does not answer it.

Bottom line: A real mechanism in a mouse is not protection in a human, and the gap between them is where this argument dies. The film’s strongest paper delivered ketones as a supplement that raised them without raising ApoB, so even at face value it argues for a ketone pill while keeping particle count low, not for a diet that drives ApoB to twice optimal. And when the protective idea was finally tested in real people in sustained ketosis, their arteries accumulated plaque anyway. Anti-inflammatory signaling is real; it does not buy back the damage of a high particle count, and no one has shown that it does.

The Correct Conclusion

The point is not that ketogenic diets are useless, that every low-carb dieter is harming himself, that every elevated LDL-C needs medication, or that CCTA is worthless. Those would all be overstatements. The point is more precise and more important: the film takes a set of interesting observations and turns them into claims the evidence does not support.

The pattern repeats in every section. Keto improves metabolic markers, therefore keto is uniquely therapeutic. LDL-C fluctuates, therefore cholesterol risk is suspect. Selected patients have clean imaging, therefore high ApoB is safe. HDL-C is high and triglycerides low, therefore particle burden no longer matters. Pharma has influence, therefore lipid biology is corrupt. Ketones affect inflammation, therefore ApoB exposure is neutralized. None of those jumps is justified. The individual observations are often true or at least interesting; the conclusions drawn from them are the overreach.

The burden of proof belongs to the people making the extraordinary claim. To assert that decades of severe LDL-C and ApoB elevation are harmless in lean ketogenic hyper-responders, you need long-term outcome data showing no excess plaque progression, infarction, stroke, revascularization, or death. They do not have it. They have a story, a phenotype, a small cross-sectional imaging study, a retracted longitudinal analysis, and a hypothesis.

The clinical framework is simple. Use low-carbohydrate nutrition when it helps a patient lose weight, improve glycemia, lower triglycerides, and control appetite. But measure ApoB and Lp(a), and assess blood pressure, family history, smoking, diabetes, renal function, inflammation, sleep apnea, and existing plaque burden; use a calcium score or CCTA selectively when the result would change management. Then be honest about the tools. In the lean-mass-hyper-responder the elevation is diet-induced, so de-restricting carbohydrate will lower it, and a patient who wants to avoid drugs can change the diet that produced the number. But diet moves particle number far less than it moves LDL-C and rarely normalizes a genuinely high ApoB, so for the patient who keeps the diet, or whose ApoB is elevated for any other reason, lipid-lowering therapy is the realistic, evidence-based lever, not blind guideline obedience. Lifestyle still does the heavy lifting for the rest of the risk picture: weight, blood pressure, glucose, and fitness.

We do not have to choose between metabolic health and lipid control. The goal is both: improve insulin sensitivity, cut visceral fat, normalize blood pressure, build fitness, avoid smoking, treat sleep apnea, and lower ApoB. The idea that one clean scan, one favorable triglyceride/HDL pattern, one documentary, or one charismatic outsider can neutralize decades of high ApoB exposure is not established science. It is a hypothesis being sold as a conclusion, and the science does not support the leap.

References

1. Dr. Eric Westman: first reaction to The Cholesterol Code documentary. Uploaded transcript reviewed for this SITREP.

2. The Cholesterol Code. Official film website.

3. The Cholesterol Code. Gathr film/event description.

4. Goldenberg JZ, Day A, Brinkworth GD, et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021;372.

5. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42(5):731-754.

6. Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss: the DIETFITS randomized clinical trial. JAMA. 2018;319(7):667-679.

7. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859-873.

8. Hall KD, Chen KY, Guo J, et al. Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men. Am J Clin Nutr. 2016;104(2):324-333.

9. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378:e34. (Republished after 2018 retraction of the 2013 report for randomization irregularities; cardiovascular benefit upheld.)

10. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.

11. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis. Curr Opin Lipidol. 2016;27(5):473-483.

12. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Discordance among ApoB, cholesterol mass, and cardiovascular risk. Eur Heart J. 2024;45(27):2410-2421.

13. Budoff M, Manubolu VS, Kinninger A, et al. Carbohydrate restriction-induced elevations in LDL-cholesterol and atherosclerosis: the KETO Trial. JACC Adv. 2024;3(8):101109.

14. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;376:1670-1681.

15. Soto-Mota A, Norwitz NG, Manubolu VS, et al. RETRACTED: Longitudinal data from the KETO-CTA study: plaque predicts plaque, ApoB does not. JACC Adv. 2025;4(7):101686.

16. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380(9841):572-580.

17. D’Agostino RB Sr, Pencina MJ. Cardiovascular disease risk assessment: insights from Framingham. Glob Heart. 2013;8(1):11-23.

18. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UKPDS 23. BMJ. 1998;316:823-828.

19. Cholesterol Treatment Trialists’ Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-125.

20. Cury RC, Leipsic J, Abbara S, et al. CAD-RADS 2.0: Coronary Artery Disease Reporting and Data System. J Cardiovasc Comput Tomogr. 2022.

21. Williams MC, Kwiecinski J, Doris M, et al. Coronary artery plaque characteristics associated with adverse outcomes in the SCOT-HEART study. J Am Coll Cardiol. 2019;73(3):291-301.

22. Dawson LP, Lum M, Nerlekar N, et al. High-risk coronary plaque features: a narrative review. Cardiovasc Diagn Ther. 2022;12(5):640-651.

23. Javier DAR, Manubolu VS, Norwitz NG, et al. The impact of carbohydrate restriction-induced elevations in low-density lipoprotein cholesterol on progression of coronary atherosclerosis: the ketogenic diet trial study design. Coron Artery Dis. 2024;35(7):577-583.

24. JACC: Advances. Retraction notice for: Longitudinal Data From the KETO-CTA Study: Plaque Predicts Plaque, ApoB Does Not. JACC Adv. 2026;5(5):102824.

25. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res. 2010;51(8):2032-2057.

26. Norwitz NG, Feldman D, Soto-Mota A, et al. Elevated LDL cholesterol with a carbohydrate-restricted diet: evidence for a lean mass hyper-responder phenotype. Curr Dev Nutr. 2021;6(1).

27. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2024.

28. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.

29. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099.

30. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933-1942.

31. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372:2387-2397.

32. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376:1713-1722.

33. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med. 2023;388:1353-1364.

34. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21:263-269.

35. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). N Engl J Med. 2017;377:1119-1131.

36. Zhang SJ, Li ZH, Zhang YD, et al. Ketone body 3-hydroxybutyrate ameliorates atherosclerosis via receptor Gpr109a-mediated calcium influx. Adv Sci. 2021;8:2003410.

37. Soto-Mota A, Norwitz NG, Manubolu VS, et al. The impact of sustained LDL-C elevation on plaque changes: primary coronary plaque progression results from the KETO-CTA study. medRxiv. 2026. Preprint, not peer-reviewed. doi:10.64898/2026.01.15.26343955

38. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients (ASCOT-LLA). Lancet. 2003;361:1149-1158.

39. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes (CARDS). Lancet. 2004;364:685-696.

40. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359:2195-2207.

41. Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009;122(1 Suppl):S3-S14.

42. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study. JAMA. 1999;281(8):727-735.

This article is for education only and is not personal medical advice. It does not create a physician-patient relationship. Medical decisions should be made with a qualified clinician who knows your history, labs, medications, risk factors, and goals.

Subscribe now

Don’t believe everything you hear about testosterone. That may sound obvious, but right now it needs to be said clearly because the testosterone conversation has become one of the most distorted conversations in men’s health. What should be a serious discussion about physiology, diagnosis, sleep, body composition, fertility, metabolic health, and evidence-based treatment has been turned into a marketing category. Online clinics, influencers, podcast doctors, supplement companies, and “optimization” personalities have created a world where ordinary fatigue, stress, lack of motivation, reduced training output, and normal life strain are immediately reframed as signs of low testosterone.

That doesn’t mean testosterone deficiency is fake. It isn’t. Primary hypogonadism is real. Secondary hypogonadism is real. Pituitary disease, testicular disease, chemotherapy, chronic opioid use, anabolic steroid suppression, severe obesity, untreated sleep apnea, and systemic illness can all affect testosterone production. Testosterone therapy can be very helpful in the right man, for the right reason, with the right diagnosis. But that’s completely different from the message being sold online, which is that men are hormonally broken and that testosterone is the missing ingredient between them and energy, discipline, muscle, motivation, confidence, and longevity.

That message isn’t science; it’s marketing. And we know marketing changes behavior. A 2017 study published in JAMA examined direct-to-consumer testosterone advertising in 75 large United States media markets from 2009 through 2013. The authors found that regional exposure to testosterone advertising was associated with increased testosterone testing, new testosterone treatment initiation, and even treatment initiation without recent testosterone testing.[1] That matters, because it shows this isn’t just a theoretical concern. Advertising can move men toward testing and treatment before a proper diagnosis has been made.

What this really means: Testosterone deficiency is a real diagnosis, but the modern testosterone industry has turned it into a commercial identity. The selling works by getting healthy men to mistake an ordinary rough stretch for a medical condition.

The 26-Year-Old Who Wanted His Testosterone Checked

I recently spoke with a 26-year-old man who wasn’t a patient. He knew I worked in men’s health, and at one point he casually said he probably needed to get his testosterone checked. I asked him why. His answer wasn’t unusual. He had heard that testosterone can get low. He was tired. His energy wasn’t great. He had heard enough online to wonder if testosterone might be the problem.

That interaction is exactly why this SITREP needs to be written. A 26-year-old man with nonspecific fatigue now believes testosterone should be near the top of the list. Not because he had delayed puberty. Not because he had testicular trauma. Not because he had chemotherapy. Not because he had pituitary disease. Not because he had infertility, loss of morning erections, gynecomastia, unexplained anemia, or a clear medical history suggesting true hypogonadism. He believed it because the culture around men’s health has been flooded with the idea that low energy equals low testosterone.

That’s the problem. Everybody gets tired. Everybody has periods of lower energy. Everybody has times when motivation is poor, training feels harder, sleep is disrupted, work is stressful, body composition worsens, and life feels heavier than it used to. Those symptoms are real, but they aren’t specific. They don’t automatically point to testosterone deficiency, especially in an otherwise healthy young man who wasn’t known to have a problem with puberty, testicular development, or hormone production.

What this really means: A tired 26-year-old almost certainly doesn’t need a testosterone test; he needs a real evaluation. Nonspecific symptoms like fatigue and low motivation point in a hundred directions, and testosterone is rarely the first one worth chasing.

Low Testosterone Is Real, But the Answer Lives in the Middle

Testosterone deficiency is a real diagnosis, and I treat it. There are men whose lives genuinely change when a true deficiency is found and treated correctly, and none of that is in question. What’s in question is what the diagnosis actually means, and right now two camps are fighting over it from opposite directions. Both are wrong, and the truth sits between them.

On one side is the conservative establishment position. The 2018 Endocrine Society Clinical Practice Guideline recommends diagnosing hypogonadism only in men who have both symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone concentrations. It recommends fasting morning total testosterone as the initial test, repeat morning testing to confirm, and free testosterone when total testosterone is near the lower limit of normal or when SHBG is altered.[2] The American Urological Association uses a total testosterone below 300 ng/dL as a reasonable cut-off, but it won’t make the diagnosis without compatible symptoms or signs and two early-morning measurements on separate occasions.[3] These guidelines get one thing right, and it matters: you can’t diagnose a deficiency from a feeling. A tired man who heard online that testosterone might help isn’t a diagnosis. But I don’t treat these guidelines as the final word, and patients shouldn’t assume I do. A rigid reading turns a single threshold into the whole story and dismisses real men who don’t fit the narrowest possible box. I’m not willing to tell a man with genuine symptoms, a real clinical picture, and a testosterone level sitting one point above an arbitrary cut-off that nothing is wrong with him.

On the other side is the online world, and it’s the exact opposite. There, every tired, stressed, under-recovered man is told he’s hormonally broken and that testosterone is the missing ingredient between him and energy, muscle, motivation, and confidence. That isn’t medicine; it’s marketing. And it’s the more dangerous of the two extremes, because it’s everywhere and it asks nothing of the man except a credit card.

The answer lives in the middle, and it’s neither of these. There are men who don’t fit the cartoon version of primary hypogonadism but who still have a clinically meaningful testosterone problem. A man with secondary hypogonadism, appropriate symptoms, properly interpreted labs, and a complete evaluation may absolutely benefit from treatment. I don’t believe testosterone should be reserved only for the most extreme cases, and I don’t believe a man should be dismissed because he misses the strictest line in a guideline by a few points. The deepest error both camps make, in opposite directions, is the same error: they reduce a man to a number. One side fixates on a threshold; the other chases an “optimized” value. Both are staring at a single lab number and ignoring the man attached to it. Low testosterone isn’t a vibe, and it isn’t just a number; it’s a clinical picture.

That’s why a level alone never settles it. You have to look at the entire patient. Is he sleeping enough, and is that sleep restorative? Has sleep apnea been ruled out or treated? Is he carrying excess visceral fat? Is he strength training and doing real aerobic work? Is he metabolically healthy? Is his alcohol intake undermining him? Is chronic stress driving his physiology into the ground? SHBG, free testosterone, body composition, sleep, metabolic health, medications, and alcohol all change what a testosterone level even means, and none of that shows up in a single number.

This is where a lot of men get uncomfortable, because the middle asks something of them. They say they want to feel better, but they won’t go to bed on time. They say they want better energy, but they won’t train consistently. They say they want better body composition, but they won’t control nutrition or alcohol. They say they want discipline, but they’re looking for a prescription to replace it. That’s not a testosterone problem; it’s a foundation problem. Testosterone therapy can be exactly right once the diagnosis is real and the context is understood, but it should never become a way to skip the work. Ignore the foundations and you’ll improve a lab number while the man stays fundamentally unchanged.

What this really means: Testosterone deficiency is real, but it lives in the whole clinical picture, not in a guideline threshold or an online promise. The rigid camp and the optimization camp make the same mistake from opposite ends: they treat a man as a number. I’m not against testosterone, and I’m not for treating a number. I’m for treating the entire man.

The “Men Today Have Lower Testosterone” Claim

One of the most common online arguments is that men today have lower testosterone than men in prior generations. There’s some truth buried inside that claim, but the internet version is usually sloppy. Several population studies have suggested that average testosterone levels may have declined over time in certain male populations. That deserves scientific attention. It may reflect changes in obesity, sleep, physical activity, metabolic health, environmental exposures, medications, chronic stress, diet, alcohol use, or other features of modern life. But those studies don’t prove that every tired man is testosterone deficient, and they don’t prove that testosterone therapy is the answer.

One of the most frequently cited papers is the Massachusetts Male Aging Study analysis published in The Journal of Clinical Endocrinology & Metabolism in 2007. This was a population-based study of men in the greater Boston area, with data collected across three waves between 1987 and 2004. The authors reported an age-independent population-level decline in serum testosterone in American men, even after attempting to account for some observed health and lifestyle variables.[4] That’s an important finding, but it wasn’t a study of healthy 26-year-old men seeking “optimization,” and it doesn’t convert nonspecific fatigue into a testosterone diagnosis.

Another important study, also published in The Journal of Clinical Endocrinology & Metabolism in 2007, analyzed 5,350 male serum samples from four large Danish population surveys conducted between 1982 and 2001. This Danish study measured total testosterone and SHBG and calculated free testosterone. The investigators found that total testosterone and SHBG were lower in later surveys, but they didn’t find the same significant age-independent decline in calculated free testosterone. After adjustment for BMI, the total testosterone trend was no longer significant, while SHBG changes remained important.[5] That study is a major reason to be careful with the simplistic claim that men’s biologically active testosterone is universally collapsing.

The Danish study doesn’t prove that testosterone hasn’t changed over time, and it doesn’t erase every other study. But it does prove that the story is more complicated than total testosterone. Total testosterone isn’t the same thing as free testosterone, and total testosterone can be misleading when sex hormone-binding globulin, or SHBG, is abnormal. SHBG is one of the major binding proteins that carries testosterone in the blood. When SHBG is low, total testosterone may look lower than expected even when free testosterone isn’t equivalently low. When SHBG is high, total testosterone may look more reassuring than the free testosterone signal actually is. The point isn’t that SHBG mechanically explains every testosterone result; it’s that total testosterone can’t always be interpreted intelligently without considering SHBG and free testosterone.

There are also more recent data in younger men, but those data have limitations too. A 2021 European Urology Focus paper used National Health and Nutrition Examination Survey data from 1999 to 2016 to examine total testosterone trends in adolescent and young adult males in the United States. The authors reported declining mean total testosterone levels over time, including after adjustment for several measured variables, and they noted that higher BMI was associated with lower total testosterone.[6] That finding deserves attention, but it remains a total-testosterone analysis and doesn’t settle the question of whether free testosterone, androgen action, or clinically meaningful hypogonadism has declined in the same way.

This is where the commercial narrative goes wrong. A population-level observation gets turned into an individual diagnosis. Men hear that testosterone may be declining across society and then assume their own fatigue must be testosterone deficiency. That’s not a valid conclusion. A public-health trend may tell us something important about modern male health. It doesn’t mean every tired man needs to chase a testosterone number.

What this really means: The testosterone-decline literature is real but messier than the internet admits, and it doesn’t convert a population trend into your personal diagnosis. A graph of average levels drifting down across decades says nothing definitive about why one tired man feels the way he does.

Lower-Normal Testosterone Is a Signal, Not a Prescription

Consider the man in his 40s or 50s with a total or free testosterone level in the lower portion of the normal range. He’ll often be told, or assume, that he needs treatment. That’s too simplistic. Lower-normal testosterone isn’t clinically diagnosed hypogonadism, and it’s usually a signal that the rest of the physiology needs a careful look.

A man with higher body fat, poor sleep, chronic stress, and weak metabolic health often carries values that sit lower in the range because his physiology isn’t optimized, not because he’s missing a hormone. That doesn’t mean he needs injections. It means the upstream causes have to be addressed first, and then the testosterone question can be answered honestly.

The relationship between obesity and testosterone is especially important because it’s often oversimplified. Male obesity-related secondary hypogonadism is a recognized clinical pattern, and reviews of the subject describe obesity as one of the major risk factors for secondary hypogonadism in men.[7] But this isn’t simply because body fat “turns testosterone into estrogen,” although adipose tissue does express aromatase, an enzyme that can convert androgens into estrogens. The physiology is broader than that. Obesity-related testosterone suppression can involve visceral adiposity, insulin resistance, inflammatory signaling, leptin and adipokine effects, sleep apnea physiology, altered SHBG, and hypothalamic-pituitary-testicular axis regulation.[7,8]

Sleep is another major example. A small experimental study published in JAMA in 2011 restricted healthy young men to five hours of sleep per night for one week and found a reduction in daytime testosterone levels.[9] That doesn’t mean every low-normal testosterone value is caused by sleep loss, and it doesn’t mean testosterone therapy is the solution for unrestorative sleep. It means sleep is part of the endocrine system. If a man is chronically sleep-deprived, has untreated sleep apnea, or wakes up exhausted every morning, the correct medical response isn’t to skip over the sleep problem and inject testosterone.

This is the distinction that gets lost online. A lower-normal level should prompt better clinical thinking, not reflexive prescribing. The question shouldn’t be, “How do we push this number up with testosterone?” It should be, “Why is this number here, and what is it telling me about the rest of this man’s health?”

What this really means: A lower-normal testosterone level is a warning light, not a command to start treatment. The right move is to find out why the light is on, since body fat, sleep, and metabolic health all pull the number down, before deciding the hormone itself is the problem.

Testosterone Is Not a Longevity Drug

Testosterone therapy isn’t a longevity drug for men with normal or lower-normal testosterone. There’s no convincing evidence that giving testosterone to men without true hypogonadism makes them live longer. There’s no evidence that it replaces the need for strength training, aerobic conditioning, sleep, nutrition, metabolic health, blood pressure control, ApoB control, body fat reduction, or cardiovascular prevention. Testosterone isn’t a miracle cure, and it isn’t a substitute for doing the hard work.

This is one of the most important points for men to understand. Low testosterone is often associated with worse health, but that doesn’t automatically mean testosterone therapy creates better health. Association isn’t causation. A man with obesity, sleep apnea, insulin resistance, chronic inflammation, poor fitness, and lower testosterone may have that pattern because his overall physiology is unhealthy. Inject testosterone without addressing the things that actually drive his health, and you may improve the number without fixing the man.

The Testosterone Trials help put this in perspective. These were coordinated placebo-controlled trials in older men with low testosterone, published in The New England Journal of Medicine in 2016. Testosterone treatment produced some benefits in sexual function and some other domains, but it didn’t produce a significant benefit in vitality as measured by the primary FACIT-Fatigue outcome.[10] That’s a major point, because “energy” and “vitality” are exactly the symptoms most commonly used in marketing to pull men toward testosterone.

That’s what happens clinically all the time. A man starts testosterone because he’s tired and feels run down. For the first couple of months, he may feel something. Sometimes that’s real. Sometimes it’s expectation. Sometimes it’s the acute effect of starting a hormone. But over time, many men simply return to feeling normal again, and the original problems remain. The poor sleep is still there. The excess body fat is still there. The stress is still there. The lack of conditioning is still there. The alcohol is still there. The weak training architecture is still there. The life structure that created the fatigue in the first place is still there.

Testosterone can help true hypogonadism. It can’t rescue a man from every other neglected part of his physiology.

What this really means: Testosterone can correct a true deficiency, but it can’t correct a disorganized life. If the sleep, body fat, conditioning, and stress that produced the fatigue are left in place, you’ll move a lab value and change very little else.

The Podcast Problem

A lot of men are now getting their medical worldview from podcasts and social media. Some of these voices are thoughtful; many aren’t. The testosterone space is full of men sitting on camera in tight shirts, muscles visible, speaking with absolute confidence about hormones, masculinity, optimization, and what every man supposedly needs. Some of them may believe what they’re saying. That doesn’t make it true. Some of them may have good intentions. That doesn’t make their claims evidence-based. Some of them may look the part. That doesn’t make them physiologists.

This concern isn’t just personal opinion. A 2022 JAMA Internal Medicine cross-sectional “secret shopper” study examined direct-to-consumer online testosterone platforms. The secret shopper presented as a 34-year-old man with low energy and low libido, normal total testosterone, normal free testosterone, and a desire for future fertility. Despite that, testosterone therapy was offered by six of seven platforms. The authors concluded that these platforms offered testosterone therapy and off-label therapies to men who didn’t meet guideline-based criteria, while often failing to convey risks and benefits appropriately.[11]

The visual message online is powerful. Men watch these personalities and think, “If I do what he does, I’ll look like him, feel like him, and become like him.” But that’s not medicine; it’s aspiration marketing. The body on the screen isn’t proof of the claim. A muscular man making a confident statement about testosterone isn’t the same thing as a properly designed clinical trial. A clinic selling testosterone isn’t a neutral source of information about who needs testosterone. A podcast built around hormone optimization isn’t the same thing as a medical evaluation.

I don’t care whether the claim comes from a famous podcaster, a physician with a large online audience, a clinic selling testosterone, or an influencer who has built an identity around hormone optimization. The question isn’t whether the person is confident; it’s whether the claim is true. A person can sound certain and still be wrong. A person can be popular and still be wrong. A person can have a large audience and still be speaking outside the limits of the evidence.

The problem isn’t that men want to feel better. They should want to feel better. The problem is that they’re being taught to skip the real work and look for the most marketable explanation. Testosterone has become a shortcut narrative. Instead of asking the harder questions about sleep, body fat, training, alcohol, and stress, the online world hands a man a simpler answer: your testosterone is low.

That answer sells, but it isn’t always true.

What this really means: A confident influencer isn’t a lab result, and a podcast isn’t a medical evaluation. The physique on the screen and the certainty in the voice are marketing, not evidence, no matter how large the audience.

The Young Man Has More to Lose Than He Realizes

Young men need to be especially cautious. Starting testosterone isn’t like starting a multivitamin. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis. It can suppress sperm production. It can cause testicular atrophy. It can create fertility problems. It can increase hematocrit. It can worsen acne. It can contribute to fluid retention. It can raise blood pressure. It may worsen untreated sleep apnea. It can turn a normal endocrine system into a medically managed system.

The fertility issue isn’t theoretical. Reviews of exogenous testosterone and male fertility describe testosterone therapy as a preventable cause of male infertility because exogenous testosterone suppresses gonadotropin signaling and can markedly impair spermatogenesis.[12] This is why young men, especially men who may want children, need to be cautious about casual testosterone use.

That doesn’t mean testosterone should never be used in young men. Sometimes it should. But the threshold has to be serious, especially in a man who may want children, and the fertility risk alone should slow the conversation down. A 26-year-old shouldn’t casually trade his natural reproductive axis for a prescription because the internet convinced him that fatigue equals low testosterone. If he wants future fertility, testosterone shouldn’t be started without a clear discussion of the risk, the alternatives, and how it would be managed.

What this really means: In a young man, casually starting testosterone can create problems he didn’t have before, including fertility loss that isn’t always reversible. Trading a working reproductive axis for a prescription over nonspecific fatigue is a bad deal he often doesn’t understand he’s making.

This Is Not Just My Opinion

Some people will read this and say, “That’s just your opinion.” That’s fine. I understand why they say it. Men hear one thing from me, another thing from a podcast, another thing from a testosterone clinic, and another thing from a doctor online. Then they have to decide whom to believe.

But that’s exactly the point. Don’t decide based on what you wanted to hear before you started listening. That’s not thinking; it’s confirmation bias. Too many men already want testosterone to be the answer. They want someone to tell them that their fatigue, weight gain, low motivation, poor sleep, and declining fitness aren’t the result of neglected fundamentals. They want someone to tell them it’s hormonal. Then, when they finally find a voice saying exactly that, they decide that person must be right.

That’s not intelligence or scientific reasoning. It’s a man choosing the explanation that asks the least of him.

The evidence isn’t hidden; it’s sitting in the open. The major guidelines don’t recommend diagnosing testosterone deficiency based on vague symptoms alone.[2,3] The secular-decline literature is real but complicated, and it doesn’t prove that every tired man has a testosterone problem.[4-6] The Danish data show why total testosterone alone can be misleading when SHBG and free testosterone aren’t considered.[5] The Testosterone Trials didn’t show a meaningful vitality benefit on the primary fatigue measure in older men with low testosterone.[10] Direct-to-consumer advertising and online testosterone platforms have been shown to drive testing and guideline-discordant treatment.[1,11] Exogenous testosterone can suppress sperm production and create fertility consequences, especially relevant to younger men.[12]

So no, this isn’t simply my opinion. This is my interpretation of the evidence as a physician who actually works in this field and has no interest in turning every tired man into a testosterone patient. I don’t need you to be on testosterone. I don’t need you to avoid testosterone. My interest is that the decision be made honestly, intelligently, and with respect for physiology instead of marketing.

You’re free to believe whomever you want. But at least know what you’re doing. If you choose the voice that tells you exactly what you already wanted to hear, don’t confuse that with evidence-based thinking.

What this really means: The evidence is sitting in the open, and none of it supports diagnosing every tired man with low testosterone. The real question isn’t whom to believe; it’s whether you want the truth or a permission slip for the explanation that asks the least of you.

What Men Should Do Instead

If a man is tired, gaining fat, losing his edge, and not feeling like himself, he should take that seriously. But taking it seriously means doing the unglamorous work first: the sleep, the visceral fat, the strength and aerobic training, the alcohol, the stress he’s pretending is free. Most men who handle those honestly find they didn’t need a more complicated explanation.

If testosterone is still on the table after that, it should be checked correctly and read in context: a fasting morning level, repeated on a second morning, with free testosterone and SHBG, interpreted against the whole clinical picture. One number pulled out of context isn’t a diagnosis. A lower-normal value isn’t automatically disease, and a normal free testosterone usually isn’t a reason to start injections because someone wants to feel “optimized.”

What this really means: Treat the man before you treat the number. Address sleep, body fat, training, alcohol, and stress first; if testosterone still needs checking, check it properly and read it in context. A low-normal value is a reason to look closer, not a reason to inject.

The Bottom Line

Low testosterone is real. I treat it. I understand it. I know what it looks like when a man truly has it, and I know how helpful testosterone therapy can be when it’s used correctly. I’m not interested in pretending that testosterone therapy has no place in modern men’s health. It does. But I’m equally unwilling to pretend that every tired, stressed, overweight, under-recovered man is testosterone deficient simply because the internet taught him to think that way.

A tired 26-year-old almost certainly doesn’t need testosterone supplementation. A 45-year-old with lower-normal testosterone and poor sleep doesn’t automatically need injections. A 52-year-old with excess visceral fat, untreated sleep apnea, high stress, and poor conditioning doesn’t get to bypass the foundations of health by calling it low T. Testosterone may be part of the evaluation, and in the right man it may be part of the treatment. But it should rarely be the first explanation and never be a substitute for the full evaluation.

Some men will read all of this and reach for the obvious objection: “I can’t fix my sleep, lose the fat, or train hard, because my testosterone is low.” It sounds airtight, and it isn’t. The relationship runs both ways, which is exactly what makes the excuse tempting; low testosterone can blunt energy and drive, but in most tired men, poor sleep, excess body fat, inactivity, and alcohol are what’s suppressing the testosterone in the first place. Losing weight raises testosterone. Treating sleep apnea raises testosterone. The foundations aren’t blocked by a low number; in most cases they’re the thing that moves it. And remember what the Testosterone Trials found: men who genuinely had low testosterone, and had it corrected, still didn’t get a reliable improvement in energy on the primary fatigue measure.[10] A hormone isn’t the gate standing between you and a walk, an earlier bedtime, or a few fewer drinks, and it won’t do that work for you after a prescription either. When a man truly is deficient, I treat it, and I treat it while he builds the foundations, not as a reason to postpone them.

The modern testosterone industry wants men to believe that a number explains everything. It doesn’t. Your energy, performance, body composition, libido, mood, recovery, and long-term health are regulated by a much larger system. Sleep matters. Strength matters. Aerobic fitness matters. Body fat matters. Metabolic health matters. Alcohol matters. Stress matters. Purpose matters. Discipline matters. Testosterone matters too, but it’s not magic.

Testosterone deficiency is a diagnosis. Testosterone therapy is a treatment. Neither one should be turned into a sales funnel for men who are tired, stressed, overweight, under-recovered, undertrained, or simply looking for a shortcut.

What this really means: Testosterone is a powerful tool when it’s used correctly, but it should come from a diagnosis and a full picture of the man, not from marketing and wishful thinking. Used for the right reason it helps; used as a shortcut it just hides the work that still needs doing.

References

[1] Layton JB, Kim Y, Alexander GC, Emery SL. Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009–2013. JAMA. 2017;317(11):1159–1166.

[2] Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715–1744.

[3] Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. Journal of Urology. 2018;200(2):423–432.

[4] Travison TG, Araujo AB, O’Donnell AB, Kupelian V, McKinlay JB. A Population-Level Decline in Serum Testosterone Levels in American Men. Journal of Clinical Endocrinology & Metabolism. 2007;92(1):196–202.

[5] Andersson AM, Jensen TK, Juul A, Petersen JH, Jørgensen T, Skakkebaek NE. Secular Decline in Male Testosterone and Sex Hormone Binding Globulin Serum Levels in Danish Population Surveys. Journal of Clinical Endocrinology & Metabolism. 2007;92(12):4696–4705.

[6] Lokeshwar SD, Patel P, Fantus RJ, et al. Decline in Serum Testosterone Levels Among Adolescent and Young Adult Men in the USA. European Urology Focus. 2021;7(4):886–889.

[7] Fernandez CJ, Chacko EC, Pappachan JM. Male Obesity-related Secondary Hypogonadism: Pathophysiology, Clinical Implications and Management. European Endocrinology. 2019;15(2):83–90.

[8] Genchi VA, Rossi E, Lauriola C, et al. Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism. International Journal of Molecular Sciences. 2022;23(15):8194.

[9] Leproult R, Van Cauter E. Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy Men. JAMA. 2011;305(21):2173–2174.

[10] Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. New England Journal of Medicine. 2016;374(7):611–624.

[11] Dubin JM, Jesse E, Fantus RJ, et al. Guideline-Discordant Care Among Direct-to-Consumer Testosterone Therapy Platforms. JAMA Internal Medicine. 2022;182(12):1321–1323.

[12] Crosnoe LE, Grober E, Ohl D, Kim ED. Exogenous Testosterone: A Preventable Cause of Male Infertility. Translational Andrology and Urology. 2013;2(2):106–113.

Subscribe now

This article is for education only and is not personal medical advice. It does not create a physician-patient relationship. Medical decisions should be made with a qualified clinician who knows your history, labs, medications, risk factors, and goals.

Most of what you hear about food and health comes from observational research, where investigators watch what people already eat and look for patterns. That’s useful for raising questions and weak for proving cause. It shows correlation, meaning two things travel together; it never shows causation, meaning one caused t…

Read more

Read more